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Abstract 
The use of ontologies in the mapping of gene expression events provides an 
effective and comparable method to determine the expression profile of an entire 
genome across a large collection of experiments derived from different expression 
sources.  In this dissertation I describe the development of the developmental 
human and mouse eVOC ontologies and demonstrate the ontologies by 
identifying genes showing a bias for developmental brain expression in human 
and mouse, identifying transcription factor complexes, and exploring the mouse 
orthologs of human cancer/testis genes.   
Model organisms represent an important resource for understanding the 
fundamental aspects of mammalian biology.  Mapping of biological phenomena 
between model organisms is complex and if it is to be meaningful, a simplified 
representation can be a powerful means for comparison.  
The implementation of the ontologies has been illustrated here in two ways.  
Firstly, the ontologies have been used to illustrate methods to determine clusters 
of genes showing tissue-restricted expression in humans.  The identification of 
tissue-restricted genes within an organism serves as an indication of the fine-
tuning in the regulation of gene expression in a given tissue.  Secondly, due to the 
differences in human and mouse gene expression on a temporal and spatial level, 
the ontologies were used to identify mouse orthologs of human cancer/testis genes 
showing cancer/testis characteristics.  With the use of model systems such as 
mouse in the development of gene-targeted drugs in the treatment of disease, it is 
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important to establish that the expression characteristics and profiles of a drug 
target in the model system is representative of the characteristics of the target in 
the system for which it is intended.  
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Preface 
In the post-genomic era, much of the focus of research has shifted from 
identifying each gene in the human genome, to creating a catalogue of genes 
listing their corresponding function, regulatory potential, expression profile and 
disease involvement.   
Each cell in an organism contains a complete copy of its genome, thereby 
providing the expression potential of the organism.  Since cells do not 
simultaneously express all genes in the genome, it is important to determine the 
location and timing of each gene expression event.  This expression profiling can 
lead to the identification of genes biased in their expression for the developmental 
program or diseases such as cancer.  The identification of genes whose expression 
is biased for tumorigenic tissues provides the context for the development of 
drugs or vaccines in the treatment of cancer.  The significance of this knowledge 
is also evident when comparing two species whose genomes show considerable 
overlap.  For example, an orthologous gene may be expressed in both human and 
mouse but will not necessarily share the same expression profile in both species.  
Therefore, knowing when and where a gene is expressed is of great importance in 
drug discovery for disease treatment and understanding the relationship between 
human genes and their counterparts in the model organisms. 
A popular technique used to determine the expression status of a cell is to create a 
cDNA library from which expressed sequence tags are derived.  An expressed 
sequence tag (EST) is a 200-800 nucleotide sequence from a cDNA clone.  An 
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EST is generated randomly and represents a segment of an mRNA molecule 
(Adams et al., 1991; Nagaraj et al., 2007).  The source of ESTs, namely mRNA, 
enables these tags to provide a view of the expression state of a cell by identifying 
the mRNA being expressed in a particular cell at any given time.   
Although ESTs provide insights into many biological phenomena such as gene 
discovery, alternative transcript identification and genome annotation (Nagaraj et 
al., 2007), the EST transcripts are generated by single-pass sequencing and are 
therefore very susceptible to errors.  The advantage of using ESTs in exploring 
cellular gene expression lies in their low complexity and cost-effectiveness.  Since 
the use of any technology is dictated by its financial impact, ESTs will continue to 
be a popular low-cost method among researchers as the current, high-impact 
sequencing methods become more established. 
With the continuous generation of genome-scale data, it is imperative that the 
biological data be annotated in such a way that it is possible to adequately share 
and compare data from different biological sources, experiments or laboratories. 
Since 2000 (Stevens et al., 2000), ontologies have become an accepted method in 
bioinformatics with which to describe experimental tissue sources and gene 
expression data.  Table 1 lists the 26 anatomical ontologies available from the 
Open Biomedical Ontology (OBO) Foundry (Smith et al., 2007) as of August 
2009.  The OBO Foundry provides a library of reference ontologies for the 
biomedical domain.  Strict requirements need to be met for an ontology to be 
endorsed by the OBO Foundry such as providing a definition for every term 
within the ontology.  Since the implementation of the OBO requirements, the  
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Table 1  
A list of ontologies available from the Open Biomedical Ontologies (OBO) 
Foundry.  The eVOC ontology is not officially distributed via the OBO 
foundry, but is included here to give context.   
Ontology Namespace 
Common Anatomy Reference Ontology  CARO 
Subcellular anatomy ontology  SAO 
Teleost anatomy and development  TAO 
C. elegans gross anatomy  WBbt 
Spider Ontology  SPD 
Mouse adult gross anatomy  MA 
Mouse gross anatomy and development  EMAP 
Amphibian gross anatomy  AAO 
Drosophila gross anatomy  FBbt 
Fungal gross anatomy  FAO 
Cellular component  GO 
Xenopus anatomy and development  XAO 
Plant growth and developmental stage  PO 
Plant structure  PO 
Spatial Ontology  BSPO 
C. elegans development  WBls 
Mosquito gross anatomy  TGMA 
Drosophila development  FBdv 
Human developmental anatomy, timed version  EHDA 
Dictyostelium discoideum anatomy  DDANAT 
Zebrafish anatomy and development  ZFA 
Tick gross anatomy  TADS 
Foundational Model of Anatomy (subset)  FMA 
Medaka fish anatomy and development  MFO 
Cell type  CL 
Human developmental anatomy, abstract version  EHDAA 
  
eVOC Expression vocabulary  eVOC 
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eVOC ontology is no longer part of the OBO distribution as it does not provide 
definitions for all its terms.  It is an important aim of the project to be included in 
the OBO distribution and further curation of the ontologies will ensure this.  
An ontology is a hierarchical vocabulary used to describe a particular domain, and 
consists of parent and child terms defined by relationships between them.  The 
most well-known ontology is the Gene Ontology (Ashburner et al., 2000) which 
describes three domains: the cellular component, molecular function and 
biological process of an organism. Ontologies are used by most database systems 
where a user is able to select a search term from a drop-down menu to select, for 
example the FANTOM3 CAGE Basic Viewer where the user selects the tissue for 
which expression information is required (http://fantom3.gsc.riken.jp/). 
The problem with ontologies is the inability to adequately compare human and 
mouse gene expression events computationally through ontologies due to their 
individual structures and inherent complexities.  An effective tool to enable the 
ontological comparison between human and mouse will enable the direct inter-
species comparison of gene expression events, providing insight into the 
differences and similarities between the species – an integral aspect of model 
organism biology.   
Model organisms are an important part of biological research because they allow 
researchers to perform experiments that would be either unethical or fatal if 
performed on humans.  For example, it is considered unethical to genetically 
modify a human embryo by creating a knock-out of a particular gene purely to 
determine a possible function for that gene.  Model organisms therefore allow us 
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to study genes in vivo, they allow us to test experimental drugs for efficacy and 
lethality, and they enable us to explore gene expression events throughout the life-
span of the organism since its gestation and developmental periods are typically 
on a scale of days and weeks rather than months and years.  The laboratory mouse 
is a particularly good model for studying cancer because mice have a high tumour 
incidence, are cheap and easy to handle, can be inbred to eliminate genetic 
variation effects, and many may be treated at a time to provide replicate data.  
However, in order for model organism experiments to be informative, it is 
imperative that we know and understand the similarities and differences between 
the models and humans.  A robust system for comparing human and mouse 
biology and expression data is therefore critical.   
This dissertation describes the development and implementation of an ontology-
based system as a consistent approach to gene discovery.  The processes required 
to successfully develop and apply a set of ontologies are to: 
1) develop a set of ontologies; 
2) map data to the ontologies by using them to annotate expression data; 
and 
3) query the system to answer specific questions regarding the data. 
Chapter 1 describes the development of a mouse ontology that conforms to the 
structure of an established human ontology to provide a tool to compare 
biological aspects of the two species.  Both the mouse and human ontologies are 
also further developed to include the ontological representation of the developing 
mouse and human, enabling the alignment of mouse and human anatomical 
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structures for the annotation of expression events.  In addition to developing the 
ontologies, this chapter also describes using the ontologies to annotate 8 852 
human and 1 210 mouse cDNA libraries obtained from the Cancer Genome 
Anatomy Project (CGAP) as an initial dataset with which to illustrate the use of 
the ontologies. 
The remaining two chapters describe how the ontologies developed in Chapter 1 
are used in two major collaborations.  Both chapters describe two aspects of each 
collaboration, namely a publication resulting from the collaborative efforts of all 
the members of the collaboration and an independent study I performed within 
each collaboration that is unpublished.  I therefore, for each chapter, briefly 
describe my role in the collaboration and the work I performed that resulted in the 
publications, and thereafter describe in detail the unpublished analyses.  
Chapter 2 describes how the ontologies developed in Chapter 1 are used to 
determine the expression profile of human transcription factors.  The investigation 
of the expression profile enables the identification of transcription factor 
complexes that show tissue-restricted expression patterns. 
The analysis presented as Chapter 3 uses the ontologies described in Chapter 1 to 
explore the expression profile of the mouse orthologs of human cancer/testis 
genes with the aim of comparing the human and mouse expression profiles of 
these genes.   
 
 
 
 
 
 
  
Chapter 1 
Simplified ontologies allowing comparison of 
developmental mammalian gene expression 
1.1 Summary 
The concept of creating a developmental mouse ontology that is structured in the 
same way as the existing human eVOC ontologies was suggested as a viable 
approach while establishing a collaboration as part of the FANTOM consortium - 
a collaborative effort by many international laboratories with the aim to map out 
the transcriptional landscape of mouse and human.  I was responsible for 
developing and applying the method of ontology generation for both the mouse 
and human developmental ontologies.  I was also responsible for collecting and 
annotating the mouse and human CGAP cDNA libraries that have been mapped to 
the ontologies, as well as the data provided by the FANTOM3 project.  The 
ontologies that I developed, along with the FANTOM data that I mapped to it, 
were incorporated into the FANTOM CAGE databases (CAGE Basic Viewer and 
CAGE Analysis Viewer) available online (http://fantom3.gsc.riken.jp/).   
The FANTOM3 project culminated in a main publication in Science (of which I 
was co-author (Carninci et al., 2005)) as well as many satellite papers in PLoS 
Genetics – including a paper which I co-authored (Bajic et al., 2006).  For ‘The 
transcriptional landscape of the mammalian genome’ published in Science 
(Appendix I), I was responsible for the development of the ontologies which were 
1
 
 
 
 
  
used to annotate the expression data used in the paper.  In the PLoS Genetics 
paper, ‘Mice and men: their promoter properties’ (Appendix II), the aim was to 
classify transcription start sites (TSS) based on the GC content of the 5’ upstream 
region of each gene.  I used the ontology system described in this chapter to 
provide the expression information for the dataset used in the paper, which shows 
enrichment of certain tissue categories in each of the four TSS categories 
identified (Table 6 of Appendix II).  The methods and results for both analyses are 
described in detail in the publications appended.   
In addition to developing the ontologies, I was responsible for preparing the 
manuscript describing the development and application of these ontologies, which 
is presented here as Chapter 1.  My responsibilities included the development of 
the manuscript concept, all data generation and analysis, as well as the preparation 
and submission of the manuscript. 
Dr Yoshihide Hayashizaki and Dr Piero Carninci provided the request of the 
developmental ontologies as well as access to the FANTOM3 data.  Dr Oliver 
Hofmann and Dr Winston Hide provided guidance regarding ontology 
development and application, and oversaw the production of the manuscript. 
 
1.2 Aim 
The aim of the work presented in this chapter is to develop an ontology system 
that enables the comparison of human and mouse anatomy throughout 
development.  The use of the ontologies in the annotation of human and mouse 
2
 
 
 
 
  
gene expression data provides a means to accurately compare gene expression 
between human and mouse, thereby identifying similar and unique gene 
expression patterns between the two species. 
 
1.3 Background 
1.3.1 Ontologies and gene expression 
Biological investigation into mammalian biology employs standardized methods 
of data annotation by consortia such as MGED (Microarray Gene Expression Data 
Society) and CGAP (Cancer Genome Anatomy Project) or collaborative groups 
such as the Genome Network Project group at the Genome Sciences Centre at 
RIKEN, Japan (http://gsc.riken.go.jp/indexE.html).  Data generated by these 
consortia include microarray, CAGE (Cap Analysis of Gene Expression), SAGE 
(Serial Analysis of Gene Expression) and MPSS (Massively Parallel Signature 
Sequencing) as well as cDNA and EST (Expressed Sequence Tags) libraries. The 
diversity of data types offers the opportunity to capture several views on 
concurrent biological events, but without standardization between these platforms 
and data types information is lost, reducing the value of comparison between 
systems.  The terminology used to describe data provides a means for the 
integration of different data types such as EST or CAGE. 
An ontology is a commonly used method of standardization in biology. It is often 
defined as a formal description of entities and the relationships between them, 
providing a standard vocabulary for the description and representation of terms in 
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a particular domain (Bard and Winter, 2001; Gkoutos et al., 2005).  Given a need 
and obvious value in comparison of gene expression between species, anatomical 
systems and developmental states, we have set out to discover the potential and 
applicability of such an approach to compare mouse and human systems. 
Many anatomical and developmental ontologies have been created, each focusing 
on their intended organisms.  As many as 62 ontologies describing biological and 
medical aspects of a range of organisms can be obtained from the Open 
Biomedical Ontologies (OBO) website (http://www.obofoundry.org/), a system 
set up to provide well-structured controlled vocabularies of different domains in a 
single website.  The Edinburgh Mouse Atlas Project (EMAP) (Baldock et al., 
2003) and Adult Mouse Anatomy (MA) (Hayamizu et al., 2005) ontologies are 
the most commonly used ontologies to describe mouse gene expression, 
representing mouse development and adult mouse with 13 730 (October, 2005) 
and 7 702 (October, 2004) terms respectively.  Mouse Genome Informatics 
(MGI), the most comprehensive mouse resource available, uses both ontologies.  
Human gene expression however, can be represented as developmental and adult 
ontologies by the Edinburgh Human Developmental Anatomy (HUMAT) 
ontology (Hunter et al., 2003) consisting of 8 316 terms (October, 2005) and the 
mammalian Foundational Model of Anatomy (FMA) (Rosse and Mejino, 2003) 
consisting of more than 110 000 terms (January, 2002).  Selected terms from the 
above ontologies have been used to create a cross-species list of terms known as 
the SOFG Anatomy Entry List (SAEL) (Parkinson et al., 2004).  Although these 
ontologies more than adequately describe the anatomical structures of the 
developing organism, with the exception of SAEL, they are structured as Directed 
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Acyclic Graphs (DAG), defined as a hierarchy where each term may have more 
than one parent term (Hayamizu et al., 2005).  The DAG structure adds to the 
inherent complexity of the ontologies, hampering efforts to align them between 
two species, making the process of a comparative study of gene expression events 
a challenge.  
Efforts are being implemented in order to simplify ontologies for gene expression 
annotation.  The Gene Ontology (GO) Consortium’s GO slim (Martin et al., 2004) 
contains less than 1% of terms in the GO ontologies.  GO slim is intended to 
provide a broad categorization of cDNA libraries or microarray data when the 
fine-grained resolution of the original GO ontologies are not required.  Another 
set of simplified ontologies are those from eVOC (Kelso et al., 2003).  The core 
eVOC ontologies consist of four orthogonal ontologies with a strict hierarchical 
structure to describe human anatomy, histology, development and pathology, 
currently consisting of 512, 180, 156 and 191 terms respectively (August, 2006).  
The aim of the eVOC project is to provide a standardized, simplified 
representation of gene expression, unifying different types of gene expression data 
and increasing the power of gene expression queries.  The simplified 
representation achieved by the eVOC ontologies is due to the implementation of 
multiple orthogonal ontologies with a lower level of granularity than it’s 
counterparts.  
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1.3.2 Mammalian development 
The laboratory mouse is being used as a model organism to study the biology of 
mammals (Marra et al., 1999).  The expectation is that these studies will provide 
insight into the developmental and disease biology of humans, coloured by the 
finding that 99% of the 25 000 – 30 000 mouse genes may have a human ortholog 
(only 1% of mouse genes do not have a human ortholog) and at least 80% of 
mouse genes are 1:1 orthologs where the mouse sequence is the best match to the 
human sequence and vice versa (Waterston et al., 2002).  Given the similarity 
between the two species, it is possible to perform functional experiments on 
mouse and transfer any knowledge obtained to enhance our understanding of 
human biology.  In addition, cDNA libraries can be prepared from very early 
mouse developmental stages for gene expression analysis. 
The study of developmental biology incorporates the identification of both the 
temporal and spatial expression patterns of genes expressed in the embryo and 
fetus (Magdaleno et al., 2006).  It is important to understand developmental gene 
expression because many genetic disorders originate during this period (Lindsay 
and Copp, 2005).  Similarities in behavior and expression profiles between cancer 
cells and embryonic stem cells (Kho et al., 2004) also fuel the need to investigate 
developmental biology. 
Using mice as model organisms in research requires the need for comparison of 
resulting data and provides a means to compare mouse data to humans (Lindsay 
and Copp, 2005).  The cross-species comparison of human and mouse gene 
expression data can highlight fundamental differences between the two species 
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such as greater olfactory and immune capabilities, impacting on areas as diverse 
as the effectiveness of therapeutic strategies in the treatment of cystic fibrosis or 
Alzheimer’s to the elucidation of the components such as tail, fur and whiskers 
that determine species.  Using ontology-annotated gene expression events to 
compare across species provides a structured and accurate means of identifying 
identical gene expression context between the species, particularly if the 
annotation of each species differs in granularity.  
 
1.3.3 Cross-species gene expression comparison 
Function of most human genes has been inferred from model organism studies, 
based on the transitive assumption that genes sharing sequence similarity also 
share function when conserved across species (Zhou and Gibson, 2004).  The 
same principle can be applied to gene regulation.  The first step is to find not only 
the orthologs, but the commonly expressed orthologs.  We predict that although 
two genes are orthologous between human and mouse, their expression patterns 
differ on the temporal and spatial level, indicating that their regulation may differ 
between the two species.   
The terminology currently used to annotate human and mouse gene expression 
can be ambiguous (Eilbeck et al., 2005) among species since one term may be 
used to describe many different structures or one structure may be defined by 
more than one term, which is a result of different ontologies being used to 
annotate different species.  The way in which we circumvented this issue is to 
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effectively map the ontology terms across species by using the same terminology 
for each species.  This adaptation allows the integration of human and mouse 
ontologies as well as the comparison of the data it is used to annotate – a feature 
not possible with current ontologies.  Although the EMAP, MA, HUMAT and 
FMA ontologies describe the anatomical structures throughout the development of 
the mouse and human, their complexities complicate the alignment of the 
anatomy between the two species.  With the alignment of terms between a mouse 
and human ontology, the data mapped to each term becomes comparable, 
allowing efficient and accurate comparison of mammalian gene expression.  A 
SAEL-related project, XSPAN (Dennis et al., 2003), is aimed at providing a web 
tool to enable users to find equivalent terms between ontologies of different 
species.  Although useful, the ontologies used describe only spatial anatomy and 
are not temporal. 
We have attempted to address the issue by developing simplified ontologies that 
allow the comparison of gene expression between human and mouse on a 
temporal and spatial level.  The distribution of human and mouse anatomy terms 
across development match the structure of the human adult ontologies that form 
the core of the eVOC system.   
Due to the ambiguous annotation of current gene expression data between human 
and mouse, and the lack of data mappings accompanying the available ontologies, 
the ontologies presented here have been developed in concert with semi-automatic 
mapping and curation of 8 852 human and 1 210 mouse cDNA libraries.  We have 
therefore created a resource of simplified, standardized gene expression enabling 
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cross-species comparison of gene expression between mammalian species that is 
publicly available.  
 
1.4 Materials and methods 
1.4.1 Ontology development 
The ontologies were constructed using the COBrA (Aitken et al., 2005) and 
DAG-edit (http://www.geneontology.org/GO.tools.shtml#dagedit) ontology 
editors.  Each term has a unique accession identifier with ‘EVM’ as the 
namespace for mouse and ‘EV’ for human, followed by seven numbers.  This is 
consistent with the rules defined by the GO consortium (Ashburner et al., 2000). 
Using the human adult eVOC anatomical system ontology as a template, terms 
from the Theiler stage 26 (mouse developmental stage immediately prior to birth) 
section of the EMAP ontology were inserted to create the Theiler stage 26 
developmental eVOC mouse ontology.  Proceeding from Theiler stage 26 to 
Theiler stage 1, each stage was used as a template for the next stage and any term 
not occurring at that specific stage, using EMAP as reference, was removed. 
Similarly, if a term occurred in EMAP that was not present in the previous stage, 
it was added to the ontology.  The result is a set of 26 ontologies, one for each 
Theiler stage of mouse development, with many terms appearing and disappearing 
throughout the ontologies according to changes of anatomy during mouse 
development. 
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The Theiler stage 28 (adult mouse) ontology was constructed in the same way as 
the developmental ontologies, using the MA ontology as a reference.  A 
previously not available Theiler stage 27 ontology was developed by comparing 
Theiler stage 26 and Theiler stage 28.  Any terms that differed between the two 
stages were manually curated and included or removed in Theiler stage 27 as 
needed.  The Theiler stage 27 ontology therefore represents all immature, post-
natal anatomical structures.  Theiler stage 28 ontology terms have been mapped to 
the adult human eVOC terms by using the human eVOC accession identifiers as 
database cross-references in the mouse ontology.  Similarly, the EMAP accession 
number for each term was mapped to the developmental mouse ontologies.  The 
result is a set of 28 ontologies that are an untangled form of the EMAP and MA 
ontologies, with mappings between them. 
A set of human developmental ontologies were created by using the same method 
as was used for mouse.  The reference ontologies for human development were 
the HUMAT ontologies, which describes the first 23 Carnegie stages of 
development, classified according to morphological characteristics. 
The 28 mouse and 23 human ontologies were merged into two ontologies – one 
for mouse and one for human.  Each merged ontology (named Mouse 
Development and Human Development) contains all terms present in the 
individual ontologies.  A Theiler Stage ontology was created for mouse, which 
contains all 28 Theiler stages categorized into embryo, fetus or adult.  The 
existing eVOC Development Stage ontology serves as the human equivalent of 
the mouse Theiler Stage ontology.  The Mouse Development, Human 
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Development, Theiler Stage and the existing Development Stage ontologies form 
the core of the Developmental eVOC ontologies. 
 
1.4.2 Data mapping 
Mouse and human cDNA libraries were obtained from the publicly available 
CGAP resource (January, 2006) and mapped (semi-automated) to the entire set of 
eVOC ontologies.  The eVOC ontologies consist of Anatomical System, Cell 
Type, Developmental Stage, Pathology, Associated With, Treatment, Tissue 
Preparation, Experimental Technique, Pooling and Microarray Platform.  The 
‘age’ annotation of the mouse CGAP libraries were manually checked against the 
Gene Expression Database (version 3.41; December, 2005) (Hill et al., 2004) to 
determine the Theiler stage of each library.  Due to the lack of a resource 
providing the Carnegie stage annotation for cDNA libraries, the human cDNA 
libraries were annotated according to the age annotation originally provided by 
CGAP.  Genes associated with each mouse and human cDNA library were 
obtained from NCBI’s UniGene (March, 2006) 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene).  A list of human-
mouse orthologs were obtained from HomoloGene (build 53) 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=homologene). 
 
 
11
 
 
 
 
  
1.4.3 Data mining 
The genes were filtered according to the presence or absence of expression 
evidence and homology.  A gene passed the selection criteria if it has an ortholog 
and if both genes in the ortholog pair have eVOC-annotated expression.  
According to eVOC annotation, genes were categorized into those that showed 
expression in normal adult brain and those expressed in normal developmental 
brain, many genes appearing in more than one category.  Genes expressed in 
normal adult brain were subtracted from those with expression in normal 
developmental brain to establish genes whose expression in the brain occurs only 
during development.  The expression profiles of the developmentally-biased 
genes annotated to female reproductive system, heart, kidney, liver, lung, male 
reproductive system and stem cell for post-natal and developmental expression 
were determined according to the eVOC annotation of the cDNA libraries, and the 
correlation coefficient of the ortholog-pairs were calculated. 
 
1.5 Results and discussion 
1.5.1 Ontology development 
The ontologies were originally created to accommodate requests by the 
FANTOM3 consortium (Carninci et al., 2005) for a simple mouse ontology that 
could be used in alignment to the human eVOC ontologies.  The FANTOM3 
project was a collaborative effort by many international laboratories to analyze the 
mouse and human transcriptome.  The aim was to generate a transcriptional 
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landscape of the mouse genome that lead to the evolutionary and comparative 
developmental analysis in mammals.  The ontologies presented here provided the 
FANTOM3 consortium with a platform to compare the human and mouse 
transcriptome in the context of mammalian development. 
Shared structure between the ontologies ensures effective interoperability on the 
developmental and species level.  The importance of shared structure between two 
ontologies becomes apparent when attempting to align them for comparison.  If 
two terms in an ontology are mapped to each other, ontology rules infer that the 
children terms in each of the ontologies share the same characteristics.  For 
example, if gene X is mapped to ‘heart’ in a human ontology and gene Y is 
mapped to ‘cardiovascular system’ in mouse, we can infer that because 
‘cardiovascular system’ is the parent of ‘heart’ in both ontologies, gene X and 
gene Y have an association with respect to their expression in the cardiovascular 
system although their annotations are not identical.  This is especially important 
when the granularity of annotation in one species is different to that of another. 
Terms from the EMAP, MA and HUMAT ontologies have been used to create 28 
mouse and 23 human ontologies, representing the 28 Theiler stages and 23 
Carnegie stages of mouse and human development, respectively.  The 28 Theiler 
stages represent mouse embryonic, fetal and adult anatomical development, 
whereas the 23 Carnegie stages only represents human embryonic development.  
Human adult is represented by the Anatomical System ontology of the eVOC 
system, upon which the other ontologies are based.  The terms from the source 
ontologies (EMAP, MA and HUMAT) have been mapped to the equivalent term 
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in the developmental eVOC ontologies to ensure interoperability between external 
ontologies and eVOC.  Terms from the mouse have also been mapped to those 
from human to enable cross-species comparison of the data mapped.  
The integration of the ontologies is described in Figure 1, where ‘Mouse eVOC’ 
refers to the individual mouse ontologies and ‘Human eVOC’ refers to the 
individual human ontologies (including the adult human ontology).  The EMAP 
and MA ontologies represent mouse pre- and post-natal developmental anatomical 
structures, respectively, and therefore exhibit no commonality.  The mouse 
developmental eVOC ontologies integrate the two ontologies by containing terms 
from, and mappings to, both the EMAP and MA ontologies.  Of the 2 840 terms 
in the individual mouse ontologies, 1 893 and 237 map to EMAP and MA.  The 
human developmental eVOC ontology is an untangled version of the HUMAT 
ontology and has one-to-one mappings to the mouse developmental ontology, 
providing a link between the terms and data mappings between the mouse and 
human ontologies. 
The presence of species-specific anatomical structures posed a challenge when 
aligning the mouse and human terms.  An obvious example is the presence of a 
tail in mouse but not in human.  We decided that there would simply be no 
mapping between the two terms.  Further challenges involved structures such as 
paw and hand.  The two terms cannot be made identical because it is incorrect to 
refer to the anterior appendage of a mouse as a hand.  However, due to the fact 
that the mouse paw and human hand share functional similarities, the two terms 
are not identical, but are mapped to each other based on functional equivalence. 
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Figure 1 
Venn diagram illustrating the integration of mouse and human ontologies 
represented by the eVOC system.  The total number of terms in each 
ontology is in parentheses.  The numbers in each set are the number of terms 
in the intersection represented by that set.  'Mouse eVOC' represents the 28 
individual mouse ontologies and 'Human eVOC' represents the 23 individual 
human and adult ontologies; therefore, the numbers in parentheses refer to 
the total number of terms in all the eVOC ontologies for each species.  The 
intersection of the Mouse eVOC with the EMAP and MA ontologies 
represents the number of terms in Mouse eVOC that have database cross-
references to EMAP and MA.  Similarly, the intersection of the Human 
eVOC and HUMAT sets represents the number of Human eVOC terms that 
map to HUMAT terms.  The number within the arrows represents the 
number of mapped human and mouse eVOC terms. 
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In order to provide simplified ontologies, the 28 mouse and 23 human ontologies 
were merged to create two ontologies – one for each species.  In addition, a 
Theiler Stage ontology was created that represents the Theiler stages of mouse 
development.  The human stage ontology is represented by the current eVOC 
Development Stage.  A cross-product of two terms (one from the merged and one 
from the stage ontology) for a species can therefore represent any anatomical 
structure at any stage of development.   
The relationship between the Developmental Mouse and individual ontologies is 
illustrated in Figure 2, where the term ‘brain’ is mapped to 12 terms in the 
individual ontologies and therefore occurs in 12 of the 28 Theiler stages. All 
terms in the individual ontologies that are derived from EMAP or MA for mouse, 
and HUMAT for human are mapped to the corresponding term by adding the 
term’s accession from the external ontology as a database cross-reference in the 
eVOC ontologies. Figure 3 shows that the database cross-reference is the 
accession of the EMAP term, indicating that ‘intestine’ of the ‘Theiler stage 13’ 
ontology is equivalent to the term represented by ‘EMAP:600’.  This feature 
allows cross-communication, and thereby integration, of the EMAP, MA, 
HUMAT and eVOC ontologies.   
The ontologies presented here are simplified versions of existing human and 
mouse developmental and adult ontologies, containing 1 670 and 2 840 terms 
respectively.  Table 1 shows the number of terms and database cross-references 
for the individual mouse and human ontologies.  The Theiler Stage 4 ontology 
contains 12 terms and has 9 mappings to the EMAP ontology.  The mouse and 
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Figure 2 
Screenshot of the Mouse Development ontology, visualised in COBrA.  The left panel shows the hierarchy of the ontology, with 
'brain' as the highlighted term.  The right panel lists the 12 database cross-references mapped to 'brain', representing the accession 
of 'brain' in each of the 12 individual ontologies. 
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Figure 3 
Screenshot of the individual Theiler Stage 13 ontology, visualised in COBrA.  The left panel displays the ontology with terms of 
anatomical structures occurring only in Theiler stage 13 of mouse development.  The right panel lists the accession of the 
equivalent term in the external ontology as a database cross-reference. 
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Table 1  
Statistics of the individual developmental eVOC ontologies, representing the 
alignment between human and mouse stages.  The first three columns display 
the individual mouse ontologies, the number of terms in each ontology, and 
the number of external references of each.  The last three columns display 
the individual human ontologies, the number of terms, and the number of 
external references of each.  The external references refer to the EMAP and 
MA ontologies for mouse, and to HUMAT for human.  The alignment of the 
rows between the mouse and human ontologies represents the alignment of 
the Theiler and Carnegie stages of development based on morphological 
similarities.  For example, the Theiler Stage 4 ontology contains 12 terms and 
has 9 mappings to the EMAP ontology.  Mouse Theiler Stage 4 is equivalent 
to human Carnegie Stage 3.  The Carnegie Stage 3 ontology contains 13 
terms and has 11 mappings to terms from the HUMAT ontology. 
Theiler 
Stage 
Mouse 
Terms 
External 
Reference 
Carnegie 
Stage 
Human 
Terms 
External 
Reference 
1 6 4 1 5 4 
2 5 3 2 5 4 
3 6 4    
4 12 9 3 13 11 
5 9 6    
6 10 7 4 10 8 
7 11 9    
8 12 10 5a 10 8 
   5b 11 10 
   5c 9 8 
9 14 14 6a 14 16 
   6b 19 18 
10 14 18 7 20 17 
11 32 29 8 22 19 
12 56 63 9 52 54 
13 55 64 10 60 80 
14 67 85 11 72 92 
15 80 109 12 80 98 
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Theiler 
Stage 
Mouse 
Terms 
External 
Reference 
Carnegie 
Stage 
Human 
Terms 
External 
Reference 
16 93 128 13 103 131 
17 103 137 14 122 149 
18 116 155 15 131 165 
19 134 173 16 155 178 
20 157 171 17 170 184 
21 193 239 18 188 223 
   19 199 237 
22 209 299 20 200 237 
23 216 303    
24 226 316    
25 234 339    
26 238 348    
27 266 0    
28 266 246 adult 512  
TOTAL 2840 3288 TOTAL 2049 1951 
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human stages have been aligned in the table and therefore shows that mouse 
Theiler Stage 4 is equivalent to human Carnegie Stage 3, based on morphological 
similarities during development (http://www.ana.ed.ac.uk/anatomy/database/ 
humat/MouseComp.html).  The Carnegie Stage 3 ontology contains 13 terms and 
has 11 mappings to the HUMAT ontology.  The difference in the number of 
ontology terms and external references is attributed to the addition of terms to 
maintain the standard structure of the eVOC system.  In this example, the term 
‘germ layers’ is in the eVOC ontologies, but not in the EMAP or HUMAT 
ontologies.  Many eVOC terms are mapped to more than one term in the external 
referencing ontology as an artifact of the simplification of the ontologies, 
resulting in a one-to-many relationship between eVOC and it’s reference 
ontology.  For example, ‘myocardium’ at Theiler Stage 12 in the eVOC 
ontologies is mapped to five EMAP identifiers.  Each EMAP identifier references 
a cardiac muscle, but at a different location.  eVOC does not distinguish between 
cardiac muscle of the common atrial chamber (EMAP:337) and cardiac muscle of 
the rostral half of the bulbus cordis (EMAP:330).  Compared to their counterparts, 
the Developmental eVOC ontologies represent 22% of both the human HUMAT 
and mouse EMAP ontologies, with the only relationship between the terms being 
‘IS_A’.  Note that relationships within the eVOC ontologies only indicate an 
association between parent and child term and do not systematically distinguish 
between is_a or part_of relationships. As eVOC moves to adopt relationship types 
from the OBO Relation Ontology (Smith et al., 2005) relations will be reviewed 
and curated.  Using a principle of data-driven development, eVOC terms are 
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added at an annotator’s request, resulting in a dynamic vocabulary describing 
gene expression. 
 
1.5.2 Data mapping 
The resources providing ontologies to annotate gene expression do not always 
provide the data itself.  In order to obtain mouse and human data, one would have 
to search separate databases for each species.  An example of this would be 
searching MGI for mouse gene expression data, and ArrayExpress for human.  
Apart form having to access different databases to obtain data, the terminology 
used to describe the data is ambiguous and differs in the level of granularity, 
impacting on the accuracy of inter-species data comparison.  The ontology terms 
have therefore been used to annotate 8 852 human and 1 210 mouse cDNA 
libraries from the Cancer Genome Anatomy Project (CGAP) (January, 2006) 
(http://cgap.nci.nih.gov/).   
The mapping process revealed inconsistencies in the annotation of the human and 
mouse CGAP cDNA libraries, requiring manual intervention and emphasizing the 
need for a standardized annotation.  All genes associated with the libraries have 
been extracted by association through UniGene (March, 2006).  A gene was 
considered to be associated with a cDNA library if at least one EST was evident 
for the gene in a particular library.  The result is a set of 21 152 human and 24 047 
mouse genes from UniGene that are represented by CGAP cDNA libraries and 
annotated with eVOC terms, and represent the set of human and mouse genes for 
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which there is expression evidence.  CGAP represents an ascertainment bias 
where there is a strong over-representation for cancer genes, and therefore future 
efforts for this research will include obtaining a well-represented, evenly 
distributed dataset of human and mouse gene expression.  The list of human and 
mouse orthologs were extracted from HomoloGene to represent the 16 324 
human-mouse orthologs.  Two genes were considered to be orthologs if they 
shared the same HomoloGene group identifier (March, 2006). 
 
1.5.3 Data mining 
Genes may be categorized according to their eVOC annotation on a spatial or 
temporal level, or a combination of both.  An example of this would be genes 
expressed in the heart at Theiler Stage 26 for mouse.  For the purposes of this 
study, we searched for human-mouse orthologs that are expressed in the normal 
postnatal and developmental brain of both species, where a gene is classified as 
normal if it’s originating library was annotated as ‘normal’.  Research involving 
gene expression of the brain aims at identifying causes of psychological and 
neurological diseases, many of these diseases originating during development.  
With the use of mice as model organisms in this kind of research, it is important 
to identify genes which are co-expressed in human and mouse on the temporal 
and spatial level.  The results of our analysis show that of the available 16 324 
human-mouse orthologs, 14 434 can be found in CGAP libraries for both human 
and mouse.  When looking at brain gene expression, we could segregate genes 
according to their spatial and temporal expression patterns.  We found that of all 
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the orthologs expressed in the brain, 10 980 genes were expressed in the post-
natal brain of both species whereas 1 692 genes were expressed in the developing 
brain of both species.  Of these two sets of genes, 90 genes were found to have 
biased expression for developmental brain (Table 2) where developmentally 
biased genes are those that are expressed during development and not the post-
natal organism in either human, mouse or both species (see Figure 4 for 
illustration).  It is important to note that only genes whose orthologs also have 
expression evidence were considered for analysis.  This small number of genes 
found to be biased for expression during brain development in both species may 
be a result of data-bias due to the difficulty involved in accessing developmental 
libraries.  Our future efforts will include expanding the data platforms to provide 
data that is representative of the biology.  This analysis does however demonstrate 
the usefulness of the ontologies in performing cross-species gene expression 
analyses. 
The Gene Ontology (GO) categories that are highly associated with the 90 genes 
biased for developmental brain expression were extracted with the use of the 
DAVID bioinformatics resource (Dennis et al., 2003).  The human representatives 
of the human-mouse orthologs cluster with GO terms such as ‘nervous system 
development’ and ‘cell differentiation’, suggesting a shared role for development 
of the mammalian brain, and therefore may be potential targets for the analysis in 
neurological diseases.  Given the existence of ascertainment bias on these kinds of 
data, it was still surprising to see how many genes passed the stringent selection 
criteria.  Searching the Online Mendelian Inheritance of Man (OMIM) database 
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Figure 4 
Diagram illustrating the sets of genes analysed for developmental brain 
expression bias.  Genes for human and mouse grouped together if they are 
expressed in post-natal or developmental brain, respectively.  The 
intersection between the human and mouse developmental brain genes 
represent those genes showing common expression in the two species.  
Subtracting genes commonly expressed in human and mouse post-natal brain 
determines those genes that show developmental restriction in either human, 
mouse or both species.  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Table 2   
Genes showing developmental expression bias in human and mouse brain.  
The table lists the HomoloGene group identifier, Entrez Gene identifier and 
gene symbol of the 90 human-mouse orthologs found to have an expression 
bias towards the embryonic and fetal stages of brain development, without 
expression during postnatal development.  Genes were only considered for 
analysis if they have an ortholog, and if the ortholog also has expression 
evidence based on eVOC annotation. 
HomoloGene 
group identifier 
Human 
Entrez 
Gene ID 
Human Entrez Gene 
Symbol 
Mouse 
Entrez Gene 
ID 
Mouse Entrez Gene 
Symbol 
32 435 ASL 109900 Asl 
268 5805 PTS 19286 Pts 
413 353 APRT 11821 Aprt 
1028 1606 DGKA 13139 Dgka 
1290 9275 BCL7B 12054 Bcl7b 
1330 857 CAV1 12389 Cav1 
1368 1054 CEBPG 12611 Cebpg 
1871 4760 NEUROD1 18012 Neurod1 
1933 5050 PAFAH1B3 18476 Pafah1b3 
2212 6182 MRPL12 56282 Mrpl12 
2593 7913 DEK 110052 Dek 
2880 8835 SOCS2 216233 Socs2 
3476 9197 SLC33A1 11416 Slc33a1 
4397 8971 H1FX 243529 H1fx 
4983 10991 SLC38A3 76257 Slc38a3 
6535 11062 DUS4L 71916 Dus4l 
7199 11054 OGFR 72075 Ogfr 
7291 10683 DLL3 13389 Dll3 
7500 5806 PTX3 19288 Ptx3 
7516 389075 RESP18 19711 Resp18 
7667 1154 CISH 12700 Cish 
7717 24147 FJX1 14221 Fjx1 
7922 6150 MRPL23 19935 Mrpl23 
9120 25851 DKFZP434B0335 70381 2210010N04Rik 
9355 51637 C14orf166 68045 2700060E02Rik 
9813 55627 FLJ20297 77626 4122402O22Rik 
10026 55172 C14orf104 109065 1110034A24Rik 
10494 58516 FAM60A 56306 Tera 
10518 84273 C4orf14 56412 2610024G14Rik 
10663 57171 DOLPP1 57170 Dolpp1 
10695 57120 GOPC 94221 Gopc 
10774 57045 TWSG1 65960 Twsg1 
11653 79730 FLJ14001 70918 4921525L17Rik 
11920 84303 CHCHD6 66098 Chchd6 
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HomoloGene 
group identifier 
Human 
Entrez 
Gene ID 
Human Entrez Gene 
Symbol 
Mouse 
Entrez Gene 
ID 
Mouse Entrez Gene 
Symbol 
11980 84262 MGC10911 66506 1810042K04Rik 
12021 84557 MAP1LC3A 66734 Map1lc3a 
12418 124056 NOXO1 71893 Noxo1 
12444 84902 FLJ14640 72140 2610507L03Rik 
12993 84217 ZMYND12 332934 Zmynd12 
14128 91107 TRIM47 217333 Trim47 
14157 90416 CCDC32 269336 Ccdc32 
14180 115294 PCMTD1 319263 Pcmtd1 
14667 113510 HEL308 191578 Hel308 
15843 79591 C10orf76 71617 9130011E15Rik 
16890 399664 RKHD1 237400 Rkhd1 
17078 387914 TMEM46 219134 Tmem46 
17523 115290 FBXO17 50760 Fbxo17 
18123 140730 RIMS4 241770 Rims4 
18833 143678 LOC143678 75641 1700029I15Rik 
18903 440193 KIAA1509 68339 0610010D24Rik 
19028 146167 LOC146167 234788 Gm587 
20549 4324 MMP15 17388 Mmp15 
21334 10912 GADD45G 23882 Gadd45g 
22818 29850 TRPM5 56843 Trpm5 
24848 266629 SEC14L3 380683 RP23-81P12.8 
26702 93109 TMEM44 224090 Tmem44 
27813 84865 FLJ14397 243510 A230058J24Rik 
31656 27000 ZRF1 22791 Dnajc2 
32293 51018 CGI-115 67223 2810430M08Rik 
32331 51776 ZAK 65964 B230120H23Rik 
32546 64410 KLHL25 207952 Klhl25 
32633 136647 C7orf11 66308 2810021B07Rik 
35002 93082 LINCR 214854 Lincr 
37917 1293 COL6A3 12835 Col6a3 
40668 9646 SH2BP1 22083 Sh2bp1 
40859 27166 PX19 66494 2610524G07Rik 
41703 118881 COMTD1 69156 Comtd1 
45198 65117 FLJ11021 208606 1500011J06Rik 
45867 139189 DGKK 331374 Dgkk 
46116 401399 LOC401399 101359 D330027H18Rik 
49899 143282 C10orf13 72514 2610306H15Rik 
49970 83879 CDCA7 66953 Cdca7 
55434 1289 COL5A1 12831 Col5a1 
55599 669 BPGM 12183 Bpgm 
55918 6882 TAF11 68776 Taf11 
56005 6328 SCN3A 20269 Scn3a 
56571 26503 SLC17A5 235504 Slc17a5 
56774 54751 FBLIM1 74202 Fblim1 
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HomoloGene 
group identifier 
Human 
Entrez 
Gene ID 
Human Entrez Gene 
Symbol 
Mouse 
Entrez Gene 
ID 
Mouse Entrez Gene 
Symbol 
64353 126374 WTIP 101543 Wtip 
65280 286128 ZFP41 22701 Zfp41 
65318 23361 ZNF629 320683 Zfp629 
65328 7559 ZNF12 231866 Zfp12 
68420 9559 VPS26A 30930 Vps26 
68934 57016 AKR1B10 14187 Akr1b8 
68973 1663 DDX11 320209 Ddx11 
68998 170302 ARX 11878 Arx 
78698 387876 LOC387876 380653 Gm872 
81871 56751 BARHL1 54422 Barhl1 
82250 150678 MYEOV2 66915 Myeov2 
84799 22835 ZFP30 22693 Zfp30 
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implicated some of the 90 genes, such as GOPC, ARX and DEK, in diseases such 
as astrocytoma, lissencephaly and leukemia. 
To assess the similarity in expression across major human and mouse tissues other 
than brain, the expression profiles of the 90 genes with bias for developmental 
expression were determined for developmental and adult expression in the 
following tissues: female reproductive system, heart, kidney, liver, lung, male 
reproductive system and stem cell.  These tissues were chosen based on the 
availability of data for each tissue in the developmental and adult categories.  For 
each ortholog-pair, we determined the correlation between their expression 
profiles (see Appendix III).  We found that, according to the cDNA libraries, one 
mouse gene was found to be expressed in all the tissues in both post-natal and 
development (Twsg1), and three mouse genes were expressed only in the mouse 
brain (Resp18, Gm872, Barhl1) as opposed to all other tissues (see Appendix IV 
for expression profile).  The highest correlation score between an ortholog-pair is 
0.646 (HomoloGene identifier: 27813) having identical expression profiles during 
development (expressed in liver and stem cell), but differing during post-natal 
expression (expression in mouse heart, kidney and stem cell but not in their 
human counterparts).  The correlations observed suggest that the expression 
profiles of orthologs across these major tissues are only partially conserved 
between human and mouse.  This finding strengthens our understanding of 
orthologous gene expression in that although two genes are orthologs, they do not 
share temporal and spatial expression patterns and therefore probably do not share 
a majority of their regulatory modules (Odom et al., 2007). 
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Developmental gene expression may be subdivided into embryonic and fetal 
expression which in turn may be categorized further according to the Theiler and 
Carnegie stages for mouse and human, allowing a high-resolution investigation of 
gene expression profiles between the two species.  This stage by-stage expression 
profile for human and mouse will allow investigation into common regulatory 
elements of co-developmentally expressed genes and give new insight into the 
characterization of the normal mammalian developmental program. 
 
1.6 Conclusions 
The developmental mouse ontologies were developed in collaboration with the 
FANTOM3 consortium to have the same structure and format as the existing 
human eVOC ontologies to enable the comparison of developmental expression 
data between human and mouse. The developmental ontologies have been 
constructed by integrating the Edinburgh Mouse Atlas Project, Mouse Anatomy, 
the developmental Human Anatomy and the human adult eVOC ontologies. The 
re-organization of existing ontological systems under a uniform format allows the 
consistent integration and querying of expression data from both human and 
mouse databases, creating a cross-species query platform with one-to-one 
mappings between terms within the human and mouse ontologies. 
The ontologies have been used to map human and mouse gene expression events, 
and can be used to identify differential gene expression profiles between the two 
species. In future, the ontologies presented here will be used to investigate the 
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transcriptional regulation of genes according to their characteristics based on 
developmental stage, tissue and pathological expression profiles, providing 
insight into the mechanisms involved in the differential regulation of genes across 
mammalian development. 
 
1.7 Availability 
The mouse eVOC ontologies, their mappings and the datasets referred to in this 
manuscript are available under a FreeBSD-style license at the eVOC website 
(http://www.evocontology.org) and are appended here as Appendix V and VI. 
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Chapter 2 
Expression profiling reveals tissue-restricted 
transcription factor complexes 
2.1 Summary 
The study presented in this chapter formed part of a major effort by the Genome 
Network Project (GNP) aimed at understanding the transcriptional networks 
involved in the growth arrest and differentiation in mammalian cells, using THP-1 
cells (Human acute monocytic leukemia cell line) as a model system.  My 
involvement in the project was two-fold: 
1. Assist in analysing the response of 1 805 transcription factors from THP-
1-derived macrophage cells to LPS stimulation over a range of time-
points; and 
2. Investigate the tissue expression profiles of 1 805 transcription factors 
under investigation. 
In (1) above, THP-1 cells were induced to differentiate into macrophages by 
adding phorbol myristate acetate (PMA).  After 96 hours, an immune response 
was induced by adding lipopolysaccharide (LPS) and the effect on transcription 
was monitored over a time-series of 0.5h, 1h, 2h, 3h, 4h, 8h, 10h, 12h, 18h and 
24h.  For each time-point, expression data was generated on three platforms: 
Illumina microarray, CAGE tags (cap analysis of gene expression) and qRT-PCR.  
I was part of the group that used the expression data from the Illumina platform to 
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determine which genes were up- and down-regulated during the early (0.5h, 1h, 
2h, 3h), middle (4h, 8h, 10h) and late (12h, 18h, 24h) response to LPS 
stimulation.  The results of this analysis formed the basis of the paper ‘The 
transcriptional network that controls growth and differentiation in a human 
myeloid leukemia cell line’ published in Nature Genetics by the GNP (Suzuki et 
al., 2009), wherein I am listed as co-author due to my involvement in the analysis.  
The publication is appended as Appendix VIIa.  My analysis method and 
interpretation that contributed to the publication is appended as Appendix VIIb.  
The analysis yielded the categorisation of 193 genes into 10 categories according 
to their level of expression across ten time-points.  The categorisation of these 
genes contributed to the identification of the regulatory motifs whose activity is 
significantly altered during PMA-induced differentiation.  In addition, the data 
and computational tools developed by the consortium members have been 
collated into an online database that allows users to give a gene as input and is 
provided with it’s expression on the three expression platforms across the time-
series (http://fantom.gsc.riken.jp/4/). 
In (2) above, I used the ontologies and mappings described in Chapter 1 to 
determine the tissue expression profiles of the list of transcription factors under 
investigation by the GNP (1 805 genes).  The list of genes for which an 
expression profile was required was provided to me by the GNP.  I was 
responsible for the development, implementation and interpretation of the 
analysis, which is presented here as Chapter 2.  The results of this analysis were 
provided to the GNP to assist in the interpretation and discussion of the results 
presented in the publication.   
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2.2 Aim 
The aim of this chapter is to use the Developmental eVOC system to illustrate the 
identification of tissue-restricted, co-expressing transcription factors.  The 
identification of co-expressing genes gives insight into the regulation of genes 
specific to a particular cell type or disease. 
 
2.3 Background 
Each gene in a cell has a spatial and temporal fate whereby it is only expressed in 
certain tissues at defined times throughout the life span of the organism.  The 
exact timing of gene expression is a tightly controlled process (Dynlacht, 1997) 
and a slight deviation in this process causes aberrant gene expression that could 
lead to disease or a cell following an inappropriate developmental path.  The 
origin of many diseases such as cancer (Liao et al., 2009), Alzheimer’s (de la 
Monte et al., 1995) and multiple sclerosis (Satoh et al., 2007) can be attributed to 
aberrant gene expression, making this process a topic of much investigation.  In 
order to understand how the uncontrolled regulation of gene expression causes 
disease, it is important to understand how normal gene expression events are 
regulated within the cell. 
Transcription factors are sequence-specific DNA-binding proteins forming the 
regulatory machinery responsible for the differential gene expression, 
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development and regulation of cellular processes in an organism.  Transcription 
factors function by binding to a promoter sequence in the upstream, untranslated 
region of a gene, allowing RNA polymerase II to bind and initiate transcription 
(Nikolov and Burley, 1997). 
It is widely accepted that transcription factors function in complexes (Sandelin et 
al., 2007) rather than individually.  The activation of transcription is greatly 
influenced by the composition of these transcription factor complexes where the 
presence or absence of even one transcription factor can alter the ability of the 
complex to activate transcription (Reid et al., 2009).  This sensitive transcriptional 
switch therefore affects the regulation of gene expression on a spatial and 
temporal level (Lee and Young, 2000).  In addition to one gene being controlled 
by many different combinations of transcription factors, it is also known that any 
given combination of transcription factors are able to activate more than one gene, 
providing a means to control the co-regulation of genes (Reid et al., 2009). 
The efficiency of transcription factors are also variable, with some having a high 
DNA-binding affinity and others having low affinity, creating a mechanism 
whereby the cell can control the number of mRNA molecules transcribed from a 
gene.  In addition, it is suggested that ubiquitously expressed transcription factors 
control a broad set of genes that are then fine-tuned by tissue-specific 
transcription factors (Vaquerizas et al., 2009).  Regulation of gene expression by 
transcription factors is therefore greatly influenced by their tissue expression 
profiles as well as their involvement in transcription factor complexes.   
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Conventional expression profiling experiments focus on a few individual genes of 
interest.  With the discovery of high-throughput technologies, it has become 
increasingly apparent that genes should be analysed within their genomic context.  
Since transcription factors function as groups or complexes, it is necessary that 
our investigations of gene expression events reflect this.  The aim of this study is 
to identify tissue-restricted transcription factor complexes based on the co-
expression of 1 805 transcription factors.  The rationale behind this is that the 
identification of transcription factors responsible for tissue-specific expression of 
a particular gene may be investigated across different pathological states, thereby 
giving insight into the genes responsible for the disease in question. 
 
2.4 Materials and methods 
2.4.1 Data generation 
The members of the Genome Network Project (GNP), for which this study was 
conducted, compiled a list of human transcription factors for analysis, hereafter 
referred to as the Genes Of Interest list (GOI-list) (March, 2007).  The genes in 
this list originally contained all 2 353 known human transcription factors based on 
qRT-PCR experiments.  Manual curation of the GOI-list resulted in 1 805 
transcription factors that conform to the following criteria:   
a) has a DNA-binding domain; 
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b) shows evidence of nuclear localization according to LOCATE (Sprenger 
et al., 2008); and 
c) is annotated  as a transcriptional regulator according to the Gene Ontology 
database (Ashburner et al., 2000). 
A transcription factor was excluded from the GOI-list if there was strong evidence 
supporting localisation outside of the nucleus. 
To generate expression profiles for each of the genes in the GOI-list, their Entrez 
Gene identifiers were obtained from the National Center for Biotechnology 
Information (NCBI) UniGene database (March, 2009) 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene).  The Entrez Gene 
identifiers were used to query a database of 8 852 human cDNA libraries in the 
eVOC ontology system (Kruger et al., 2007).  Only terms from the Anatomical 
System, Cell Type, Developmental Stage and Pathology ontologies were used to 
annotate the genes.  The resulting expression profile lists the annotations of all the 
cDNA libraries in which each gene is expressed. 
 
2.4.2 Pseudoarray generation and expression filtering 
The gene expression profiles were converted into a binary pseudoarray by listing 
the genes in the first column and all annotations in the first row of a table.  If a 
gene is annotated with a term, the value in the array corresponding with that gene 
and term is ‘1’.  Similarly, if a gene is not annotated with a term, the value in the 
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array is ‘0’, creating a binary code for presence (‘1’) and absence (‘0’) of 
expression of a gene across a list of tissues represented by ontology terms. 
The pseudoarray was filtered for annotations resulting from cDNA libraries 
derived from normal tissues.  A library is considered to be from normal tissue 
only if the annotation explicitly states ‘normal’.  Annotations were discarded 
where the originating tissue samples were pooled or if the Anatomical System 
term was ‘unclassifiable’, indicating the sample was from an unknown tissue type.  
In addition, the developmental stage information was removed and identical terms 
from different stages were merged.  Terms were collated if they were located on 
the same branch of a hierarchy, eg. ovary and uterus were collated and renamed 
‘female reproductive system’. 
To avoid redundant annotation, terms from the Cell Type and Anatomical System 
ontologies referring to the same tissue were merged.  The terms ‘macrophage’, 
‘lymphocyte’ and ‘bone marrow’ were merged with ‘blood’, ‘lymph’ and ‘bone’, 
respectively.  Due to ubiquitous expression, all terms relating to ‘brain’ were 
removed, and the following terms were collated as ‘other’: adipose tissue, 
auditory apparatus, bladder, cartilage, gall bladder, gastrointestinal tract, larynx, 
muscle, omentum, oral cavity, pharynx, skeletal muscle, skin, spinal cord, 
synovium, tonsil, umbilical cord and visual apparatus.  In order to explore tissue-
restricted expression, genes were further filtered based on the number of terms to 
which they are annotated.  Only genes expressed in less than 25% of tissues were 
used for further analysis. 
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2.4.3 Expression clustering 
To determine genes exhibiting similar expression patterns, the correlation 
coefficient of each gene pair was calculated.  A correlation coefficient describes 
the strength of a linear relationship between two variables and has a value 
between ‘-1’ (negatively correlated) and ‘1’ (positively correlated).  The 
correlation coefficients were calculated computationally by means of the numpy 
module of the Python scripting language.  Genes showing no correlation in their 
expression have a correlation coefficient ‘0’ and genes whose expression are 
perfectly correlated have a correlation coefficient ‘1’.  Since the aim of the study 
was to find co-expressing transcription factors, negatively correlated genes were 
not included in the analysis.  The correlation results were filtered for gene pairs 
showing at least 75% correlation (coeff = 0.75) in their expression.  For example, 
if a gene pair (A and B) has a 0.80 correlation coefficient, it indicates that gene A 
is expressed in the same tissue as gene B for 80% of the time, indicating a high 
degree of co-expression. 
Genes were defined as clustering together in a network if a node (gene) is 
connected to another node (corresponding gene pair) by an edge (correlation 
coefficient ≥ 0.75).  The nodes and edges resulting from the expression correlation 
calculations were visualised using the Cytoscape network and visualisation tool 
(Shannon et al., 2003).   
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2.4.4 Functional analysis 
The list of tissue-restricted genes was analysed through the use of Ingenuity 
Pathway Analysis (IPA) version 7.5 (http://www.ingenuity.com).  The set of 
genes was uploaded into the application as a list of Entrez Gene identifiers.  Each 
gene identifier was mapped to its corresponding gene object in the Ingenuity 
Pathways Knowledge Base.  The Functional Analysis component of the 
application identified the biological functions and diseases that were most 
significant to the data set.  A Fischer’s exact test was used to calculate a p-value 
determining the probability that each biological function and disease assigned to 
that data set is random. 
The Canonical Pathways analysis identified the pathways from the Ingenuity 
Pathways Analysis library of canonical pathways that were most significant to the 
data set (as at August 2009).  The association of a canonical pathway and the data 
set was measured by performing a Fischer’s exact test, calculating a p-value to 
illustrate the probability that the association between the pathway and genes in the 
data set is due to chance. 
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2.5 Results and discussion 
2.5.1 Data generation and expression profiling 
Of the 1 805 genes in the TF-list, 60 genes were not represented by the cDNA 
libraries in the eVOC ontology system.  The remaining 1 745 genes were 
represented by 239 unique annotation tuples, where a tuple is a list of four terms 
(one from each ontology) representing a cDNA library.  For example, the tuple 
representing a cDNA library obtained from the epithelial cells of a normal fetal 
kidney is ‘kidney|epithelial cell|fetus|normal’. Due to the hierarchical nature of an 
ontology, libraries are often annotated with differing granularity.  For example, 
one technician may annotate a cDNA library derived from hippocampus as 
‘hippocampus’, whereas another technician would annotate the same cDNA 
library as ‘brain’.  To compensate for this annotation inconsistency, terms were 
merged to reflect the least granular term.   
The merging and removal of terms resulted in 1 734 genes represented by 21 
ontology terms.  To determine which genes showed tissue-restricted expression, 
the genes were further filtered based on the number of tissues in which they are 
expressed.  Table 1 lists the 145 genes that are expressed in less than 25% of the 
tissues represented by the 21 ontology terms.  It should be noted that, as with most 
analyses, the results obtained here might be subjected to a data bias.  Since only 
one expression source (namely ESTs) is used, it is possible that the expression of 
certain genes were not captured.  Although the focus of this study is the 
development of a method to determine tissue-restricted expression factors, the 
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Table 1 
A list of the 145 genes expressed in less than 25% of all tissues.  The table 
consists of two panels, each listing the Entrez gene identifier and gene symbol 
for the human transcription factors showing tissue-restricted expression. 
GeneID GeneSymbol GeneID GeneSymbol 
326 AIRE 8345 HIST1H2BH 
430 ASCL2 8820 HESX1 
579 BAPX1 8970 HIST1H2BJ 
668 FOXL2 9970 NR1I3 
1032 CDKN2D 10215 OLIG2 
1053 CEBPE 10655 DMRT2 
1745 DLX1 10794 ZNF272 
1746 DLX2 11077 HSF2BP 
1748 DLX4 11281 POU6F2 
1761 DMRT1 25806 VAX2 
1961 EGR4 26038 CHD5 
1993 ELAVL2 26108 PYGO1 
2016 EMX1 26468 LHX6 
2020 EN2 27023 FOXB1 
2103 ESRRB 27164 SALL3 
2118 ETV4 27288 HNRNPG-T 
2294 FOXF1 27439 CECR6 
2295 FOXF2 30009 TBX21 
2297 FOXD1 30012 TLX3 
2302 FOXJ1 50805 IRX4 
2304 FOXE1 51022 GLRX2 
2306 FOXD2 51402 LW-1 
2623 GATA1 51450 PRRX2 
2672 GFI1 54626 HES2 
3007 HIST1H1D 55552 HSZFP36 
3008 HIST1H1E 55659 ZNF416 
3009 HIST1H1B 56938 ARNTL2 
3110 HLXB9 56978 PRDM8 
3198 HOXA1 57116 ZNF695 
3205 HOXA9 57332 CBX8 
3207 HOXA11 57343 ZNF304 
3209 HOXA13 57801 HES4 
3231 HOXD1 58495 OVOL2 
3234 HOXD8 60529 ALX4 
3642 INSM1 63978 PRDM14 
3975 LHX1 79192 IRX1 
4210 MEFV 79722 FLJ11795 
4656 MYOG 79816 TLE6 
4796 NFKBIL2 79862 ZNF669 
4821 NKX2-2 80032 ZNF556 
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GeneID GeneSymbol GeneID GeneSymbol 
4861 NPAS1 84127 RUNDC2A 
4901 NRL 84911 ZNF382 
5013 OTX1 85409 NKD2 
5076 PAX2 85446 ZFHX2 
5077 PAX3 89870 TRIM15 
5079 PAX5 90649 ZNF486 
5081 PAX7 94039 ZNF101 
5453 POU3F1 94234 FOXQ1 
5454 POU3F2 116448 OLIG1 
5455 POU3F3 126295 LOC126295 
5462 POU5F1P1 129025 SUHW1 
5992 RFX4 136051 DKFZp762I137 
6474 SHOX2 138474 TAF1L 
6493 SIM2 140883 SUHW2 
6496 SIX3 142689 ASB12 
6664 SOX11 146434 ZNF597 
6689 SPIB 148268 ZNF570 
6877 TAF5 148979 GLIS1 
6899 TBX1 161253 FLJ38964 
6913 TBX15 162979 ZNF342 
7023 TFAP4 163059 ZNF433 
7161 TP73 163071 ZNF114 
7291 TWIST1 170302 ARX 
7310 U2AF1L1 171392 ZNF675 
7546 ZIC2 221527 ZBTB12 
7621 ZNF70 245806 VGLL2 
7673 ZNF222 253738 EBF3 
7675 ZNF121 283078 MKX 
7710 ZNF154 285676 ZNF454 
7768 ZNF225 339416 ANKRD45 
8092 CART1 339488 TFAP2E 
8193 DPF1 341405 ANKRD33 
8320 EOMES   
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addition of data sources such as CAGE, MPSS and SAGE will dramatically 
increase the quality of the results.   
Not surprisingly, more than 80% of the restricted genes are regulators of gene 
expression according to their Gene Ontology annotations.  In addition, a small 
percentage of the restricted genes are involved in immune system development 
(BAPX1, TBX21 and SPIB), embryonic development (EOMES, OTX1, BAPX1, 
FOXE1, HOXD8, SIM2, FOXF1, LHX1, VAX2, FOXF2, TRIM15, GFI1, ASCL2, 
FOXL2, TBX1 and ZIC2) and cell fate specification (NKX2-2, TLX3 and GFI1).  
The pseudoarray illustrating the expression profiles of these genes is represented 
by Appendix VIII.  It is interesting to note that these genes showing tissue-
restricted expression are biased for expression pertaining to developmental 
processes – probably the most tightly regulated processes in an organism.  This 
observation strengthens the hypothesis that ubiquitously expressed transcription 
factors regulate a broad set of genes whereas tissue-restricted transcription factors 
are responsible for the fine-tuned regulation within a cell. 
 
2.5.2 Expression clustering 
The current knowledge of transcription factor function suggests that they function 
as protein complexes, indicating that the functional and expression profiling of a 
single transcription factor is unuseful.  In order to determine how transcription 
factors regulate gene expression, it is important to determine which transcription 
factors function together.  The correlations of gene expression profiles were 
44
 
 
 
 
  
determined in order to assess which genes co-express across a range of tissues.  
The co-expression of transcription factors implicates their involvement in the co-
regulation of their target genes, providing the basis for further functional studies. 
A moderate correlation cutoff of 75% resulted in 112 genes represented by 8 gene 
clusters.  Genes clustered together if there was at least one edge (correlation 
coefficient ≥  0.75) between two genes.  Not surprisingly, the results show one 
large gene cluster (Figure 1a) with a few smaller clusters (Figure 1b).  
Investigations of the annotations of the genes in Figure 1b reveal a few clusters (3, 
4 and 5) that exhibit tissue-restricted expression for female reproductive system, 
male reproductive system and stem cell, respectively.  In addition, clusters 6, 7 
and 8 show tissue-biased expression.  These results indicate that the genes in each 
cluster are co-expressed in certain tissues and therefore possibly function as a unit 
to activate the transcription of a gene (or sets of genes) responsible for the tissue-
specific characteristics of the tissue in which they are expressed.  For example, it 
is feasible that because the genes in cluster 5 (DLX2, BAPX1 and ZBTB12) co-
express only in the stem cell population that these transcription factors may be 
responsible for regulating the genes that define stemness (self-renewal, chemo-
resistance, pluripotency).  Since we see transcription factors biased for expression 
in tissues that have developmental functions (female reproductive system, male 
reproductive system and stem cell), we can intuitively predict that the 
corresponding transcription factors play a role in the regulation of the 
development of the cell.  It is even possible, given the tissues in which these genes 
are restricted, that they regulate the stem cell state of a cell since the male and 
female reproductive system has stem cell-containing tissues.  The tissues 
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Figure 1a 
Illustration of genes clustering together based on correlated co-expression.  
All gene clusters represent the sets of genes that cluster together based on a 
correlation coefficient larger than 0.75. 
 
(a) 
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Figure 1b 
Illustration of genes clustering together based on correlated co-expression.   
All gene clusters represent the sets of genes that cluster together based on a 
correlation coefficient larger than 0.75.  Clusters 2 – 8 represents genes and 
tissues for which there is biased expression.   
 
(b) 2 - Other 
7 – Blood, lymph, spleen, heart, 
other 
8 – Lung, bone, male 
reproductive system, blood 
vessel, stem cell 
6 – Female reproductive 
system, kidney, lymph, 
stem cell, other 
4 – Male 
reproductive system 
5 – Stem cell 
3 – Female 
reproductive system 
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represented by the tissue-biased clusters (lung, bone, kidney, heart, lymph and 
blood) also have a stem cell niche with cells progressing through a defined cell 
lineage.   
Although the above statements require experimental validation, what we see here 
is the identification of several complexes of transcription factors that show an 
expression bias towards certain tissues and therefore possibly interact with each 
other to combinatorially regulate a defined set of target genes. It is possible that 
the addition or omission of even one transcription factor in a complex may alter 
the regulation of a gene not only quantitatively, but also on a temporal and spatial 
level.  It is for this reason that it is important for researchers to determine the 
composition of transcription factor complexes in order to understand the 
regulation of any gene of interest.  This method of using ontologies to determine 
tissue-restricted transcription factor complexes can therefore be used to 
computationally predict transcription factors that co-regulate a set of genes.   
 
2.5.3 Functional analysis 
A functional analysis of a list of genes reveals processes with which the genes are 
associated, thereby giving insight into the processes governing a particular cell 
type or state.  The functional analysis of the 145 transcription factors that exhibit a 
restricted expression profile suggests a functional bias towards developmental 
processes.  Table 2a lists the top five physiological functions associated with the 
restricted gene set, showing a significant enrichment for the development of 
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Table 2a 
The top five physiological system development and functions over-
represented by genes showing restricted expression.   
 
Physiological System Development and Function P-value 
Organ development 4.73E-15 - 1.57E-02 
Nervous System Development and Function 1.33E-10 - 2.34E-02 
Lymphoid Tissue Structure and Development 3.60E-07 - 2.12E-02 
Digestive System Development and Function 1.83E-04 - 1.83E-04 
Organismal Development 2.92E-04 - 2.92E-04 
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organs and the organism as a whole.  Investigation into the top five diseases 
associated with the data set shows that cancer is significantly over-represented 
(Table 2b).  In addition, analysis of the canonical pathways suggests the Sonic 
Hedgehog Signaling pathway as the most significantly over-represented pathway 
by the data set (Table 3) with a p-value of 1.99x10-01.  Although the p-value 
presented here does not fall below the accepted 0.005, it does support the findings 
presented in 2.5.2.  The p-value obtained from enrichment analyses is influenced 
by the size of the gene list being investigated, where a larger gene list will have a 
higher statistical power resulting in more significant p-values.  Even so, the order 
of enriched terms will remain fairly stable regardless of the size of the gene list, 
provided the lists of different sizes are being sampled from the same data set 
(Huang da et al., 2009).  We can therefore argue that the Hedgehog pathway is 
significantly over-represented even though a high p-value is obtained, since it is 
most likely a result of having a small gene list.  The Hedgehog pathway is a key 
regulator of embryonic development and is highly conserved from insects to 
mammals.  Altered Hedgehog pathway activity can lead to certain cancers such as 
basal cell carcinoma.  There is also increasing evidence that this pathway is 
involved in regulating adult stem cells (Bhardwaj et al., 2001) and over-
representation of this pathway is associated with proliferation and development 
(Kenney et al., 2003). 
The over-representation of developmental functions, diseases and canonical 
pathways in the data set is strong evidence that the transcription factors showing a 
tissue-restricted expression bias are those factors that are responsible for the fine-
tuning of the regulation of developmental gene expression.  These tissue-restricted 
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Table 2b 
The top five diseases and disorders associated with the genes showing 
restricted expression in less than 25% of all tissues.   
 
Diseases and Disorders P-value 
Developmental Disorder 2.99E-03 - 3.88E-02 
Antimicrobial Response 7.87E-03 - 7.87E-03 
Cancer 7.87E-03 - 3.88E-02 
Dermatological Diseases and Conditions 7.87E-03 - 3.88E-02 
Endocrine System Disorders 7.87E-03 - 7.87E-03 
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Table 3 
A list of canonical pathways over-represented by genes showing restricted 
expression in less than 25% of all tissues.   
 
Ingenuity Canonical Pathways  -Log(P-value) 
Sonic Hedgehog Signaling 7.02E-01 
Estrogen Receptor Signaling 6.92E-01 
Allograft Rejection Signaling 6.16E-01 
T Helper Cell Differentiation 5.95E-01 
Autoimmune Thyroid Disease Signaling 5.95E-01 
Graft-versus-Host Disease Signaling 5.76E-01 
Dendritic Cell Maturation 5.07E-01 
ATM Signaling 4.79E-01 
TREM1 Signaling 4.58E-01 
Basal Cell Carcinoma Signaling 4.11E-01 
PXR/RXR Activation 4.06E-01 
Caveolar-mediated Endocytosis 3.71E-01 
CTLA4 Signaling in Cytotoxic T Lymphocytes 3.24E-01 
Melanocyte Development and Pigmentation Signaling 3.13E-01 
Virus Entry via Endocytic Pathways 3.10E-01 
p53 Signaling 3.02E-01 
Glioma Signaling 2.76E-01 
Type I Diabetes Mellitus Signaling 2.56E-01 
14-3-3-mediated Signaling 2.48E-01 
Glucocorticoid Receptor Signaling 2.42E-01 
CD28 Signaling in T Helper Cells 2.40E-01 
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transcription factors may therefore also be implicated in the development of 
cancers and developmental disorders originating from a dysregulation of genes in 
a cell.  
 
2.6 Conclusions 
This study explored the expression profiles of a list of transcription factors known 
to localise in the nucleus.  The aim of the study was to determine which 
transcription factors show tissue-restricted expression.  The use of an ontology-
based system enabled the identification of 145 transcription factors whose 
expression was limited to less than 25% of the 21 tissues represented by the 
dataset.  Investigation of the results revealed that the tissue-restricted transcription 
factors are involved in developmental processes such as immune system 
development, embryonic development and cell fate specification.  The Sonic 
Hedgehog Signaling pathway was the most significantly over-represented 
pathway in the data set, providing further evidence of a significant role of these 
genes in the development of an organism.  In addition, the tissues in which the 
transcription factors showed biased expression are those tissues in which cells are 
continuously re-generating, indicating that these transcription factors may play a 
crucial role in the regulation of the progression of a cell down a defined cell 
lineage. 
It is becoming increasingly apparent that transcription factors do not function 
individually, but rather as complexes.  The identification of co-expressing 
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transcription factors will therefore be able to make an initial identification of 
transcription factor complexes.  Clustering tissue-restricted genes based on a 75% 
correlation of their expression enabled the identification of 3 transcription factor 
complexes showing tissue-restricted (expressed in one tissue only) expression and 
3 complexes showing tissue-biased (expressed in a limited number of tissues) 
expression patterns.  The three clusters showing tissue-restricted expression 
represent the male and female reproductive systems as well as stem cells.  We 
have therefore potentially identified transcription factor complexes that are 
involved in the regulation of the development of the cell and further investigation 
of the transcription factors represented by these clusters may contribute to the 
understanding of the regulation of normal stem cells.  
The addition of expression sources to supplement the dataset used here will add 
quality to the results, however the method applied will not be affected.  We have 
therefore described a robust method that applies an ontology-based system to 
enable the identification of transcription factor complexes that may be used to 
identify transcription factor complexes that function in specific tissues thereby 
enhancing the understanding of the regulatory potential of genes of interest.  
54
 
 
 
 
  
Chapter 3 
Mouse gene expression analysis of cancer/testis orthologs 
restricts candidates for cancer therapy. 
3.1 Summary 
The work presented in this chapter was conducted as part of a project aimed at 
characterising cancer/testis genes in human and mouse.  The overall objectives of 
the project are fourfold: 
1. Characterise, and possibly re-classify, all known human cancer/testis 
genes; 
2. Identify novel human cancer/testis genes by means of expression 
profiling; 
3. Identify which cancer/testis genes are most suited for developing cancer 
drugs or vaccines; and 
4. Identify mouse cancer/testis genes to use as a model system for cancer 
drug and vaccine development. 
Objectives (1) and (2) resulted in a publication (Hofmann et al., 2008), wherein 
my contribution was to:  
a) use the ontologies presented in Chapter 1 to annotate a list of human 
cancer/testis genes and their mouse orthologs; and 
b) maintain and implement the data-generation pipeline developed by Dr 
Christopher Maher and Dr Oliver Hofmann. 
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The mouse expression information in (a) was not used in the publication due to 
the observation that the expression profiles of the orthologs did not conform to 
expected cancer/testis criteria and further investigation was required 
(subsequently resulting in this chapter).  The human expression information was 
merged with expression data derived from MPSS, qRT-PCR and CAGE 
expression data in order to perform a multi-platform expression analysis in the 
attempt to re-classify human cancer/testis genes.  The pipeline in (b) is a sequence 
of computer scripts coded in Perl, which requires raw CAGE sequence 
information (Kodzius et al., 2006) as input.  CAGE tags are short 10-12bp 
fragments derived from the 5’ coding region of an mRNA and, when mapped to 
the genome, accurately identifies the point of transcription initiation (transcription 
start site – TSS).  The pipeline orders the CAGE tags according to chromosome 
and strand, and subsequently clusters the tags to provide quantitative evidence for 
transcription initiation.  When annotated according to the ontology-based system 
described in Chapter 1, this information provides tissue-based transcription 
initiation events.  When combined with the cDNA library information from the 
eVOC system as well as qRT-PCR and MPSS data, a genome-wide analysis 
identified genes whose expression profile classifies them as cancer/testis genes, 
thereby identifying novel CT genes in human.  This work is discussed in detail in 
‘Genome-wide analysis of cancer/testis gene expression’ published in PNAS 
(Hofmann et al., 2008), which is appended as Appendix IX. 
This chapter describes objective (4), where my role was to develop, implement 
and interpret the analysis.  The results of this study will be used to make informed 
decisions regarding the use of mouse as model system for investigation of 
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cancer/testis genes, and to further understand the relationship between human and 
mouse cancer/testis orthologs.   
 
3.2 Aim 
The aim of the analysis presented here is to determine whether the mouse 
orthologs of the human cancer/testis (CT) gene set exhibits CT characteristics.  
Since CT genes are a target for gene-based cancer drug therapy, and the 
development of these drugs includes efficacy and toxicity trials in mouse, it is 
important to identify human target genes whose mouse counterpart show the same 
tissue-restricted expression. 
 
3.3 Introduction 
Cancer is a disease characterised by the uncontrolled growth of cells in any of a 
variety of tissues such as breast, prostate, lung, liver and pancreas (Jemal et al., 
2008).  Cancer is an invasive disease and can migrate to different parts of the 
body.  Although there are hundreds of cancer types, they typically fall into one of 
five categories (leukemia, sarcoma, carcinoma, lymphoma/myeloma, and central 
nervous system cancers), depending on their tissue of origin.  Leukemia is cancer 
that originates in the bone marrow where blood is formed, resulting in the 
production of a large number of abnormal blood cells.  The sarcoma cancers 
develop in the connective and supportive tissues such as bone, muscle or fat.  
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Carcinoma is referred to cancer originating in the skin or in the tissue lining the 
internal organs.  The lymphoma and myeloma cancers originate in the immune 
system, whereas the central nervous system cancers develop in the brain and 
spinal cord (http://www.cancer.gov/cancertopics/what-is-cancer).  In addition, 
cancers may be classified as either benign (non-metastasizing, non-invasive, non-
aggressive) or malignant (metastasizing, invasive, aggressive) tumors, the latter 
being the most cause of concern. 
In 2004, cancer was responsible for the deaths of 7.4 million people worldwide 
and it is estimated that this figure will rise to 12 million in the year 2030 
(http://www.who.int/en/).  The exact origin of cancer is the topic of much 
research, however the consensus is that tumorigenic cells have altered genomes 
compared to normal cells, resulting in aberrant gene expression, function and 
cellular growth (Bos, 1989).  The two main theories for the origin of cancer are 
the clonal evolution model and the cancer stem cell theory (Gil et al., 2008).  The 
clonal evolution model suggests that a cell acquires a series of mutations during 
the process of cell division.  The cancer stem cell model states that only stem cells 
proliferate enough times to accumulate cancer-causing mutations and that it is 
these cells that gives rise to tumors.  The cancer stem cell population is a subset of 
the tumor that possesses the self-renewal and multipotent qualities of normal stem 
cells. 
The cancer stem cell theory suggests that if the cancer stem cell population is not 
removed from the tumor, the patient will experience a tumor relapse.  
Conventional cancer therapy includes surgery to excise the tumor followed by 
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chemo- or radiation-therapy to kill all replicating cells.  Since cancer stem cells 
exhibit intolerance to chemotherapy (Gil et al., 2008) these conventional therapies 
are not only invasive but potentially ineffective as well.  Current research 
focusing on cancer therapy is therefore aimed at identifying genes expressed 
specifically in tumors and not in normal tissues, enabling the production of drugs 
or vaccines to target cells that have become tumorigenic.   
Cancer/testis (CT) genes are a group of genes whose expression has been 
observed in a variety of different tumors (Chitale et al., 2005).  However, when 
observed in normal tissues, the expression of CT genes is limited to the 
immunoprivileged tissues of testis, ovary and/or placenta (Cho et al., 2006).  In 
addition, many CT genes exhibit immunogenic properties, enabling them to elicit 
cellular and humoral immune responses in cancer patients (Atanackovic et al., 
2006).  The immunogenicity of CT genes coupled with their expression in 
immunoprivileged sites and in a wide range of tumors, allows these genes to be 
considered as drug target candidates for the immunotherapeutic treatment of 
cancer.  
As with many pharmaceutical products, the process of creating drug targets 
requires the use of model systems in which to test drugs before being declared fit 
for clinical trials.  Although the mouse is a common model system for studying 
biological reactions to chemical additives, it is not guaranteed that the human 
response will be identical.  Orthologous genes may be expressed in both human 
and mouse, but due to different regulators their expression does not necessarily 
occur on the same temporal and spatial level (discussed in Chapter 1), affecting 
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their eventual function.  For this reason it is important to identify mouse CT genes 
and to understand their relationship to human orthologs for the development of 
drug targets for cancer therapy. 
 
3.4 Materials and methods 
3.4.1 Data selection and generation 
A list of 181 human cancer/testis (CT) genes was obtained from the CT Antigen 
Database (April, 2009) (http://www.cta.lncc.br).  The mouse orthologs of the 
human CT genes were obtained by matching HomoloGene identifiers (as 
presented in Chapter 1) resulting in only 70 mouse genes.  Information for the 
generation of gene expression profiles of the mouse orthologs was extracted from 
1 210 cDNA libraries in the eVOC system (Chapter 1).  A gene was annotated 
with the anatomical, cellular, developmental and pathological terms associated 
with a library if the gene was found to be expressed in that particular library.  In 
the cases where anatomical terms were not available, terms relating to cell type 
were used.   
Only libraries that were annotated as having normal pathology were categorised 
as ‘normal’, whereas all other libraries not explicitly annotated as such were 
categorised as ‘unclassifiable’ in terms of pathology.  Libraries comprising of 
more that one sample were excluded from the analysis unless all the samples were 
obtained from the same anatomical structure under identical pathological 
conditions.  
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3.4.2 Expression profiling 
The expression information generated in 3.3.1 was organised in the form of an 
array.  An expression array consists of a list of genes in the first column of a table, 
with the first row consisting of all possible annotations from the expression 
sources.  The annotations are a combination of developmental stage, pathology 
and anatomical structure (or cell type) for each library used.  For example, an 
annotation for a cDNA library obtained from the normal heart of an adult mouse 
would be ‘adult|normal|heart’.  The values for the array were based on the number 
of cDNA libraries from the eVOC system in which a gene was expressed, 
summing libraries if the annotations were identical.  For example, if a gene was 
expressed in three different libraries all derived from a normal heart of an adult 
mouse, the expression value for that particular gene with ‘adult|normal|heart’ 
annotation would be 3.   
The expression array was subsequently filtered to disregard developmental stage 
information, remove annotations where the pathology was neither cancer nor 
normal, and merge terms related in terms of hierarchical structure.  Appendix X 
lists the manual filtering steps performed on the data.  A total of 7 genes were not 
represented by the data and were subsequently removed from the analysis.   
Based on the expression profiles derived, genes were classified into three 
categories: (i) testis-restricted; (ii) testis/brain-restricted; (iii) testis-selective (see 
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Table 1 for classification and Figure 1 for a flow-diagram describing the 
categorisation process). 
 
3.5 Results and discussion 
Of the 181 human CT genes, only 70 have mouse orthologs according to the 
HomoloGene database (April, 2009) (http://www.ncbi.nlm.nih.gov/entrez/ 
query.fcgi?db=homologene).  Although 80 - 99% of mouse genes have human 
orthologs (discussed in Chapter 1), these percentages still represent between 300 – 
6 000 of the estimated 30 000 genes in the mouse genome (NCBI m37, Apr 2007) 
(http://www.ensembl.org/Mus_musculus/Info/StatsTable), thereby easily 
accounting for the differences in the number of human and mouse CT genes.  In 
addition, many of the human CT genes are primate-specific.   
The data filtering process involved removing annotations where the pathology is 
unclassifiable as well as disregarding developmental stage information.  The 
filtering process is important as it discards genes whose origin is unknown and 
their expression can therefore not be specifically designated as ‘normal’ or 
‘cancer’.  The developmental stage information is discarded because there is 
simply not enough data for each developmental stage to be a category on its own.  
Terms such as cerebellum and brain that are related in the eVOC hierarchy were 
merged to reflect the least granular term, resulting in 63 genes represented by 76 
unique annotations consisting of 58 normal- and 18 cancer-related annotations.  
Unfortunately, the filtering of data resulted in 4 genes being excluded from the 
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Figure 1 
Flow-diagram representing the categorisation of mouse genes into 
cancer/testis categories. 
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Table 1 
Classification categories for cancer/testis genes.  Testis- and testis/brain-
restricted genes are those biased for expression in immunoprivileged tissues. 
Category Classification 
Testis-restricted expression in cancer and testis only 
Testis/brain- restricted expression in cancer, testis, placenta, ovary and 
brain-regions only 
Testis-selective expression in cancer, testis and two other tissues 
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analysis since they did not have any expression evidence in the remaining cDNA 
libraries.  Although this process results in a loss of data, it increases the 
confidence of the remaining genes in that they have definite expression in 
‘normal’ and ‘cancer’ tissues. 
The resulting expression profile showed that 4 of the 70 genes were not found to 
be expressed in a testis library at all (Il13ra2, Ccdc36, Otoa and Magea8).  There 
were 0 genes categorised as testis-restricted, 2 classified as testis/brain-restricted 
(Syce1 and Tssk6) and 7 classified as testis-selective (Morc1, Spa17, Dkkl1, 
Plac1, Piwil2, Ly6k and Ssxb2).  In addition, there were 17 genes expressed in 
testis, brain, ovary or placenta but not in normal or cancer tissues.  Because these 
genes are not expressed in cancer, they are not classified as cancer/testis genes.   
Figure 2 illustrates the mouse expression profile as well as the resulting 
categorisation of each gene.  (see Appendix XI for complete expression profile).  
The first panel of Figure 2 (CategoryNo.) represents the CT category each gene 
was categorised as.  The second panel represents normal testis, brain, ovary and 
placenta expression.  The third and fourth panels represent normal and cancer 
expression, respectively.  The fifth panel represents expression derived from 
normal tissues relating to the reproductive system (eg. oocyte and spermatocyte) 
and stem cells, and were not included in the CT categorisation process.  Table 2 
provides the testis-restricted, testis/brain-restricted and testis-selective genes along 
with their human orthologs. 
The results are inevitably subject to data bias since the data set is derived from 
one data type from a single origin and it is therefore possible that some genes are 
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Figure 2 
Visualisation of the gene expression profile of 63 mouse orthologs.  The coloured blocks within the array refer to the number of 
cDNA libraries a gene is expressed in (0 = black; 5 = red).  Genes are ordered from top to bottom according to their CT 
classification (testis/brain-restricted = red; no testis expression = black). 
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Table 2 
Gene identifiers and symbols of mouse genes showing testis-restricted, 
testis/brain-restricted or testis-selective expression, along with their human 
orthologs. 
Mouse Human 
GeneID GeneSymbol MouseCTcategory GeneID GeneSymbol 
74075 Syce1 testis/brain 93426 SYCE1 
83984 Tssk6 testis/brain 83983 TSSK6 
17450 Morc1 testis-selective 27136 MORC1 
20686 Spa17 testis-selective 53340 SPA17 
50722 Dkkl1 testis-selective 27120 DKKL1 
56096 Plac1 testis-selective 10761 PLAC1 
57746 Piwil2 testis-selective 55124 PIWIL2 
76486 Ly6k testis-selective 54742 LY6K 
387132 Ssxb2 testis-selective 6756 SSX1 
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more likely to be included in the data set than others.  The way in which to 
minimise the effects of data bias would be to include more data types from 
different sources.  Although it is not presented here, the addition of data sources 
to the ontology system is strongly suggested.  We can therefore not definitively 
conclude that the genes listed above are never expressed in testis or cancer and 
testis only.  We can, however, illustrate that (a) there is evidence that these genes 
may not be expressed in testis and therefore possibly not classify as CT genes, and 
(b) genes that are considered testis-restricted in humans are showing a less-
restrictive expression profile when expressed in mouse, which was the purpose of 
this study.  We have therefore assessed the expression profiles of mouse genes 
whose orthologs, when expressed in humans, show a testis-restricted or testis-
biased expression.  Because model systems are used to determine the safety and 
efficacy of a trial drug, it is important that the reaction exhibited by the mouse 
closely reflects the reaction that a human would exhibit to the same drug.  Gene-
targeted drug therapy therefore requires that any drug developed to target a human 
gene should, when tested in a mouse, exhibit the same required response.  When 
an ortholog does not show the same expression pattern in both human and mouse, 
there is a high probability that the gene performs a different function in each 
species.  It is for this reason that we have set out to determine the expression 
profile of the mouse orthologs of the human CT genes and we have identified 
only 7 mouse genes whose expression profile characterises them as potential CT 
genes and therefore potential candidates for the development of gene-targeted 
drug therapies in mouse for eventual application in humans.  In order for this 
work to make the transition from hypothetical to actual drug therapy, drugs may 
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be developed to specifically target the genes highlighted in this study.  The ability 
for a drug to identify, target and destroy a cell expressing a gene characteristic of 
cancer and no other normal tissue will result in a non-invasive and highly 
effective means of treating and eradicating cancer. 
 
3.6 Conclusions 
The answer to effective cancer therapy lies in the ability to distinguish cancer 
from normal cells.  The cancer/testis genes have proven to be promising 
candidates for drug targeted therapy due to their immunoprivileged properties.  
Despite the obvious importance of the cancer/testis genes in cancer therapy, these 
genes are not well characterised and therefore poorly understood.  The use of a 
model system such as mouse provides an effective way to advance our knowledge 
of the cancer/testis genes.  The problem however, is that it has been shown that 
the temporal and spatial gene expression of human and mouse orthologs differs 
greatly, emphasising the need to identify mouse CT gene orthologs.  The analysis 
presented here highlights that the mouse orthologs of human CT genes are not 
necessarily CT genes themselves, and identifies only 7 mouse genes showing CT 
gene characteristics and have human CT counterparts.  These findings provide 
realistic targets for drug-targeted cancer therapy and deeper characterization 
because they have, as a result of expression profiling, been identified as genes that 
potentially perform the same function due to identical expression and will 
therefore exhibit the same responses to chemical stimuli.  
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Conclusions 
I have demonstrated the need for an effective way to annotate expression sources 
such as cDNA libraries in order to allow the universal and computational 
comparison of the annotated data.  The need for the comparison of data is not only 
limited to data derived from different laboratories, but also data derived from 
different species.  I have addressed the issue of data comparison by developing a 
set of ontologies that describe human and mouse development.  The ontologies 
are aligned not only between the two species, but also to other available 
ontologies, allowing the use of computational methods to compare human and 
mouse gene expression data across a range of sources.  In addition, I have used 
the ontologies to annotate a set of 8 852 human and 1 210 mouse cDNA libraries 
as an initial dataset to showcase the ontologies. 
The use of the ontologies has been demonstrated in several ways.  Firstly, the 
ontologies have been used to compare the expression of human and mouse genes 
in the developing brain.  It was found that of the 16 324 possible human-mouse 
orthologs, only 90 genes were expressed in the developing brain of both human 
and mouse.  This finding highlights the differences in the temporal and spatial 
expression patterns of orthologous genes between the two species.  I emphasise 
here that when using model organisms to study the behaviour of genes with the 
intention of inferring structural and functional information, it is important to 
establish that the genes of interest have similar spatial and temporal expression 
profiles in both species under investigation. 
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Secondly, the ontologies have been used to determine clusters of tissue-restricted 
transcription factors.  A single gene may be expressed as several different 
transcripts in different tissues or under different conditions depending on the 
transcription factors binding to the promoter region of that gene.  In addition, it 
has been found that transcription factors function in complexes and the 
composition of the transcription factor complexes differ between tissues as well as 
disease states.  The identification of tissue-restricted transcription factors may 
therefore provide insight into the tissue- or disease-specific regulation of genes.  
The results from this analysis identified 145 human transcription factors showing 
a tissue-restricted expression pattern.  Investigation into known functions of these 
genes revealed enrichment for developmental processes such as immune system 
development, embryonic development and cell fate specification.  Clustering of 
these genes based on correlation of their expression profiles revealed tissue-
restricted and tissue-biased transcription factor complexes that are potentially 
responsible for the regulation of the stem cell state or lineage differentiation of 
cells.   
Lastly, the ontologies have been used to compare the expression profiles of a set 
of human cancer/testis genes in mouse.  Of the 181 known human cancer/testis 
genes, only 70 have a mouse ortholog according to the HomoloGene database.  Of 
these 70 mouse orthologs, only 63 have expression evidence in the system used.  
The human cancer/testis genes have been selected based on their biased 
expression for either testis and cancer, or testis, brain and cancer.  The 
investigation of the 63 mouse orthologs show that 4 genes are not expressed in the 
testis at all and only 2 and 7 genes showed testis/brain-restricted and testis-
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selective expression, respectively.  Since the cancer/testis genes are considered 
extremely good candidates for the development of cancer drugs and vaccines, 
these findings emphasise the need to consider spatial and temporal differences in 
gene expression between human and model organisms when using the model 
organism to investigate the reaction of a set of genes to a drug or vaccine.  This 
analysis also emphasises that mouse genes whose human orthologs are 
cancer/testis genes, are not necessarily cancer/testis genes themselves. 
Each of the studies presented here have provided evidence that many human and 
mouse orthologs differ in their spatial as well as temporal expression.  This would 
lead one to question whether the genes are truly orthologs even though their 
sequences have a high degree of similarity.  While it is true that two orthologs 
once performed the same function, their expression clearly has different 
consequences when it is not occurring on the same temporal and spatial level in 
both species.  Since we know regulation of expression determines the timing of 
gene expression, it is obvious that the differences between human and mouse is 
not limited to those genes without any counterparts in the opposite species, but 
also include those orthologs whose transcriptional regulators differ between the 
two species.  As discussed previously, transcription factors function in complexes 
and omission or substitution of even one transcription factor in a complex can 
change the timing of expression of a single gene.  It is this quality of 
transcriptional regulation that allows even a 1% difference in genetic composition 
to determine the difference between the mouse and human phenotype.  
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Our need to find cures for life-threatening diseases such as cancer is a major 
driving force behind biological research and with the advances of modern 
medicine we are in a position to develop non-invasive gene-targeted drug therapy.  
Due to the advantages of using mouse as a model system, the development of 
most drugs inevitably involves injecting a mouse with a drug to test its efficacy 
and toxicity.  Since gene-targeted drugs aim to identify a specific gene in humans, 
one would expect the drug to target the same gene in the mouse in which the drug 
is being tested.  It is therefore important to determine if the gene in question is 
indeed expressed in the mouse in identical tissues and developmental stages as its 
human counterpart.     
Given the importance of the regulation of gene expression timing and the 
comparison thereof between human and mouse, it is therefore imperative to 
accurately document a gene’s expression profile based on tissue, disease and 
developmental stage and the work presented here provides a method to address 
this.  It is noted that the analyses presented here used a single source of 
expression, namely cDNA libraries.  While the addition of other expression 
sources such as microarray, SAGE and CAGE experiments may alter the findings, 
the methods still apply.  I have therefore developed a robust method with which to 
investigate aspects of mammalian gene expression, which is illustrated here in 
several ways. 
Bioinformatics is, without a doubt, a collaborative science where your data 
resources are dependent on publically available data as well as that of your 
collaborators.  It is therefore inevitable that your data will be slightly biased in 
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many ways, which is why it is important to keep in consideration two aspects of 
this field.  Firstly, the integrity of your analysis and subsequent results are directly 
correlated with the quality, quantity and granularity of your input data.  Secondly, 
any computational expression results or predictions need to be experimentally 
confirmed in a laboratory.   
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Afterword 
Examination questions and answers 
1. In the first sentence of the preface you bring up the term 
“post-genomic”.  Would you not like to argue that we are not in the 
post-genomic era, but rather right in the smack middle of the genomic 
era? Is it not premature to speak of the “post-genome”? 
• In this context, the term ‘post-genomic’ refers to the fact that we 
have passed the point where we have decoded the genome.  Whole 
genomes are being sequenced on a daily basis in laboratories 
around the world and it is no longer the major bottleneck in 
genomics.  Our challenge now is to interpret the genome by 
determining the function as well as regulation of all genes and the 
networks they are involved in.  
2. What effect do you think “next-generation” technology will have on 
gene expression analysis and annotation in general? 
• The ‘next-generation’ technologies enable the sequencing of genes 
on a much larger scale and at a faster rate than before.  While this 
provides more data for gene expression analysis at higher accuracy, 
it requires effective data management strategies.  Unfortunately, 
the annotation is not a tightly controlled aspect of data generation 
and it is my opinion that with the increase in the speed at which 
data can be generated that this process will be neglected.  In order 
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for us to exploit data to its full potential it should be a requirement 
that all data submitted to public venues be annotated according to a 
strict set of rules involving the use of ontologies.  
3. What are annotations? 
• An annotation is a ‘label’ associated with a particular object with 
the purpose of describing that object.  Data annotations are 
therefore a set of words used by the researcher generating the data 
to describe it.  A gene will, for example, be annotated according to 
the tissue from which it was sequenced, such as ‘lung’ or ‘liver’.  
The more annotations associated with the gene, the more 
descriptive it becomes (such as annotating the gene according to 
the developmental stage or pathological state of the originating 
tissue).  Because annotations are assigned by different individuals 
who would not necessarily annotate a tissue with the same level of 
detail, all annotations are effectively open to interpretation and 
prone to errors. 
4. What is the difference between orthologs and paralogs? 
• Orthologs are genes in different species whose sequences diverged 
during speciation.  Paralogs are genes that originated in the same 
species as a duplication event and the sequences of the two genes 
subsequently diverged.  Orthologs are therefore genes separated by 
speciation whereas paralogs are genes separated by a duplication 
event. 
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5. What is wrong with this statement: “These two genes are 90% 
homologous”? 
• Homology refers to two sequences having common ancestry and 
cannot be quantified.  When comparing the composition of two 
sequences, a percentage is a degree of their SIMILARITY. 
6. How has Open Access affected your field of research? (has it?). What 
should the community do differently to make this kind of data more 
useful? Are there some requirements on data annotation that would 
make this more useful? If you could change one thing that was done in 
the past that would have made your work more useful, what would it 
be? 
• I have used Open Access data in my research and it has enabled me 
to place my work into context with respect to what other 
researchers are doing.  Although most data is freely-available it is 
not easily understandable – almost as if it is just dumped into a 
database because it is a requirement for publication.  Adequate 
descriptions of Open Access data would therefore make it more 
valuable.  One of the stumbling-blocks of my research was the lack 
of accurate annotation of the data that is provided in public 
databases, which forced me to discard most of the data anyway (for 
example cDNA libraries annotated as ‘unclassifiable’ on the 
anatomical, developmental and pathological level are useless).  In 
hindsight, making an effort to resolve annotations such as 
‘unclassifiable’ would have increased the size and value of the data 
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set used in all my analyses.  This would have required contacting 
the researcher producing each cDNA library and would be 
extremely time-consuming.  In terms of publications, I was limited 
to the subscriptions of my host institution and Open Access 
journals.  I found that much of the literature required in my 
research was not freely-available and therefore inaccessible to me.   
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only LKS stations in NH), are fully consist-
ent with this assumption, particularly for the
tropical stations. In the extratropics there are
only four daytime-only stations so the MSU
test is less meaningful, but the two indepen-
dent estimates do agree within 0.03-C per
decade.
To illustrate the importance of the heating
bias, we have computed its impact dsol on the
trends at LKS stations. The LKS f factors,
unhomogenized trends, and trends adjusted
only for solar heating are given for the middle
troposphere and lower stratosphere in Table 2.
In the stratosphere, our dsol is similar to the
total adjustments by LKS and others, with
trends moving closer to those from MSU (13).
At the tropical tropopause (of relevance to
stratospheric water vapor), dsol is somewhat
smaller than LKS_s. In the troposphere, how-
ever, dsol is much larger than previous adjust-
ments. Indeed, the tropical trend with this
adjustment (0.14-C per decade over 1979 to
1997) would be consistent with model simu-
lations driven by observed surface warming,
which was not true previously (1). One inde-
pendent indication that the solar-adjusted
trends should be more accurate is their con-
sistency across latitude belts: for the period
1979 to 1997, the spread of values fell by
70% in the lower stratosphere and 25% in
the troposphere.
Though this is encouraging, our confidence
in these nighttime trends is still limited given
that other radiosonde errors have not been
addressed. SH trends from 1958 to 1997 seem
unrealistically high in the troposphere, espe-
cially with the dsol adjustment, although this
belt has by far the worst sampling. Previous
homogenization efforts typically produced
small changes to mean tropospheric trends,
which could mean that other error trends
cancel out dsol in the troposphere. In our judg-
ment, however, such fortuitous cancellation of
independent errors is unlikely compared to the
possibility that most solar artifacts were pre-
viously either missed or their removal negated
by other, inaccurate adjustments. To be de-
tected easily, a shift must be large and abrupt,
but dsol was spread out over so many stations
(79% of stations during 1979 to 1997 and
90% during 1959 to 1997 experienced DT
trends significant at 95% level), at such
modest levels, and of sufficient frequency at
many stations that many may have been
undetectable. Most important, jumps in the
difference between daytime and nighttime
monthly means would be detectable at only a
few tropical stations because most lack suffi-
cient nighttime data. In any case, we conclude
that carefully extracted diurnal temperature
variations can be a valuable troubleshooting
diagnostic for climate records, and that the
uncertainty in late–20th century radiosonde
trends is large enough to accommodate the
reported surface warming.
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The Transcriptional Landscape of
the Mammalian Genome
The FANTOM Consortium* and RIKEN Genome Exploration
Research Group and Genome Science Group
(Genome Network Project Core Group)*
This study describes comprehensive polling of transcription start and
termination sites and analysis of previously unidentified full-length comple-
mentary DNAs derived from the mouse genome. We identify the 5¶ and 3¶
boundaries of 181,047 transcripts with extensive variation in transcripts arising
from alternative promoter usage, splicing, and polyadenylation. There are
16,247 new mouse protein-coding transcripts, including 5154 encoding
previously unidentified proteins. Genomic mapping of the transcriptome reveals
transcriptional forests, with overlapping transcription on both strands,
separated by deserts in which few transcripts are observed. The data provide
a comprehensive platform for the comparative analysis of mammalian
transcriptional regulation in differentiation and development.
The production of RNA from genomic DNA
is directed by sequences that determine the
start and end of transcripts and splicing into
mature RNAs. We refer to the pattern of tran-
scription control signals, and the transcripts
they generate, as the transcriptional landscape.
To describe the transcriptional landscape of
the mammalian genome, we combined full-
length cDNA isolation (1) and 5¶- and 3¶-end
sequencing of cloned cDNAs, with new cap-
analysis gene expression (CAGE) and gene
identification signature (GIS) and gene sig-
nature cloning (GSC) ditag technologies for
the identification of RNA and mRNA se-
quences corresponding to transcription initi-
ation and termination sites (2, 3). A detailed
description of the data sets generated, mapping
strategies, and depth of coverage of the mouse
transcriptome is provided in supporting online
material (SOM) text 1 (Tables 1 and 2). We
have identified paired initiation and termi-
nation sites, the boundaries of independent
transcripts, for 181,047 independent tran-
scripts in the transcriptome (Table 3). In
total, we found 1.32 5¶ start sites for each 3¶
end and 1.83 3¶ ends for each 5¶ end (table
S1). Based on these data, the number of
transcripts is at least one order of magnitude
larger than the estimated 22,000 Bgenes[ in
the mouse genome (4) (SOM text 1), and the
R E P O R T S
www.sciencemag.org SCIENCE VOL 309 2 SEPTEMBER 2005 1559
Appendix I Transcriptional landscape of the mammalian 
genome, Science.  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large majority of transcriptional units have
alternative promoters and polyadenylation
sites. The use of genome tiling arrays (5–7)
in humans has also implied that the number
of transcripts encoded by the genome is at
least 10 times as great as the number of
Bgenes.[ To extend the mouse data, two
HepG2 CAGE libraries, one constructed with
random primers and the other with oligo-dT
primers, were combined to produce 1,000,000
CAGE tags. Mapping of these tags to the
human genome identified the likely promoters
and transcriptional starting site (TSS) of many
of the gene models identified by tiling array,
also called transfrags (5), and clearly indicates
that the same level of transcriptional diversity
occurs in humans as in mice (table S2).
The mapping of ends of transcripts can be
used to identify the genomic span of the pri-
mary transcript. Figure 1A shows length dis-
tributions of the predicted genomic regions
spanned by mouse cDNAs showing a bi-
modal distribution and compares them with
one peak for unspliced and another for
spliced RNAs. At the upper end of the dis-
tribution are candidate mega transcripts (tran-
scripts originating from genomic regions
in the order of millions of base pairs). For
example, we located six pairs of genome sig-
nature cloning (GSC) ditags to RIKEN clone
ID 9330159J16 and corresponding RIKEN
expressed sequence tags (ESTs). This clone
encodes for a previously unidentified large
transcript that is similar to a protein tyrosine
phosphatase, receptor type D (accession
no. BC086654), the genomic structure of
which has not been previously reported (8).
The predicted mRNA is 2475 base pairs in
length but spans a genomic region of 2.2
megabases (Mb).
We previously coined the term transcrip-
tional units (TUs), which groups mRNAs
that share at least one nucleotide and have
the same genomic location and orientation
(9). However, TU fusions can join unrelated
and differently annotated transcripts (SOM
text 2). Therefore, we define a transcription-
al framework (TK) as grouping transcripts
that share common expressed regions as well
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Fig. 1. Genome-transcriptome relation. (A) Genome span covered by full-length cDNA and GIS/GSC
ditags shows similar distribution with two main peaks. Ditags mapping follows the same distribution
profile at various mapping thresholds, with a minimum around 2 to 2.5 Mb. Mapping events above this
genomic span are nonspecific. Count displays the number of events in the size interval. (B) Asymptotic
unit collapse. Due to extensive overlap of the genome, transcripts overlap to the extent that they
collapse to a few GFs. Simulating addition of ditags shows the collapsing rate of the known annotated
genes into 9976 elements only. Primary transcripts only, GFs identified by GSC ditags only; Ensembl
only, GFs produced by the 3332 Ensembl-only annotated transcripts; total, the total number of GFs.
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as splicing events, TSS, or termination events
(SOM text 1).
TKs can be clustered together into tran-
script forests (TFs), genomic regions that
are transcribed on either strand without
gaps. TFs encompass 62.5% of the genome
(table S1) and are separated by regions
devoid of transcription, or transcription des-
erts. With the inclusion of GSC tags in ad-
dition to full-length cDNA and paired EST
sequences, the estimated total number of
transcript forests is 18,461,which will col-
lapse further with increasing depth of cover-
age (Fig. 1B).
The approach used to isolate full-length
cDNAs, based on library subtraction and pre-
viously unidentified 5¶/3¶ end selection before
full-insert sequencing, was weighted toward
identification of representative transcripts.
Nevertheless, 78,393 different splicing variants
were identified, such that 65% of TUs contain
multiple splice variants (Table 2), an increase
from our previous estimate (41%) (9). This
is still expected to be an underestimate, and
new approaches will be necessary for a full
evaluation of exon diversity (10).
Transcript diversity also arises through
alternative termination. Little is known about
sequence motifs that control alternative poly-
adenylation. We identified 27 motif families
with six or more nucleotides that were statisti-
cally overrepresented within 120 base pairs of
the polyadenylation site of individual tran-
scripts in our data set. These motifs represent
candidate modulators of polyadenylation site
for eight unconventional alternative polyade-
nylation signals (1) (table S3). In addition, we
found a widespread motif family with se-
quence TTGTTT, which was associated with
both the canonical (AAUAAA and AUUAAA)
and unconventional signals (1, 11).
Gene names of 56,722 transcripts that were
protein coding were assigned according to
annotation rules (9, 12). Their encoded pro-
tein sequences were combined with the pub-
licly available proteins supported by cDNA
sequences (8). This generated a nonredundant
set of 51,135 proteins with experimental evi-
dence Eisoform protein set (IPS)^, 36,166 of
which are complete (complete IPS). By com-
parison, the mammalian gene collection (http://
mgc.nci.nih.gov) has cloned, as of July 2005,
only È16,700 transcripts (11,514 nonredun-
dant). In the FANTOM3 data set, 16,274 pro-
tein sequences are newly described. Their
splice variants were grouped together into
13,313 TKs. For 9002 of these, a previously
known sequence maps to the same TK (locus),
but 4311 clusters (5154 different proteins) map
to new TKs (SOM text 3).
There are a total of 32,129 protein-coding
TKs on the genome, of which 19,197 have only
a single protein splice form, although 2525 of
those do have an alternative noncoding splice
variant. The SUPERFAMILY analysis of
structural classification of protein database
(SCOP) domain architectures (13) was carried
out for each sequence. Of the 12,932 TKs that
show variation in splicing, 8365 showed vari-
ation in SCOP domain prediction. Of the
12,932 variable TKs, 2392 produce proteins
with different observed contents of InterPro
entries. More than two alternatives were ob-
served in 439 of the 2392 InterPro-variable
TKs. Thus, in the majority of variable loci,
splicing controls some aspect of domain con-
tent or organization. To seek evidence for such
an impact in specific sets of regulatory pro-
teins, we compared a representative protein set
Fig. 2. Transcription originating in 3¶UTRs. (A) For each analyzed exon, the fraction of tags mapped to
10 equally large subsections of the exon was calculated. (Left) CAGE tags mapping to the first exon
are prevalently located in the first part of the exon. (Middle) CAGE tags mapping to internal exons
are uniformly distributed. (Right) Last exons show a distinct overrepresentation of CAGE tags
mapping close to the 3¶ end. (B) Distance to the closest downstream gene for the set of highly
expressed TUs that have extreme tag density in the 3¶ of the terminal exons. Transcript pairs were
grouped into tail-to-head (3¶ exon and downstream TU on same strand) or tail-to-tail (3¶ exon and
downstream TU on opposite strand) configurations. Remaining TUs were used as control groups. For
TUs with strong 3¶ transcriptional activity, the distance to the next TU is significantly smaller than
expected when the gene pair is in a tail-to-tail configuration (P e 0.001107, Wilcoxon test),
suggesting regulatory mechanisms based on natural antisense influencing the downstream gene (26).
Table 1. Data set resources.
Total
Number of
libraries
Safely mapped
RIKEN full-length cDNAs 102,801 237 100,313
Public (non-RIKEN) mRNAs 56,009 52,119
CAGE tags (mouse) 11,567,973 145 7,151,511
CAGE tags (human) 5,992,395 24 3,106,472
GIS ditags 385,797 4 118,594
GSC ditags 2,079,652 4 968,201
RIKEN 5¶ESTs 722,642 266 607,462
RIKEN 3¶ESTs 1,578,610 265 907,007
5¶/3¶EST pairs of RIKEN cDNA 448,956 264 277,702
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(RPS) and a variant protein set (VPS) of
phosphatases and kinases that have been
comprehensively annotated (14) by looking
at domain composition counts (table S4).
These phosphoregulators could be function-
ally modulated through alteration in their in-
tracellular location. Among the 21 receptor
tyrosine phosphatase loci, we identified 23
variant transcripts from 14 loci with predicted
changes to the subcellular localization and
function of the encoded peptides. Of these, we
identified two noncatalytic classes: secreted
(10) and tethered (3). Furthermore, we iden-
tified two catalytic classes that lack the ex-
tracellular domains: catalytic only (5) and
tethered catalytic (5). Similarly, among the 77
receptor kinase loci, we identified 41 variant
transcripts from 33 loci which encode secreted
(16), tethered (10), catalytic only (7), or other
tethered catalytic (8) peptides. We then ana-
lyzed the membrane organization splicing
variants class within the full set of TUs (table
S5), which revealed 1287 TUs that exhibit
alternative initiation, splicing, and termina-
tion, likely to yield variant isoforms of mem-
brane proteins that differ in their cellular
location.
Of the 102,281 FANTOM3 cDNAs, 34,030
lack any protein-coding sequence (CDS) and
are annotated as non–protein coding RNA
(ncRNA) (6, 15) (table S1). Many putative
ncRNAs were singletons in the full-length
cDNA set. Among the FANTOM3 cDNA set
there was additional support from ESTs,
CAGE tags, or other cDNA clones overlapping
both the starting and termination sites for
41,025 cDNAs, of which only 3652 were
ncRNAs. This supported ncRNA set includes
many known ncRNAs (SOM text 4), and
many are dynamically expressed (SOM text
5). Following these same criteria, 3012 from
8961 cDNAs previously annotated as truncated
CDS were supported as genuine transcripts and
are believed to be ncRNA variants of protein-
coding cDNAs.
Many ncRNAs appear to start from initia-
tion sites in 3¶ untranslated regions (3¶UTRs)
of protein-coding loci (16). The normalized
distribution of CAGE tags along annotated
exons of known transcripts with more than 300
mapped tags each is shown in Fig. 2A. As
expected, the highest tag density on average
occurs at the 5¶ end, but there is also a sub-
stantial increase of tags in the last one-fifth
of the 3¶UTR. Strong evidence of 3¶ end
initiation was correlated with a short inter-
genic distance when in tail-to-tail orientation
with a neighboring gene (Fig. 2B), suggest-
ing a possible role in an intergenic regulatory
interaction.
The function of ncRNAs is a matter of de-
bate (17). Some ncRNAs are highly conserved
even in distant species: 1117 out of 2886
Fig. 3. Noncoding
RNA promoters are
highly conserved. (A)
Human-mouse conser-
vation of coding and
noncoding RNAs com-
pared with random ge-
nome sequence. (B
and C) Promoters con-
servation of noncoding
and coding mRNA
evaluated (B) by iden-
tity and (C) by align-
ment. (D) Overlap of
promoters of ncRNAs.
(E and F) Promoters of
coding mRNAs contain
a larger fraction of low
complexity and re-
peats than noncoding
promoters. LINE, long
interspersed nuclear
elements; LTR, long ter-
minal repeats; SINEs,
short interspersed nu-
clear elements.
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overlap chicken sequences, of which 780 do
not overlap known CDS and 438 do not over-
lap known mRNAs on either strand, whereas
68 out of 2886 have BLAST-like alignment
tool (BLAT) alignments to the Fugu ge-
nome, of which 40 do not overlap known
CDS on either strand. These ncRNAs are at
least as conserved as a reference set of
known ncRNAs (Fig. 3A), contrary to a pre-
vious study (17). However, ncRNAs are
slightly less conserved on average than 5¶ or
3¶UTRs. In contrast, the promoter regions of
ncRNAs are generally more conserved than
the promoters of the protein-coding mRNA,
not only between human and mouse but also
down in the evolutionary scale to chicken
(Fig. 3, B to F), and they contain binding
sites for known transcription factors (18). We
conclude that the large majority of ncRNAs
that we analyzed display positional conser-
vation across species. In considering func-
tion, one might conclude that the act of
transcription from the particular location is
either important or a consequence of ge-
nomic structure or sequence (for example,
enhancers such as that of the globin locus
can act as promoters), the transcript may
function through some kind of sequence-
specific interaction with the DNA sequence
from which it is derived, or many noncoding
RNAs have other targets but are evolving
rapidly (19, 20).
New databases have been created for cDNA
annotation, expression, and promoter analy-
sis (http://fantom3.gsc.riken.jp/db/ and SOM
text 6). The databases integrate common
gene and tissue ontologies like eVOC mouse
developmental ontologies (21), cross mapped
to Edinburgh Mouse Atlas Project (EMAP)
ontology terms (22). These eVOC terms al-
low analysis standardization of RNA sam-
ples used for cDNA and CAGE libraries in
both mouse and human and were included
into the DNA Database of Japan (DDBJ)
data submission (23).
Analysis of the output of FANTOM2 sug-
gested that there were many more tran-
scripts still to be discovered (24). Here, we
have confirmed that the majority of the
mammalian genome is transcribed, com-
monly from both strands. Such transcriptional
complexity implies caveats in interpretation
of microarray experiments (25) and genome
manipulation in mice, because these will
commonly interrupt or interrogate more than
one TK. Although the current overview gives
us an indication of the complexity of the
mammalian transcriptional landscape and a
new set of tools to begin to understand
transcriptional control (for example a very
large set of promoters that can be ascribed
to distinct classes) (16), we also gain in-
sight into the scale of the task that remains.
The ditag data indicate the existence of
very long transcripts whose isolation and
sequencing will require new cloning and
sequencing strategies. Although we have iso-
lated and sequenced many putative ncRNAs,
the FANTOM3 collection only contains 40%
of those already known. Finally, the focus
has been on polyadenylated mRNAs that
are processed and exported to the cytoplasm.
Recently, Gingeras and colleagues (5) have
shown that the set of nonpolyadenylated nu-
clear RNAs may be very large, and that many
such transcripts arise from so-called inter-
genic regions (7). The future can only reveal
additional complexity in the mammalian
transcriptome.
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Table 2. Transcript grouping and classification. The extent of splice variation was calculated by excluding
T-cell receptor and immunoglobulin genes from the transcripts. The remaining 144,351 transcripts were
grouped in 43,539 TUs, of which 18,627 (42.8%) consist of single-exon transcripts, 8110 (18.6%) contain
a single multiexon transcript, and the remaining 16,802 TUs (38.6%) contain at least two spliced
transcripts. Among these TUs, 5862 (34.9%) show no evidence of splice variation, whereas 10,940
(65.1%) contain multiple splice forms.
Total
Average
per TU
cluster
Average
per TK
cluster
Total number of transcripts 158,807 7.59 7.30
RIKEN full-length 102,801
Public (non-RIKEN) mRNAs 56,006
GFs 25,027 1.20 1.15
Framework clusters 31,992 1.53 1.47
TUs 44,147 2.11 2.03
With proteins 20,929 1.00 0.96
Without proteins 23,218 1.11 1.07
TK 45,142 2.16 2.07
With proteins 21,757 1.04 1.00
Without proteins 23,385 1.12 1.07
Splicing patterns 78,393 3.75 3.60
Table 3. Determination of transcripts start/end
accuracy. Two pieces of evidence (cDNA, tags,
ditags, EST, and 5¶-3¶ EST pairs) are required when
TSS/terminations lie inside larger transcripts, and
one piece of evidence is required when they extend
or identify new transcripts. Reliable indicates that
both ends are associated with reliable tag clusters.
Total Reliable
Total 5¶/3¶-end
pair sequence
1,507,122 1,336,397
5¶/3¶-end pair cluster 313,821 181,047
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Appendix III Correlation coefficients of genes showing biased 
expression for the developmental brain in human and mouse 
The correlation coefficients of the 90 genes showing bias for developmental 
expression in the human and mouse brain.  The table lists the HomoloGene 
group identifier, Human Entrez Gene identifier, Human Entrez gene symbol, 
Mouse Entrez Gene identifier, Mouse Entrez gene symbol and the correlation 
coefficient between the expression profiles of the genes in each species. 
Homolo- 
Gene ID 
Human 
Gene 
Human 
Symbol 
Mouse 
Gene 
Mouse Symbol Correlation 
coefficient 
7516 389075 RESP18 19711 Resp18 in mouse, only 
expressed in 
brain 
78698 387876 LOC387876 380653 Gm872 in mouse, only 
expressed in 
brain 
81871 56751 BARHL1 54422 Barhl1 in mouse, only 
expressed in 
brain 
10774 57045 TWSG1 65960 Twsg1 in mouse, 
expressed in 
all tissues 
27813 84865 FLJ14397 243510 A230058J24 Rik 0.646 
16890 399664 RKHD1 237400 Rkhd1 0.548 
2880 8835 SOCS2 216233 Socs2 0.531 
1933 5050 PAFAH1B3 18476 Pafah1b3 0.531 
55434 1289 COL5A1 12831 Col5a1 0.519 
7291 10683 DLL3 13389 Dll3 0.471 
84799 22835 ZFP30 22693 Zfp30 0.471 
7667 1154 CISH 12700 Cish 0.458 
32546 64410 KLHL25 207952 Klhl25 0.447 
17078 387914 TMEM46 219134 Tmem46 0.447 
32293 51018 CGI-115 67223 2810430M08 
Rik 
0.440 
1871 4760 NEUROD1 18012 Neurod1 0.439 
56774 54751 FBLIM1 74202 Fblim1 0.417 
68973 1663 DDX11 320209 Ddx11 0.408 
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Homolo- 
Gene ID 
Human 
Gene 
Human 
Symbol 
Mouse 
Gene 
Mouse Symbol Correlation 
coefficient 
37917 1293 COL6A3 12835 Col6a3 0.408 
55918 6882 TAF11 68776 Taf11 0.378 
10695 57120 GOPC 94221 Gopc 0.316 
14128 91107 TRIM47 217333 Trim47 0.300 
68998 170302 ARX 11878 Arx 0.300 
12418 124056 NOXO1 71893 Noxo1 0.289 
55599 669 BPGM 12183 Bpgm 0.284 
45198 65117 FLJ11021 208606 1500011J06 Rik 0.284 
18123 140730 RIMS4 241770 Rims4 0.277 
65328 7559 ZNF12 231866 Zfp12 0.273 
68934 57016 AKR1B10 14187 Akr1b8 0.258 
65280 286128 ZFP41 22701 Zfp41 0.258 
22818 29850 TRPM5 56843 Trpm5 0.258 
10663 57171 DOLPP1 57170 Dolpp1 0.251 
45867 139189 DGKK 331374 Dgkk 0.240 
17523 115290 FBXO17 50760 Fbxo17 0.207 
4397 8971 H1FX 243529 H1fx 0.207 
2212 6182 MRPL12 56282 Mrpl12 0.194 
11980 84262 MGC10911 66506 1810042K04 
Rik 
0.167 
26702 93109 TMEM44 224090 Tmem44 0.149 
56571 26503 SLC17A5 235504 Slc17a5 0.141 
7717 24147 FJX1 14221 Fjx1 0.122 
18903 440193 KIAA1509 68339 0610010D24 
Rik 
0.101 
1028 1606 DGKA 13139 Dgka 0.101 
4983 10991 SLC38A3 76257 Slc38a3 0.055 
9813 55627 FLJ20297 77626 4122402O22 
Rik 
0.055 
1368 1054 CEBPG 12611 Cebpg 0.055 
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Homolo- 
Gene ID 
Human 
Gene 
Human 
Symbol 
Mouse 
Gene 
Mouse Symbol Correlation 
coefficient 
64353 126374 WTIP 101543 Wtip 0.026 
12993 84217 ZMYND12 332934 Zmynd12 0.000 
7199 11054 OGFR 72075 Ogfr 0.000 
46116 401399 LOC401399 101359 D330027H18 
Rik 
0.000 
7500 5806 PTX3 19288 Ptx3 0.000 
413 353 APRT 11821 Aprt -0.026 
49899 143282 C10orf13 72514 2610306H15 
Rik 
-0.026 
12021 84557 MAP1LC3A 66734 Map1lc3a -0.043 
11920 84303 CHCHD6 66098 Chchd6 -0.050 
32633 136647 C7orf11 66308 2810021B07 
Rik 
-0.050 
7922 6150 MRPL23 19935 Mrpl23 -0.050 
1290 9275 BCL7B 12054 Bcl7b -0.050 
9355 51637 C14orf166 68045 2700060E02 Rik -0.077 
40668 9646 SH2BP1 22083 Sh2bp1 -0.101 
40859 27166 PX19 66494 2610524G07 
Rik 
-0.113 
10494 58516 FAM60A 56306 Tera -0.113 
6535 11062 DUS4L 71916 Dus4l -0.122 
65318 23361 ZNF629 320683 Zfp629 -0.125 
14180 115294 PCMTD1 319263 Pcmtd1 -0.145 
32 435 ASL 109900 Asl -0.145 
68420 9559 VPS26A 30930 Vps26 -0.167 
32331 51776 ZAK 65964 B230120H23 
Rik 
-0.175 
11653 79730 FLJ14001 70918 4921525L17 Rik -0.194 
49970 83879 CDCA7 66953 Cdca7 -0.207 
1330 857 CAV1 12389 Cav1 -0.213 
14157 90416 CCDC32 269336 Ccdc32 -0.213 
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Homolo- 
Gene ID 
Human 
Gene 
Human 
Symbol 
Mouse 
Gene 
Mouse Symbol Correlation 
coefficient 
56005 6328 SCN3A 20269 Scn3a -0.240 
10026 55172 C14orf104 109065 1110034A24 
Rik 
-0.273 
31656 27000 ZRF1 22791 Dnajc2 -0.273 
41703 118881 COMTD1 69156 Comtd1 -0.289 
14667 113510 HEL308 191578 Hel308 -0.300 
268 5805 PTS 19286 Pts -0.330 
2593 7913 DEK 110052 Dek -0.330 
20549 4324 MMP15 17388 Mmp15 -0.354 
18833 143678 LOC143678 75641 1700029I15 Rik -0.354 
9120 25851 DKFZP434B0
335 
70381 2210010N04 
Rik 
-0.372 
15843 79591 C10orf76 71617 9130011E15 Rik -0.372 
3476 9197 SLC33A1 11416 Slc33a1 -0.389 
21334 10912 GADD45G 23882 Gadd45g -0.389 
19028 146167 LOC146167 234788 Gm587 -0.408 
10518 84273 C4orf14 56412 2610024G14 
Rik 
-0.411 
35002 93082 LINCR 214854 Lincr -0.411 
12444 84902 FLJ14640 72140 2610507L03 Rik -0.452 
82250 150678 MYEOV2 66915 Myeov2 -0.646 
24848 266629 SEC14L3 380683 RP23-81P12.8 -0.646 
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Appendix IV Expression profile of genes showing biased expression for the developmental brain in human 
and mouse 
The expression profiles of the 90 genes showing bias for developmental expression across major human and mouse tissues in the 
form of a binary pseudoarray.  The tissues represented are female reproductive system, heart, kidney, liver, lung, male 
reproductive system and stem cell for both post-natal and developmental expression.  The table lists the HomoloGene group 
identifier, Entrez Gene identifier and Entrez gene symbol for human and mouse, as well as the species each row represents.  Values 
in the table are 1 if the genes (in rows) are expressed in the given tissues (in columns) and 0 if the genes are not found to be 
expressed in the tissues (PN – post-natal; D – development; FRS – female reproductive system; MRS – male reproductive system). 
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413 353 APRT Human 1 0 1 0 1 1 1 1 1 0 1 1 1 1 
32 435 ASL Human 1 1 1 1 1 1 0 1 1 0 1 1 0 1 
55599 669 BPGM Human 1 0 1 1 1 1 0 1 1 1 1 1 1 1 
1330 857 CAV1 Human 1 1 1 0 1 1 0 1 1 0 1 1 1 1 
1368 1054 CEBPG Human 1 0 0 1 1 1 0 1 1 0 1 1 1 1 
7667 1154 CISH Human 1 0 1 0 1 1 0 0 0 0 1 1 0 0 
55434 1289 COL5A1 Human 1 0 1 0 1 1 0 1 1 0 1 1 1 1 
37917 1293 COL6A3 Human 1 0 1 1 1 1 0 1 1 1 1 1 1 1 
1028 1606 DGKA Human 1 0 0 1 1 1 0 0 1 0 1 1 0 1 
68973 1663 DDX11 Human 1 0 1 1 1 1 0 1 1 1 1 1 1 1 
20549 4324 MMP15 Human 1 1 0 0 0 1 0 1 1 0 0 1 1 1 
1871 4760 NEUROD1 Human 0 0 0 0 0 1 0 0 0 0 0 0 0 0 
1933 5050 PAFAH1B3 Human 1 0 0 1 1 1 0 1 1 1 1 1 1 1 
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268 5805 PTS Human 1 0 0 1 1 1 0 1 1 0 1 1 1 1 
7500 5806 PTX3 Human 1 1 0 0 1 1 0 1 1 0 0 0 0 1 
7922 6150 MRPL23 Human 1 0 0 1 1 1 0 1 1 0 1 1 1 1 
2212 6182 MRPL12 Human 1 0 0 1 1 1 0 1 1 0 1 1 1 1 
56005 6328 SCN3A Human 0 0 1 0 0 1 0 0 0 0 1 1 1 1 
55918 6882 TAF11 Human 1 0 1 0 1 1 0 0 1 0 1 1 1 1 
65328 7559 ZNF12 Human 1 0 0 1 1 1 0 1 1 1 1 1 1 1 
2593 7913 DEK Human 1 1 0 1 1 1 0 1 1 1 0 1 1 1 
2880 8835 SOCS2 Human 1 0 1 1 1 1 0 1 1 0 1 1 1 1 
4397 8971 H1FX Human 1 0 0 0 1 1 0 1 1 0 1 1 1 1 
3476 9197 SLC33A1 Human 1 0 0 1 1 1 0 1 1 1 1 1 1 1 
1290 9275 BCL7B Human 1 0 1 1 1 1 0 0 1 0 1 1 1 1 
68420 9559 VPS26A Human 1 0 1 1 1 1 0 1 1 1 1 1 1 1 
40668 9646 SH2BP1 Human 1 1 0 1 1 1 0 0 1 1 1 1 1 1 
7291 10683 DLL3 Human 1 0 0 0 0 1 0 1 1 0 0 0 1 1 
21334 10912 GADD45G Human 1 0 0 1 1 1 0 1 1 0 0 1 1 1 
4983 10991 SLC38A3 Human 1 0 0 1 0 0 0 0 0 0 1 1 0 0 
7199 11054 OGFR Human 1 0 0 1 1 1 0 0 0 0 0 1 1 1 
6535 11062 DUS4L Human 1 0 0 1 1 1 0 1 1 0 1 1 0 1 
84799 22835 ZFP30 Human 1 0 0 0 1 1 0 1 1 1 1 1 1 1 
65318 23361 ZNF629 Human 1 0 0 0 1 1 0 1 0 0 1 1 1 1 
7717 24147 FJX1 Human 0 0 0 0 1 1 0 0 0 0 1 1 0 1 
9120 25851 DKFZP434B0335 Human 1 0 0 0 1 1 0 0 0 0 0 0 1 1 
56571 26503 SLC17A5 Human 1 0 0 1 1 1 0 1 1 0 1 1 1 1 
31656 27000 ZRF1 Human 1 0 1 1 1 1 0 1 1 0 1 1 1 1 
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40859 27166 PX19 Human 1 0 1 1 1 1 0 1 1 1 1 1 1 1 
22818 29850 TRPM5 Human 0 0 0 0 0 0 0 1 1 1 1 1 1 0 
32293 51018 CGI-115 Human 1 0 0 1 1 0 0 1 1 1 1 1 1 1 
9355 51637 C14orf166 Human 1 1 1 1 1 1 0 1 1 1 1 1 1 1 
32331 51776 ZAK Human 1 1 1 1 1 1 0 1 1 1 1 1 1 1 
56774 54751 FBLIM1 Human 1 1 1 0 1 1 0 1 1 1 1 1 1 1 
10026 55172 C14orf104 Human 1 0 1 1 1 1 0 1 1 0 1 1 1 1 
9813 55627 FLJ20297 Human 1 0 1 0 1 1 0 1 1 1 1 1 1 1 
81871 56751 BARHL1 Human 0 0 0 0 0 0 0 1 1 1 1 1 1 0 
68934 57016 AKR1B10 Human 1 0 1 1 1 1 0 1 1 1 1 1 1 1 
10774 57045 TWSG1 Human 1 0 0 0 1 1 0 1 1 0 1 1 1 1 
10695 57120 GOPC Human 1 0 1 0 1 1 0 1 1 0 1 1 1 1 
10663 57171 DOLPP1 Human 1 0 0 0 1 0 0 1 1 0 1 1 1 1 
10494 58516 FAM60A Human 1 0 1 1 1 1 0 1 1 1 1 1 1 1 
32546 64410 KLHL25 Human 1 0 0 0 0 1 0 1 1 0 0 1 1 1 
45198 65117 FLJ11021 Human 1 0 1 1 1 1 0 1 1 0 1 1 1 1 
15843 79591 C10orf76 Human 1 1 1 1 1 1 0 1 1 1 1 1 1 1 
11653 79730 FLJ14001 Human 1 0 1 0 0 1 0 1 1 1 1 1 1 1 
49970 83879 CDCA7 Human 1 0 0 0 1 1 0 1 1 0 1 1 1 1 
12993 84217 ZMYND12 Human 0 0 0 0 0 1 0 1 1 1 1 1 1 0 
11980 84262 MGC10911 Human 1 0 0 0 1 1 0 1 0 0 1 1 1 1 
10518 84273 C4orf14 Human 1 0 0 1 0 1 0 1 1 1 1 1 1 1 
11920 84303 CHCHD6 Human 1 0 1 0 1 1 0 1 1 0 1 1 1 1 
12021 84557 MAP1LC3A Human 1 0 1 0 1 1 0 1 1 0 0 1 0 1 
27813 84865 FLJ14397 Human 1 0 0 1 0 1 0 0 0 0 1 0 0 1 
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12444 84902 FLJ14640 Human 1 0 1 0 1 1 0 1 1 1 1 1 1 1 
14157 90416 CCDC32 Human 1 0 1 1 1 1 0 1 1 0 1 1 1 1 
14128 91107 TRIM47 Human 1 0 1 1 1 1 0 1 1 0 1 1 1 0 
35002 93082 LINCR Human 0 0 0 0 1 1 0 1 1 1 1 1 1 0 
26702 93109 TMEM44 Human 1 0 0 0 1 1 0 1 1 0 1 1 1 1 
14667 113510 HEL308 Human 1 0 0 0 1 1 0 1 1 1 1 1 1 1 
17523 115290 FBXO17 Human 1 0 1 1 0 1 0 0 1 0 1 1 1 1 
14180 115294 PCMTD1 Human 1 0 1 1 1 1 0 1 1 0 1 1 1 1 
41703 118881 COMTD1 Human 1 0 0 0 1 1 1 0 0 0 0 1 1 0 
12418 124056 NOXO1 Human 1 0 0 0 0 1 0 1 1 0 0 1 1 1 
64353 126374 WTIP Human 1 0 0 1 1 1 0 1 1 1 1 1 1 1 
32633 136647 C7orf11 Human 1 0 0 1 1 1 0 1 1 0 1 1 1 1 
45867 139189 DGKK Human 1 0 0 0 0 0 0 1 1 1 1 1 1 1 
18123 140730 RIMS4 Human 1 0 0 0 1 1 0 0 1 0 0 1 1 1 
49899 143282 C10orf13 Human 0 0 0 0 0 1 0 1 1 0 1 0 0 1 
18833 143678 LOC143678 Human 0 0 0 0 0 0 0 1 1 1 1 1 1 0 
19028 146167 LOC146167 Human 0 0 0 0 0 1 0 1 1 1 1 1 1 0 
82250 150678 MYEOV2 Human 1 0 0 0 1 1 0 1 0 0 1 1 1 1 
68998 170302 ARX Human 1 0 0 0 1 1 0 1 0 0 0 0 0 0 
24848 266629 SEC14L3 Human 0 0 0 0 0 0 0 1 1 1 1 1 1 0 
65280 286128 ZFP41 Human 1 0 1 0 1 1 0 0 0 0 0 0 0 1 
78698 387876 LOC387876 Human 0 0 0 0 0 0 0 1 1 1 1 1 1 0 
17078 387914 TMEM46 Human 0 0 0 1 1 0 0 1 1 1 1 1 1 1 
7516 389075 RESP18 Human 0 0 0 0 0 0 0 1 1 1 1 1 1 0 
16890 399664 RKHD1 Human 1 0 0 0 1 1 0 1 1 1 1 1 1 1 
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46116 401399 LOC401399 Human 0 0 0 0 0 0 0 1 1 1 1 1 1 1 
18903 440193 KIAA1509 Human 1 0 1 0 1 1 0 1 1 1 1 1 1 1 
3476 11416 Slc33a1 Mouse 1 1 1 1 1 1 1 0 0 0 0 0 1 1 
413 11821 Aprt Mouse 1 0 1 1 1 1 0 0 1 1 1 0 0 1 
68998 11878 Arx Mouse 0 0 0 0 0 1 0 1 1 0 0 0 1 0 
1290 12054 Bcl7b Mouse 1 1 1 1 1 1 0 1 1 1 1 0 0 0 
55599 12183 Bpgm Mouse 1 1 1 1 1 1 0 1 1 1 1 0 1 0 
1330 12389 Cav1 Mouse 1 1 1 1 1 1 1 1 1 1 1 1 0 0 
1368 12611 Cebpg Mouse 1 1 1 1 1 1 0 0 1 1 1 0 1 1 
7667 12700 Cish Mouse 1 1 1 1 1 1 0 0 1 0 1 0 0 0 
55434 12831 Col5a1 Mouse 1 1 1 0 1 1 0 0 1 0 1 0 1 1 
37917 12835 Col6a3 Mouse 1 0 1 0 0 1 0 1 1 0 1 0 1 0 
1028 13139 Dgka Mouse 1 0 0 0 0 1 1 0 0 0 0 0 0 0 
7291 13389 Dll3 Mouse 0 0 0 0 0 1 0 0 0 0 0 0 0 1 
68934 14187 Akr1b8 Mouse 0 0 0 1 1 1 0 0 0 0 0 0 1 0 
7717 14221 Fjx1 Mouse 1 0 0 0 1 0 0 0 0 0 0 0 0 0 
20549 17388 Mmp15 Mouse 1 1 1 1 1 1 1 1 1 1 1 1 0 0 
1871 18012 Neurod1 Mouse 0 1 1 1 0 1 0 0 0 0 0 0 0 0 
1933 18476 Pafah1b3 Mouse 1 1 1 1 1 1 0 1 1 1 1 1 1 1 
268 19286 Pts Mouse 1 1 1 1 0 1 1 1 1 1 1 0 0 1 
7500 19288 Ptx3 Mouse 0 1 0 0 0 0 0 0 1 0 1 0 1 0 
7516 19711 Resp18 Mouse 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
7922 19935 Mrpl23 Mouse 1 1 1 1 1 1 0 0 0 1 1 1 0 1 
56005 20269 Scn3a Mouse 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
40668 22083 Sh2bp1 Mouse 1 1 1 1 0 1 1 0 0 0 0 0 1 1 
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84799 22693 Zfp30 Mouse 0 0 0 0 0 0 0 1 1 1 1 1 0 0 
65280 22701 Zfp41 Mouse 0 0 1 0 0 1 0 0 0 1 1 0 1 1 
31656 22791 Dnajc2 Mouse 1 1 1 1 0 1 1 1 1 1 1 0 0 1 
21334 23882 Gadd45g Mouse 1 1 1 0 0 0 1 1 1 1 1 1 1 1 
68420 30930 Vps26 Mouse 1 1 1 1 1 1 1 1 1 1 1 1 0 0 
17523 50760 Fbxo17 Mouse 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
81871 54422 Barhl1 Mouse 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2212 56282 Mrpl12 Mouse 1 1 1 1 1 1 0 1 1 1 1 0 1 1 
10494 56306 Tera Mouse 1 1 1 1 1 1 1 1 1 1 0 1 1 1 
10518 56412 2610024G14Rik Mouse 0 1 1 1 0 1 1 0 0 0 0 0 1 0 
22818 56843 Trpm5 Mouse 0 0 0 0 1 1 0 0 0 0 1 1 1 0 
10663 57170 Dolpp1 Mouse 1 1 1 0 1 1 1 0 1 0 1 1 1 1 
10774 65960 Twsg1 Mouse 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
32331 65964 B230120H23Rik Mouse 1 1 1 0 1 1 1 1 0 0 1 0 1 1 
11920 66098 Chchd6 Mouse 1 1 1 1 1 1 1 0 1 0 1 0 0 1 
32633 66308 2810021B07Rik Mouse 1 1 1 1 0 1 1 1 0 0 1 0 1 1 
40859 66494 2610524G07Rik Mouse 1 1 1 1 1 1 1 1 1 1 1 0 1 1 
11980 66506 1810042K04Rik Mouse 1 0 1 1 0 1 0 0 0 0 1 0 0 1 
12021 66734 Map1lc3a Mouse 1 1 1 1 0 1 1 0 1 0 0 0 1 1 
82250 66915 Myeov2 Mouse 1 1 1 1 0 1 1 0 1 1 0 0 0 1 
49970 66953 Cdca7 Mouse 1 1 1 1 0 1 1 1 1 1 1 1 1 1 
32293 67223 2810430M08Rik Mouse 1 0 0 0 1 1 1 1 1 1 1 1 1 1 
9355 68045 2700060E02Rik Mouse 1 1 1 1 1 1 1 1 1 0 1 1 1 1 
18903 68339 0610010D24Rik Mouse 1 0 1 0 0 1 1 0 1 0 1 0 0 0 
55918 68776 Taf11 Mouse 1 1 1 1 1 1 0 0 1 0 0 0 1 1 
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41703 69156 Comtd1 Mouse 1 1 1 1 0 1 0 0 0 0 1 0 0 1 
9120 70381 2210010N04Rik Mouse 1 1 1 1 1 1 1 1 1 1 1 1 0 1 
11653 70918 4921525L17Rik Mouse 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
15843 71617 9130011E15Rik Mouse 1 1 1 0 0 0 1 0 0 0 0 0 0 1 
12418 71893 Noxo1 Mouse 1 0 1 1 0 1 0 1 0 0 1 1 1 0 
6535 71916 Dus4l Mouse 0 0 0 0 0 0 1 0 0 0 0 0 0 1 
7199 72075 Ogfr Mouse 1 1 1 1 0 1 0 0 1 1 1 0 1 1 
12444 72140 2610507L03Rik Mouse 0 1 1 1 0 1 1 1 0 0 0 0 1 1 
49899 72514 2610306H15Rik Mouse 1 0 0 0 0 0 0 0 1 0 0 0 1 0 
56774 74202 Fblim1 Mouse 1 1 1 1 1 1 0 1 1 1 1 1 0 1 
18833 75641 1700029I15Rik Mouse 0 0 0 1 0 1 0 0 0 0 0 0 0 0 
4983 76257 Slc38a3 Mouse 0 0 1 1 0 0 1 0 0 0 0 0 0 0 
9813 77626 4122402O22Rik Mouse 1 0 0 1 0 1 1 1 1 1 0 1 1 1 
10695 94221 Gopc Mouse 1 0 0 0 0 1 1 1 1 0 0 0 1 1 
46116 101359 D330027H18Rik Mouse 1 0 0 0 0 0 0 0 1 0 0 0 0 0 
64353 101543 Wtip Mouse 1 1 0 0 1 0 0 0 1 0 0 1 0 0 
10026 109065 1110034A24Rik Mouse 0 1 1 1 0 1 1 1 1 1 1 0 1 1 
32 109900 Asl Mouse 1 1 1 1 1 1 1 1 1 1 1 0 1 1 
2593 110052 Dek Mouse 1 1 1 1 0 1 1 0 1 1 1 0 0 1 
14667 191578 Hel308 Mouse 0 0 1 0 0 0 1 0 0 0 1 1 0 0 
32546 207952 Klhl25 Mouse 1 0 1 0 0 1 1 1 1 1 0 1 0 1 
45198 208606 1500011J06Rik Mouse 1 0 1 1 1 1 1 1 1 1 1 0 1 1 
35002 214854 Lincr Mouse 1 0 1 0 1 0 1 0 0 0 0 0 0 0 
2880 216233 Socs2 Mouse 1 1 1 1 1 1 0 1 1 1 1 1 1 1 
14128 217333 Trim47 Mouse 1 1 1 1 1 1 1 0 1 0 1 0 1 0 
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17078 219134 Tmem46 Mouse 0 0 1 0 0 0 0 1 1 1 1 1 1 0 
26702 224090 Tmem44 Mouse 1 0 1 0 1 1 0 0 1 1 0 0 1 0 
65328 231866 Zfp12 Mouse 1 0 0 0 0 1 0 0 0 0 0 1 0 0 
19028 234788 Gm587 Mouse 1 1 1 1 1 1 1 1 1 1 1 0 0 1 
56571 235504 Slc17a5 Mouse 1 0 1 1 0 0 0 0 0 0 1 0 0 1 
16890 237400 Rkhd1 Mouse 1 0 0 0 1 1 0 0 1 0 0 1 1 0 
18123 241770 Rims4 Mouse 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
27813 243510 A230058J24Rik Mouse 1 1 1 1 0 1 1 0 0 0 1 0 0 1 
4397 243529 H1fx Mouse 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
14157 269336 Ccdc32 Mouse 1 1 1 1 0 1 1 1 1 1 1 1 0 1 
14180 319263 Pcmtd1 Mouse 1 1 1 1 1 1 1 1 1 1 1 1 0 1 
68973 320209 Ddx11 Mouse 1 0 0 0 0 1 0 1 1 1 1 0 0 1 
65318 320683 Zfp629 Mouse 0 0 1 0 0 1 1 0 1 0 1 0 0 1 
45867 331374 Dgkk Mouse 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
12993 332934 Zmynd12 Mouse 1 0 0 0 0 1 0 0 0 0 0 0 0 0 
78698 380653 Gm872 Mouse 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
24848 380683 RP23-81P12.8 Mouse 1 0 1 1 1 0 0 0 0 0 0 0 0 1 
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Appendix V The individual mouse developmental ontologies 
TS01 
 first polar body 
 one-cell stage 
 second polar body 
 unclassifiable 
 zona pellucida 
 
TS02 
 second polar body 
 two-cell stage 
 unclassifiable 
 zona pellucida 
 
TS03 
 4-8 cell stage 
 compacted morula 
 second polar body 
 unclassifiable 
 zona pellucida 
 
TS04 
 blastocoelic cavity 
 embryo 
  compacted morula 
  inner cell mass 
 germ layers 
  trophectoderm 
   mural trophectoderm 
   polar trophectoderm 
 second polar body 
 unclassifiable 
 zona pellucida 
 
TS05 
 blastocoelic cavity 
 embryo 
  inner cell mass 
 germ layers 
  trophectoderm 
   mural trophectoderm 
   polar trophectoderm 
 unclassifiable 
 
TS06 
 blastocoelic cavity 
 embryo 
  epiblast 
 germ layers 
  primitive endoderm 
  trophectoderm 
   mural trophectoderm 
   polar trophectoderm 
 unclassifiable 
 
TS07 
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 embryo 
  epiblast 
 germ layers 
  endoderm 
  trophectoderm 
   mural trophectoderm 
   polar trophectoderm 
    ectoplacental cone 
 unclassifiable 
 yolk sac cavity 
 
TS08 
 embryo 
  epiblast 
 germ layers 
  ectoderm 
  endoderm 
  trophectoderm 
   mural trophectoderm 
   polar trophectoderm 
    ectoplacental cone 
 unclassifiable 
 yolk sac cavity 
 
TS09 
 embryo 
 germ layers 
  ectoderm 
  endoderm 
  mesoderm 
  trophectoderm 
   mural trophectoderm 
   polar trophectoderm 
    ectoplacental cone 
 primitive streak 
 proamniotic cavity 
 unclassifiable 
 yolk sac cavity 
 
TS10 
 allantois 
 embryo 
 germ layers 
  ectoderm 
  endoderm 
  mesoderm 
  trophectoderm 
   mural trophectoderm 
   polar trophectoderm 
    ectoplacental cone 
 primitive streak 
 unclassifiable 
 yolk sac 
 
TS11 
 allantois 
 amnion 
 anatomical site 
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  head 
  trunk 
  whole body 
 cardiovascular system 
  heart 
 chorion 
 germ layers 
  ectoderm 
  endoderm 
  mesoderm 
   mesenchyme 
  trophectoderm 
   mural trophectoderm 
   polar trophectoderm 
    ectoplacental cone 
 hematological system 
  blood island 
 nervous system 
  central nervous system {CNS} 
   future brain 
   future spinal cord 
   neural crest 
 notochordal plate 
 primitive streak 
 unclassifiable 
 yolk sac 
 
TS12 
 alimentary system 
  diverticulum 
  intestine {gut} 
  mesentery 
 allantois 
 amnion 
 anatomical site 
  head 
  trunk 
  whole body 
 branchial arch 
 cardiovascular system 
  artery 
   dorsal aorta 
  heart 
   common atrial chamber 
   mesocardium 
   myocardium 
   primitive ventricle 
   sinus venosus 
  vein 
 chorion 
 germ layers 
  ectoderm 
  endoderm 
  mesenchyme 
  trophectoderm 
   mural trophectoderm 
   polar trophectoderm 
    ectoplacental cone 
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 hematological system 
  blood island 
 nervous system 
  central nervous system {CNS} 
   floor plate 
   future brain 
    future midbrain 
    future prosencephalon 
    future rhombencephalon 
   future spinal cord 
    neural tube 
   neural crest 
   notochord 
  peripheral nervous system {PNS} 
   auditory apparatus {ear} 
    internal ear 
   visual apparatus {eye} 
 primitive streak 
 unclassifiable 
 yolk sac 
 
TS13 
 alimentary system 
  diverticulum 
  intestine {gut} 
  mesentery 
 anatomical site 
  head 
  trunk 
  whole body 
 branchial arch 
 cardiovascular system 
  artery 
   carotid artery 
   dorsal aorta 
  heart 
   common atrial chamber 
   mesocardium 
   myocardium 
   primitive ventricle 
   sinus venosus 
  vein 
 endocrine system 
  thyroid primordium 
 germ layers 
  ectoderm 
  endoderm 
  mesenchyme 
 hematological system 
  blood 
 nervous system 
  central nervous system {CNS} 
   floor plate 
   future brain 
    future midbrain 
    future prosencephalon 
    future rhombencephalon 
   future spinal cord 
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    neural tube 
   neural crest 
   notochord 
  peripheral nervous system {PNS} 
   auditory apparatus {ear} 
    internal ear 
   olfactory apparatus 
   visual apparatus {eye} 
 primitive streak 
 unclassifiable 
 urogenital system 
  nephric cord 
  presumptive nephric duct 
 
TS14 
 alimentary system 
  diverticulum 
  intestine {gut} 
  mesentery 
 anatomical site 
  anterior limb bud 
  head 
  tail bud 
  trunk 
  whole body 
 branchial arch 
 cardiovascular system 
  artery 
   carotid artery 
   dorsal aorta 
  heart 
   common atrial chamber 
   mesocardium 
   myocardium 
   primitive ventricle 
   sinus venosus 
  vein 
 endocrine system 
  pituitary gland 
  thyroid primordium 
 germ layers 
  ectoderm 
  endoderm 
  mesenchyme 
 hematological system 
  blood 
 nervous system 
  central nervous system {CNS} 
   floor plate 
   future brain 
    future forebrain 
     future diencephalon 
    future midbrain 
    future rhombencephalon 
    prosencephalon 
    ventricular system 
     fourth ventricle 
     third ventricle 
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   future spinal cord 
    neural tube 
   neural crest 
   notochord 
  peripheral nervous system {PNS} 
   auditory apparatus {ear} 
    internal ear 
   olfactory apparatus 
   visual apparatus {eye} 
 primitive streak 
 respiratory system 
  nose 
 unclassifiable 
 urogenital system 
  nephric cord 
  nephric duct 
  pronephros 
 
TS15 
 alimentary system 
  diverticulum 
  gall bladder primordium 
  intestine {gut} 
  mesentery 
   dorsal meso-oesophagus 
  oral cavity 
  pharynx 
 anatomical site 
  anterior limb bud 
  head 
  posterior limb ridge 
  tail 
  trunk 
  whole body 
 branchial arch 
 cardiovascular system 
  artery 
   carotid artery 
   dorsal aorta 
  heart 
   atrium 
    common atrial chamber 
   mesocardium 
   myocardium 
   primitive ventricle 
   sinus venosus 
  vein 
 endocrine system 
  pituitary gland 
  thyroid primordium 
 germ layers 
  ectoderm 
  endoderm 
  mesenchyme 
 hematological system 
  blood 
 musculoskeletal system 
  pre-cartilage condensation 
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 nervous system 
  central nervous system {CNS} 
   floor plate 
   future brain 
    future forebrain 
     diencephalon 
     telencephalon 
    future midbrain 
    future rhombencephalon 
    ventricular system 
     fourth ventricle 
     third ventricle 
   future spinal cord 
    neural tube 
   neural crest 
   notochord 
  peripheral nervous system {PNS} 
   auditory apparatus {ear} 
    internal ear 
     otocyst 
   ganglion 
   olfactory apparatus 
   visual apparatus {eye} 
    intraretinal space 
    optic stalk 
 respiratory system 
  lung 
  nose 
  tracheal diverticulum 
 unclassifiable 
 urogenital system 
  mesonephros 
  nephric cord 
  nephric duct 
 
TS17 
 alimentary system 
  diverticulum 
  intestine 
   large intestine 
    anal region 
   small intestine 
  liver and biliary system 
   cystic duct 
   gall bladder primordium 
   hepatic duct 
   liver 
  mesentery 
  oesophagus 
  oral cavity 
  pharynx 
  stomach 
 anatomical site 
  anterior limb bud 
  head 
  posterior limb bud 
  tail 
  trunk 
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  whole body 
 branchial arch 
 cardiovascular system 
  artery 
   carotid artery 
   dorsal aorta 
  heart 
   atrium 
    common atrial chamber 
   mesocardium 
   myocardium 
   primitive ventricle 
   sinus venosus 
   valve 
  vein 
 dermal system 
  dermis 
  epidermis 
 endocrine system 
  pituitary gland 
  thyroid primordium 
 germ layers 
  ectoderm 
  endoderm 
  mesenchyme 
 hematological system 
  blood 
 lymphoreticular system 
 musculoskeletal system 
  cartilage condensation 
  pre-cartilage condensation 
 nervous system 
  central nervous system {CNS} 
   brain 
    forebrain 
     diencephalon 
     telencephalon 
    hindbrain 
     trigeminal V 
    midbrain 
    ventricular system 
     fourth ventricle 
     lateral ventricle 
     third ventricle 
   floor plate 
   future spinal cord 
    neural tube 
   notochord 
  peripheral nervous system {PNS} 
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    vulva 
   male reproductive system 
    epididymis 
    penis 
     foreskin 
     glans 
    prostate 
    testis 
     seminiferous tubule 
    vas deferens 
     seminal vesicle 
  urinary system 
   bladder 
   kidney 
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    nephron 
     renal corpuscle 
      glomerulus 
     renal tubule 
      loop of Henle 
      renal collecting duct 
      renal distal convoluted tubule 
      renal proximal convoluted tubule 
   ureter 
   urethra 
 
TS28 
 alimentary system 
  intestine 
   large intestine 
    anus 
    colorectal 
     cecum 
     colon 
     rectum 
   small intestine 
    duodenum 
    ileum 
    jejunum 
  liver and biliary system 
   bile duct 
   cystic duct 
   gall bladder 
   hepatic duct 
   liver 
  mesentery 
  oesophagus 
  omentum 
   greater omentum 
   lesser omentum 
  oral cavity 
   jaw 
    gum 
    mandible 
    maxilla 
    premaxilla 
    tooth 
     molar 
   salivary gland 
    parotid gland 
    sublingual gland 
    submandibular gland 
   tongue 
  pancreas 
  pharynx 
   hypopharynx 
   nasopharynx 
   oropharynx 
  stomach 
 anatomical site 
  anterior limb 
  head 
  posterior limb 
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  tail 
  trunk 
  whole body 
 cardiovascular system 
  artery 
   aorta 
   carotid artery 
  capillary 
  heart 
   atrium 
   cardiac valve 
   endocardium 
   myocardium 
   pericardium 
   ventricle 
  vein 
   vena cava 
    inferior vena cava 
    superior vena cava 
 dermal system 
  appendages 
   hair 
   hair follicle 
   sebaceous gland 
   sweat gland 
   vibrissa 
  skin 
   dermis 
   epidermis 
 endocrine system 
  adrenal gland 
   adrenal cortex 
   adrenal medulla 
  parathyroid 
  pineal gland 
  pituitary gland 
  thymus 
  thyroid 
 hematological system 
  blood 
  bone marrow 
 lymphoreticular system 
  lymph node 
  spleen 
  tonsil 
   lingual tonsil 
   palatine tonsil 
 musculoskeletal system 
  bone 
  cartilage 
  joint 
   ligament 
   synovium 
  muscle 
   skeletal muscle {striated muscle} 
   smooth muscle 
  tendon 
 nervous system 
150
 
 
 
 
  central nervous system {CNS} 
   brain 
    forebrain 
     diencephalon 
      epithalamus 
      hypothalamus 
      thalamus 
     hippocampus 
     telencephalon 
      caudate nucleus 
      cerebral cortex 
       olfactory I 
      corpus striatum 
      lentiform nucleus 
      olfactory lobe 
      temporal lobe 
    hindbrain 
     medulla oblongata 
      hypoglossal XII 
      olivary nuclei 
      vagal X 
     metencephalon 
      cerebellum 
      pons 
       abducent VI 
       facial VII 
       trigeminal V 
       vestibulocochlear VIII 
    meninges 
     arachnoid 
     dura mater 
     pia mater 
    midbrain 
     oculomotor III 
     tegmentum 
     trochlear IV 
    ventricular system 
     cerebral aqueduct 
     fourth ventricle 
     lateral ventricle 
     third ventricle 
   spinal cord 
  peripheral nervous system {PNS} 
   auditory apparatus {ear} 
    auditory ossicle 
    auditory tube 
    external ear 
     auricle 
     external acoustic meatus 
    internal ear 
     membranous labyrinth 
      saccule 
      utricle 
     osseous labyrinth 
      cochlea 
       spiral organ of Corti 
      semicircular canal 
      vestibule 
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    middle ear 
    tympanum {tympanic membrane} 
   ganglion 
    spinal ganglion 
    sympathetic ganglion 
   olfactory apparatus 
   peripheral nerve 
   visual apparatus {eye} 
    choroid 
    ciliary body 
    conjunctiva 
    cornea 
    eyelid 
    iris 
    lacrimal gland 
    lens 
    optic chiasma 
    optic stalk 
    retina 
     fovea centralis 
     macula lutea 
    sclera 
    vitreous humor 
 respiratory system 
  bronchus 
  diaphragm 
  larynx 
  lung 
   alveolus 
  nose 
  pleura {pleural cavity} 
  sinus 
  trachea 
 unclassifiable 
 urogenital system 
  reproductive system 
   female reproductive system 
    amnion 
    breast 
     mammary gland 
    ovary 
    oviduct 
    placenta 
    uterus 
     cervix 
     endometrium 
     myometrium 
    vagina 
    vulva 
   male reproductive system 
    epididymis 
    penis 
     foreskin 
     glans 
    prostate 
    testis 
     seminiferous tubule 
    vas deferens 
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     seminal vesicle 
  urinary system 
   bladder 
   kidney 
    nephron 
     renal corpuscle 
      glomerulus 
     renal tubule 
      loop of Henle 
      renal collecting duct 
      renal distal convoluted tubule 
      renal proximal convoluted tubule 
   ureter 
   urethra 
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Appendix VI The merged mouse developmental ontologies 
Mouse developmental ontology 
 4-8 cell stage 
 alimentary system 
  diverticulum 
  intestine 
   large intestine 
    anal pit 
    anal region 
    anus 
    colorectal 
     cecum 
     colon 
     rectum 
   small intestine 
    duodenum 
    ileum 
    jejunum 
  liver and biliary system 
   bile duct 
   common bile duct 
   cystic duct 
   gall bladder 
   gall bladder primordium 
   hepatic duct 
   liver 
  mesentery 
   dorsal meso-oesophagus 
  oesophagus 
  omentum 
   greater omentum 
   lesser omentum 
  oral cavity 
   jaw 
    gum 
    mandible 
    maxilla 
    premaxilla 
    tooth 
     molar 
   mandibular process 
    mandible primordium 
   maxillary process 
    maxilla primordium 
   salivary gland 
    parotid gland 
    sublingual gland 
    sublingual gland primordium 
    submandibular gland 
    submandibular gland primordium 
   tongue 
  pancreas 
  pancreas primordium 
  pharynx 
   hypopharynx 
   nasopharynx 
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   oropharynx 
  stomach 
 allantois 
 anatomical site 
  anterior limb 
  anterior limb bud 
  head 
  posterior limb 
  posterior limb bud 
  posterior limb ridge 
  tail 
  tail bud 
  trunk 
  whole body 
 blastocoelic cavity 
 branchial arch 
 cardiovascular system 
  artery 
   aorta 
   carotid artery 
   dorsal aorta 
  capillary 
  heart 
   atrium 
    common atrial chamber 
   cardiac valve 
   endocardium 
   mesocardium 
   myocardium 
   pericardium 
   primitive ventricle 
   sinus venosus 
   valve 
   ventricle 
  vein 
   vena cava 
    inferior vena cava 
    superior vena cava 
 chorion 
 dermal system 
  appendages 
   hair 
   hair follicle 
   sebaceous gland 
   sweat gland 
   vibrissa 
  skin 
   dermis 
   epidermis 
 embryo 
  compacted morula 
  epiblast 
  inner cell mass 
 endocrine system 
  adrenal gland 
   adrenal cortex 
   adrenal medulla 
  parathyroid 
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  pineal gland 
  pineal primordium 
  pituitary gland 
  thymus 
  thymus primordium 
  thyroid 
  thyroid primordium 
 first polar body 
 germ layers 
  ectoderm 
  endoderm 
  mesenchyme 
  mesoderm 
  primitive endoderm 
  trophectoderm 
   mural trophectoderm 
   polar trophectoderm 
    ectoplacental cone 
 hematological system 
  blood 
  blood island 
  bone marrow 
 lymphoreticular system 
  lymph node 
  lymph sac 
  spleen 
  spleen primordium 
  tonsil 
   lingual tonsil 
   palatine tonsil 
 musculoskeletal system 
  bone 
  cartilage 
  cartilage condensation 
  joint 
   ligament 
   synovium 
  muscle 
   skeletal muscle 
   smooth muscle 
  pre-cartilage condensation 
  tendon 
 nervous system 
  central nervous system 
   brain 
    forebrain 
     diencephalon 
      epithalamus 
      hypothalamus 
      thalamus 
     hippocampus 
     telencephalon 
      caudate nucleus 
      cerebral cortex 
       olfactory I 
      corpus striatum 
      lentiform nucleus 
      olfactory lobe 
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      temporal lobe 
    hindbrain 
     medulla oblongata 
      floor plate 
      hypoglossal XII 
      olivary nuclei 
      vagal X 
     metencephalon 
      cerebellum 
      cerebellum primordium 
      pons 
       abducent VI 
       facial VII 
       trigeminal V 
       vestibulocochlear VIII 
     myelencephalon 
    meninges 
     arachnoid 
     dura mater 
     pia mater 
    midbrain 
     oculomotor III 
     tegmentum 
     trochlear IV 
    ventricular system 
     cerebral aqueduct 
     fourth ventricle 
     lateral ventricle 
     third ventricle 
   future brain 
    future forebrain 
     future diencephalon 
    future midbrain 
    future prosencephalon 
    future rhombencephalon 
    prosencephalon 
   future spinal cord 
    neural tube 
   neural crest 
   notochord 
   spinal cord 
  peripheral nervous system 
   auditory apparatus 
    auditory ossicle 
    auditory tube 
    external ear 
     auricle 
     external acoustic meatus 
    future tympanum 
    internal ear 
     membranous labyrinth 
      saccule 
      utricle 
     osseous labyrinth 
      cochlea 
       spiral organ of Corti 
      semicircular canal 
      vestibule 
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     otocyst 
    middle ear 
    tympanum 
    tympanum primordium 
   ganglion 
    spinal ganglion 
    sympathetic ganglion 
   olfactory apparatus 
   peripheral nerve 
   visual apparatus 
    choroid 
    ciliary body 
    conjunctiva 
    cornea 
    eyelid 
    intraretinal space 
    iris 
    lacrimal gland 
    lens 
    lens vesicle 
    optic chiasma 
    optic stalk 
    retina 
     fovea centralis 
     macula lutea 
    sclera 
    vitreous humor 
 notochordal plate 
 one-cell stage 
 primitive streak 
 proamniotic cavity 
 respiratory system 
  bronchus 
  diaphragm 
  larynx 
  lung 
   alveolus 
  nose 
  pleura 
  sinus 
  trachea 
  tracheal diverticulum 
 second polar body 
 two-cell stage 
 unclassifiable 
 urogenital system 
  presumptive nephric duct 
  pronephros 
  reproductive system 
   female reproductive system 
    amnion 
    breast 
     mammary gland 
    Mullerian tubercle 
    ovary 
    oviduct 
    paramesonephric duct 
    placenta 
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    uterus 
     cervix 
     endometrium 
     myometrium 
    vagina 
    vulva 
   genital tubercle 
   gonad 
   gonad primordium 
   gonadal component 
   male reproductive system 
    epididymis 
    mesonephric duct 
    penis 
     foreskin 
     glans 
    prostate 
    testis 
     primitive seminiferous tubule 
     seminiferous tubule 
    vas deferens 
     seminal vesicle 
  urinary system 
   bladder 
   degenerating mesonephros 
   kidney 
    nephron 
     renal convoluted tubule 
     renal corpuscle 
      glomerulus 
     renal tubule 
      loop of Henle 
      renal collecting duct 
      renal distal convoluted tubule 
      renal proximal convoluted tubule 
   mesonephros 
   metanephros 
   nephric cord 
   nephric duct 
   primitive ureter 
   ureter 
   ureteric bud 
   urethra 
 yolk sac 
 yolk sac cavity 
 zona pellucida 
 
Theiler Stage 
 adult 
   Theiler Stage 27 {TS 27; TS27}  
   Theiler Stage 28 {TS 28; TS28}  
 embryo  
   Theiler Stage 01 {TS 01; TS01}  
   Theiler Stage 02 {TS 02; TS02} 
   Theiler Stage 03 {TS 03; TS03}  
   Theiler Stage 04 {TS 04; TS04}  
   Theiler Stage 05 {TS 05; TS05}  
   Theiler Stage 06 {TS 06; TS06}  
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   Theiler Stage 07 {TS 07; TS07}  
   Theiler Stage 08 {TS 08; TS08}  
   Theiler Stage 09 {TS 09; TS09}  
   Theiler Stage 10 {TS 10; TS10}  
   Theiler Stage 11 {TS 11; TS11}  
   Theiler Stage 12 {TS 12; TS12}  
   Theiler Stage 13 {TS 13; TS13}  
   Theiler Stage 14 {TS 14; TS14}  
   Theiler Stage 15 {TS 15; TS15}  
   Theiler Stage 16 {TS 16; TS16}  
   Theiler Stage 17 {TS 17; TS17}  
   Theiler Stage 18 {TS 18; TS18}  
   Theiler Stage 19 {TS 19; TS19}  
   Theiler Stage 20 {TS 20; TS20}  
   Theiler Stage 21 {TS 21; TS21}  
   Theiler Stage 22 {TS 22; TS22}  
 fetus  
   Theiler Stage 23 {TS 23; TS23}  
   Theiler Stage 24 {TS 24; TS24}  
   Theiler Stage 25 {TS 25; TS25}  
   Theiler Stage 26 {TS 26; TS26}  
 Theiler Stage Unclassifiable {TS UN; TSUN}  
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The transcriptional network that controls growth arrest
and differentiation in a human myeloid leukemia cell line
The FANTOM Consortium and the Riken Omics Science Center1
Using deep sequencing (deepCAGE), the FANTOM4 study measured the genome-wide dynamics of transcription-start-site usage
in the human monocytic cell line THP-1 throughout a time course of growth arrest and differentiation. Modeling the expression
dynamics in terms of predicted cis-regulatory sites, we identified the key transcription regulators, their time-dependent activities
and target genes. Systematic siRNA knockdown of 52 transcription factors confirmed the roles of individual factors in the
regulatory network. Our results indicate that cellular states are constrained by complex networks involving both positive and
negative regulatory interactions among substantial numbers of transcription factors and that no single transcription factor is
both necessary and sufficient to drive the differentiation process.
Development, organogenesis and homeostasis in multicellular
systems involve the proliferation of precursor cells, followed by
growth arrest and the acquisition of a differentiated cellular
phenotype. Upon stimulation with phorbol myristate acetate
(PMA), human THP-1 myelomonocytic leukemia cells cease pro-
liferation, become adherent and differentiate into a mature mono-
cyte- and macrophage-like phenotype1,2. This study aimed to
understand the transcriptional network underlying growth arrest
and differentiation in mammalian cells using THP-1 cells as a
model system.
Most existing methods for regulatory network reconstruction
collect genes into coexpressed clusters and associate these clusters
with regulatory motifs or pathways (for example, see refs. 3–5).
Alternatively, one can model the expression patterns of all genes
explicitly in terms of predicted regulatory sites in promoters and the
post-translational activities of their cognate transcription factors
(TFs)6–8. Although this approach is challenging in complex eukaryotic
genomes owing to large noncoding regions, ChIP-chip data9 indicates
that the highest density of regulatory sites is found near transcription
start sites (TSSs) and regulatory regions originally thought to be distal
may often be alternative promoters10,11. Precise identification of TSS
locations is thus likely to be a crucial factor for accurate modeling of
transcription regulatory dynamics in mammals.
In this study, we extend our previous observations of genome-wide
TSS usage by Cap Analysis of Gene Expression (CAGE)12 and using
deep sequencing to identify promoters active during a time course of
differentiation and quantify their expression dynamics. DeepCAGE
data are used in combination with cDNA microarrays, other genome-
scale approaches, novel computational methods and large-scale siRNA
validation to provide a comprehensive analysis of growth arrest and
differentiation in the THP-1 cell model.
RESULTS
Outline of the analysis strategy
In most cell line models, only a subset of cells undergoes growth arrest
and differentiation. To maximize the sensitivity in this study, we
identified a subclone of THP-1 cells in which the large majority of cells
became adherent in response to PMA (Supplementary Fig. 1 online).
Our strategy began with deepCAGE, which identified active TSSs at
single-base-pair resolution, and simultaneously measured their time-
dependent expression (using normalized tag frequency) as cells
differentiated in response to PMA. The same RNA was subjected to
cDNA microarray analysis on an Illumina platform. The differentia-
tion of the cells was evident from the large increase in expression of
macrophage-specific genes such as CD14 and CSF1R detected by
both deepCAGE and microarray in all replicates (Supplementary
Fig. 2 online).
Figure 1 summarizes our Motif Activity Response Analysis (MARA)
strategy. Promoters were defined as local clusters of coexpressed
TSSs and promoter regions as their immediate flanking sequences
(Fig. 1a,b). To reconstruct transcription regulatory dynamics we
refined earlier computational methods6–8 by incorporating compara-
tive genomic information and each TF’s positional preferences relative
to the TSS in the prediction of regulatory sites. Binding sites for a
comprehensive and unbiased collection of mammalian regulatory
motifs were predicted in all proximal promoter regions (Fig. 1c) and
the observed promoter expression profiles (Fig. 1d) were combined
with the predicted site-counts (Fig. 1e) to infer time-dependent
activity profiles of regulatory motifs (Fig. 1f). We inferred individual
regulatory interactions (edges) between motifs and promoters by
comparing the promoter expression and motif activity profiles
(Fig. 1g). Rigorous Bayesian probabilistic methods were developed
for all steps of the computational analysis. Finally, a core network was
Received 16 July 2008; accepted 25 March 2009; published online 19 April 2009; doi:10.1038/ng.375
1A full list of authors and affiliations is provided at the end of this paper.
NATURE GENETICS VOLUME 41 [ NUMBER 5 [ MAY 2009 553
ART I C LES
©
20
09
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
Appendix VIIa The transcriptional network that controls growth 
arrest and differentiation in a human myeloid leukemia cell line. 
Nat Genet.                          
161
 
 
 
 
 constructed by selecting the motifs that explained the greatest propor-
tion of the expression variance, obtaining all predicted regulatory edges
between TFs corresponding to these motifs and selecting those reg-
ulatory edges that had independent experimental support. Using this
approach, we reconstructed the transcriptional regulatory dynamics
associated with cellular differentiation in human THP-1 cells, and
validated a subset of predicted regulatory interactions.
DeepCAGE quantification of dynamic TSS usage
CAGE tags generated from mRNA harvested at each time point were
mapped to the human genome. Promoters were defined as clusters of
nearby TSSs that showed identical expression profiles (within mea-
surement noise) and were substantially expressed in at least one time
point (Fig. 1a,b). Using these criteria we identified 29,857 promoters
expressed in THP-1 cells containing 381,145 unique TSS positions
(which is a subset of the nearly 2 million TSSs detected at least once in
THP-1). These promoters were contained within 14,607 promoter
regions (separated by at least 400 bp; Methods and Supplementary
Fig. 3 online). The deepCAGE data was validated using genome tiling-
array ChIP for markers of active transcription. Of the promoters
identified, 79% and 78% were associated with H3K9Ac and RNA
polymerase II, respectively (both markers of active transcription13,14),
compared to 18% and 27% for inactive promoters (Supplementary
Note online).
Among the identified promoters 84% (24,984) were within 1 kb of
the starts of known transcripts and 81% (24,327) could be associated
with 9,452 Entrez genes. Approximately half of the remaining pro-
moters were more than 1 kb away from the loci of known genes
(Supplementary Fig. 4 online). These newly identified promoters are
conserved across mammals, suggesting that they are true transcription
starts of currently unknown transcripts (Supplementary Fig. 5
online). The association of 24,327 promoters with 9,452 Entrez
genes extends previous evidence of alternative promoter usage11—in
this case even within a single cell type (Supplementary Table 1
online)—and demonstrates that promoter regions frequently contain
multiple promoters with distinguishable expression profiles (Supple-
mentary Table 2 online). In addition, for genes with known multiple
promoters deepCAGE frequently identified only one promoter to be
active in the THP-1 samples (Supplementary Fig. 6 online). Hence,
deepCAGE samples a distinct aspect of transcriptional activity that can
and does vary independently of mRNA abundances as measured by
hybridization to representative microarray probes.
Promoter expression
Using the normalized tags per million (tpm) counts assigned to the
promoters, we tested reproducibility among the three biological
replicates and compared the outcome to the Illumina array
from the same samples (Supplementary Fig. 7 online). DeepCAGE
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Figure 1 Motif Activity Response Analysis (MARA). (a) CAGE tags are mapped to the human genome and their expression is normalized; vertical lines
represent TSS positions, and their height is proportional to the normalized expression. (b) Mapped tags are clustered into promoters on the basis of their
relative expression, and neighboring promoters are joined into promoter regions. (c) A window of !300 to +100 flanking each promoter region is extracted,
multiply aligned and the MotEvo algorithm is used to predict binding sites for known motifs. (d–f) Observed expression of all promoters (d) and predicted
site-counts (e) are used to infer motif activities (f). (g) The statistical significance of the regulatory edge from motif to promoter is calculated based on
correlation of the promoter expression and motif activity profiles.
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expression measurements were comparatively noisy (Supplementary
Fig. 7a). Nevertheless, the median Pearson correlation between the
replicate-averaged expression profiles of CAGE and microarray was
around 0.72 (Supplementary Fig. 7b), which is comparable to that
observed with other deep transcriptome sequencing datasets15. As
predicted, the correlation is lower for genes with multiple promoter
regions (Supplementary Fig. 7b and discussed further in Supple-
mentary Note).
Comprehensive regulatory site prediction
Known binding sites from the JASPAR and TRANSFAC databases16,17
were used to construct a set of 201 regulatory motifs (position-specific
weight matrices, WMs), which represent the DNA binding specificities
of 342 human TFs. We predicted transcription factor binding sites
(TFBSs) for all motifs within the proximal promoter regions (!300 to
+100 bps) of all CAGE-defined promoters. Extending the proximal
promoter regions beyond the !300 to +100 window decreased the
quality of the fitted model described below (data not shown). In
contrast to previous approaches that used simple WM scanning6, we
incorporated information from orthologous sequences in six other
mammals and used a Bayesian regulatory-site prediction algorithm
that uses explicit models for the evolution of regulatory sites18,19
(Fig. 1c and Methods). Notably, different motifs had distinct and
highly specific positional preferences with respect to TSS (Supple-
mentary Fig. 8 online), extending a previous genome-scale analysis20.
Positional preferences were incorporated in the TFBS prediction by
assigning each site a probability that it is under selection and correctly
positioned. This analysis generated approximately 245,000 predicted
TFBSs for the 201 motifs genome-wide. For each promoter–motif
combination, the TFBS prediction was summarized by a count Npm,
which represents the estimated total number of functional TFBSs for
motif m in promoter p. The TFBS predictions were compared with
published high-throughput protein–DNA interaction datasets (ChIP-
chip) and predicted target genes were significantly (P values ranged
from 0.02 for ETS1 to 6.60E–263 for GABPA) enriched among genes
for which binding was observed (Supplementary Table 3 online).
Inferring key TFs and their time-dependent activities
The details of our Motif Activity Response Analysis (MARA) are
described in Methods. Briefly, for each motifm and each time point t,
there is an (unknown) motif activity Amt, which represents the time-
dependent nuclear activity of positive and negative regulatory factors
that bind to the sites of the motif (for example, the E2F activity
will depend on nuclear E2F1-8, and DP1-2 levels, as well as RB1
phosphorylation status). As in previous work6–8,21, motif activities
were inferred by assuming that the expression ept of promoter p
at time t is a linear function of the activities Amt of those motifs that
have predicted sites in p. Additionally, the effect of motif m on the
expression of promoter p is assumed to be proportional to the
predicted number of functional sites Npm. Assuming that the devia-
tions of the predicted expression levels etheopt ¼ constant +
P
m NpmAmt
from the observed levels ept are Gaussian distributed, and using a
Gaussian prior on the activities, we determine fitted activities A#mt that
have maximal posterior probability (Methods).
The inferred motif activities were validated using a number of
internal tests. First, our Bayesian procedure quantifies both the
significance of each motif in explaining the observed expression
variation as well as the reproducibility of its activity across replicates
(Fig. 2 and Supplementary Table 4 online). The activity profiles of
the top motifs are extremely reproducible across replicates and
different measurement technologies (Figs. 2 and 3a and Supplemen-
tary Fig. 9 online). It should be stressed that, although motif activities
are inferred by fitting the expression profiles of all promoters, the
model cannot be expected to predict expression profiles of individual
genes from the predicted TFBS in proximal promoters alone. The
effects of chromatin structure, distal regulatory sites, nonlinear inter-
actions between regulatory sites, and the contribution of the large
numbers of human TFs for which no motif is known, are not
considered. Furthermore, especially for genes that are dynamically
regulated, mature mRNA abundance can be dynamically regulated
independently of transcription initiation and promoter activity
through selective mRNA elongation, processing and degradation.
Our aim is not to predict expression profiles of individual genes but
rather to predict the key regulators and their time-dependent activ-
ities, which can be inferred from integration of global expression
information in a system undergoing dynamic change. We validated
the significance of the inferred activity profiles by comparing the
fraction of the ‘expression signal’ (expression variance minus replicate
noise) that is explained by the model, compared to randomized
versions, and under a tenfold cross-validation test (Supplementary
Fig. 10 online). The explained expression signal is highly significant
and this significance is maintained under tenfold cross-validation
(Methods). In addition, the highly peaked positional profiles of
TFBSs (Supplementary Fig. 8) suggest that knowing the exact TSS
is important for accurate TFBS prediction. Indeed, the predicted
TFBSs from CAGE promoters explain substantially more of the
expression signal in microarrays than predicted TFBSs of the asso-
ciated RefSeq promoters (Supplementary Fig. 10). We observe that
the model better predicts the expression profiles of those promoters
that are more strongly expressed, more reproducible across replicates,
and have higher expression variance (Supplementary Fig. 11 online).
Similarly, samples at the start and end of the differentiation time
course are better predicted than those at intermediate time points
(Supplementary Fig. 12 online), possibly because individual cells
differentiate at different rates and leave the cell populations less
homogeneous at intermediate time points.
Motif activities that were independently inferred from all 11,995
expressed microarray probes were combined with the inferred motif
activities from all CAGE and microarray replicates into a final set
of time-dependent motif activities (Methods). From these, we selected
30 ‘core’ motifs that contribute most to explaining the expression
161412108642
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Figure 2 Statistical significance and consistency across replicates of the
inferred motif activity profiles. Each dot corresponds to a motif. The
significance of each motif in explaining the observed expression variation is
quantified by the z value of its activity profile (horizontal axis, see Methods).
The consistency of the inferred activity profile of each motif is quantified
by the fraction of the variance (FOV) in the activity profile across all six
replicates (three biological replicates for both CAGE and Illumina), which
is reproduced in each replicate (vertical axis, see Methods).
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variation (red dots in Fig. 2) and segregated their activity profiles
using a Bayesian procedure into nine clusters (Fig. 3b and Methods),
including three clusters of upregulated motifs, three clusters of down-
regulated motifs and three clusters containing single motifs with
profiles involving different transient dynamics. The genome-wide set
of target promoters for each of the motifs was determined as described
in Methods. The significance of each regulatory ‘edge’ from a motif to
a putative target promoter (containing a predicted TFBS) was quan-
tified by the z value of the correlation between the motif ’s activity
profile and the promoter’s expression profile (Fig. 1e).
Core transcriptional regulatory network
The final aim in reconstructing transcriptional regulatory networks is
to infer not only the key regulators and their target gene sets, but also
the way in which the actions of these key regulators are coordinated.
For this purpose, we collected all 199 predicted regulatory edges
(z value Z1.5) between the 30 core motifs. Recognizing that the
prediction of individual regulatory edges is still prone to error, we
constructed a core regulatory network (Fig. 4) of 55 highly trusted
edges by filtering the predicted edges according to experimental
validation, either within our data or in existing literature (Supple-
mentary Table 5 online). In addition, for each core motif we extracted
the set of predicted target genes (z value Z1.5) and checked for
enrichment of gene ontology terms. A selection of significantly
enriched terms is shown as oval nodes in Figure 4 (full set of GO
enrichments are available as Supplementary Table 6 online).
Whereas our method infers the key regulators ab initio, the
majority of factors within this core network are known to be
important in the monocyte-macrophage lineage, thereby validating
the method. In addition the predicted targets of these motifs
are enriched for biological processes known to be involved in
differentiation of the monocytic lineage.
The gene ontology enrichments can broadly be divided into four
groups. Downregulated motifs E2F1-5, NFYA,B,C and MYB are
associated with cell cycle–related terms, consistent with the growth
arrest observed during PMA-induced differentiation and the specific
downregulation of numerous genes required for DNA synthesis and
cell cycle progression within 24 h of PMA addition. Notably, MYB
targets are also enriched specifically for microtubule-cytoskeleton–
associated genes. Conversely, targets of upregulated motifs are asso-
ciated with the terms immune response, cell adhesion, plasma
membrane, vacuole and lysosome, all of which are consistent with
differentiation into an adherent monocyte-like cell. The targeting of
lysosomal genes by cholesterol-regulated SREBFs (sterol regulatory
element-binding transcription factors) is of note, as lipid homeostasis
is important in the macrophage in atherosclerosis and lysosomal
storage diseases22. We also saw enrichment of signal transduction
genes among targets of the early induced motifs EGR1-3 and TBP.
Finally, there is a set of motifs whose targets are enriched in TFs.
These motifs correspond to the transiently induced/repressed motifs,
ATF5_CREB3, FOXO1,3,4 and SRF, and the repressed pair of OCT4
and FOXI1,J2 motifs.
Validation of edge predictions
THP-1 cells, even in an ‘undifferentiated’ state, are clearly a myeloid
cell line. In seeking to validate the transcriptional network, we noted
that there was a large set of TF genes expressed constitutively in the
cells that were rapidly downregulated in response to PMA, of which
MYB is an example, and another set that was expressed but further
upregulated during differentiation. It is technically difficult to apply
siRNA knockdown to genes that are only expressed later in the
differentiation. To validate predicted edges empirically, we therefore
chose to carry out siRNA knockdowns in undifferentiated THP-1 cells
for genes encoding 28 TFs that are expressed in the undifferentiated
state and for which we have associated motifs. To assess whether
siRNA knockdown carried out in the undifferentiated state is appro-
priate to address factors that increase expression during the time
course, we carried out the technically more difficult experiment of
siRNA knockdown combined with PMA treatment for SPI1 (more
commonly known in the literature as PU.1). All knockdowns were
carried out in biological triplicate and qRT-PCR was used to confirm
RNA-level knockdown, which in most cases was greater than 80%
(Supplementary Table 7 online; in addition, protein-level knockdown
was confirmed by protein blot for 14 siRNAs, see Supplementary
Fig. 13 online). Changes in gene expression caused by TF knockdown
were measured by Illumina microarrays. For each knocked-down TF
gene, we obtained the list of predicted regulatory targets for the
associated motif and divided the microarray probes into predicted
targets and nontargets for a range of z-value thresholds. Higher-
confidence targets in general show greater expression changes upon
knockdown (Fig. 5a shows the example TF genes MYB, SNAI3, EGR1
and RUNX1; additional examples are shown in Supplementary
Fig. 14 online). For SPI1, even in the absence of PMA treatment
siRNA knockdown caused significant downregulation of predicted
SPI1 targets, but the effects were much stronger when knockdown was
combined with 1 h or 24 h of PMA treatment (Fig. 5b), confirming
that PMA causes upregulation of SPI1 activity. A good correlation
between target confidence (z-value cut-off) and average log expression
ratio was observed for the large majority of experiments (Fig. 5c). For
an intermediate cut-off of z ¼ 1.5 we quantified the difference in log
expression ratio of predicted targets and nontargets (Fig. 5d) and
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Figure 3 Inferred time-dependent activities of the key regulatory motifs.
(a) The time-dependent activity profile of the E2F1-5 regulatory motif as
inferred from CAGE (left) and microarray (right) data. The three biological
replicates are shown in red, blue and green. (b) The 30 most significant
motifs with consistent activity profiles across all replicates (CAGE and
microarray) were clustered into nine sets of motifs with similar dynamics.
Each panel shows the activity of the members of the cluster (colored
curves), the names of motifs contributing and the cluster average activity
profile (black).
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found significant changes (z-value larger than 2) for 23 of 33 cases
with SPI1 knockdown combined with 24 h of PMA treatment and
MYB knockdown being the most significant (Supplementary Fig. 15
online shows the entire distribution of log expression ratios of targets
and nontargets for eight example TFs). Notably, for the TF genes
LMO2, MXI1 and SP1, the knockdown led to a significant upregula-
tion of their targets, suggesting that the three encoded TFs act
primarily as repressors in undifferentiated THP-1 cells (Fig. 5d, also
see Supplementary Fig. 14a). Together these results provide compel-
ling experimental validation of our predicted regulatory edges.
Single TF knockdowns affect multiple motif activities
Besides validating predicted targets, the siRNA knockdowns can also
be used to assess the effects of the knockdown of one TF gene on the
motif activities of other TFs. In addition to the 28 TFs perturbed
above, we included a further 24 TFs that lacked motifs but were
naturally repressed during PMA differentiation, or had been reported
to have a role in myeloid differentiation or leukemia (Supplementary
Table 8 online).
The motif activity inference method was used to determine the
changes in activities of all motifs upon knockdown of each TF gene.
To assess the role of each TF in differentiation, we defined the
differentiative overlap between a TF gene knockdown and the PMA
time course as the fraction of all motifs that significantly changed their
activity in the same direction upon TF gene knockdown as in the
PMA differentiation (Methods). By far the largest differentiative
overlap (69%) was observed for the MYB knockdown, which not
only affected MYB motif activity, but also the activity of most motifs
in the core network, with the most significant activity changes all in
the same direction as in the PMA time course (Fig. 6a). Knockdown
of 13 other TF genes generated an overlap greater than the negative
control (Supplementary Table 9 online), and Figure 6 shows three
further examples (E2F1, HOXA9 and CEBPG).
As for MYB, E2F1 knockdown reproduced some of the down-
regulation of MYB and E2F activity observed upon PMA stimulation,
but it failed to reproduce the upregulation of SREBF1,2, PU.1,
NFATC1-3 and FOS,B,L1_JUNB,D activity (Fig. 6b). Similarly, the
activity changes that HOXA9 knockdown induced were mostly in the
same direction as in the PMA differentiation; however, the SNAI1-3
and IRF1,2 motif activities failed to be
induced and the GATA4 and TBX4,5 motif
activities failed to be downregulated (Fig. 6c).
Notably, knockdown of CEBPG, encoding
one of the PMA-downregulated factors, for which we do not have a
motif, also generated activity changes that significantly overlapped
those observed in response to PMA (Fig. 6d). Finally, instead of
comparing the motif activity changes that different knockdowns
induced, we can also directly compare the expression changes of all
genes with the expression changes observed in the PMA time course.
We found thatMYB,HOXA9, CEBPG, GFI1, CEBPA, FLI1 andMLLT3
knockdowns all generated changes in gene expression that reiterated
some of those observed with PMA treatment (Supplementary
Table 8). MYB knockdown was exceptional, as it induced 35%
(340/967) and repressed 19% (172/916) of the genes upregulated and
downregulated with PMA, respectively. In addition the cells became
adherent (Supplementary Fig. 16 online) and began to express the
monocytic markers CD11B (ITGAM), CD54 (ICAM1), CD14, APOE
and CSF1R (Supplementary Fig. 2), three of which we confirmed by
flow cytometry (Supplementary Table 10 online). This development
of adherence could be linked to the GO enrichment for cytoskeleton-
associated genes among MYB targets noted above. Given these
observations one might wonder whether MYB is a master regulator
of the differentiation process and whether stronger and longer knock-
down would have reproduced the complete differentiation observed
under PMA treatment. Several observations argue strongly against
this. First, the gene sets perturbed by MYB and by the other pro-
differentiative TFs overlap only partially (Supplementary Table 11
online). Second, of the six other pro-differentiative TF genes only two
(CEBPG and GFI1) are affected by MYB knockdown. Both these facts
indicate that the other pro-differentiative TF genes are not simply
downstream of MYB. Third, MYB downregulation does not occur
until after the second hour of the PMA time course (Fig. 3b), which is
at odds with the idea of MYB sitting at the top of the regulatory
hierarchy. It is also worth noting that THP-1 cells harbor a leukemo-
genic fusion23 between MLL (mixed-lineage leukemia) and MLLT3
(MLL translocation partner 3) and that theMLLT3 siRNA targets this
leukemogenic fusion (note that full-lengthMLLT3 does not seem to be
expressed in THP-1 as there is no CAGE 5¢ signal for this gene). Our
data indicate that this fusion interferes with differentiation and that
neither PMA treatment nor MYB knockdown affects MLL-MLLT3
levels, suggesting these stimuli can bypass the differentiative block.
Conversely, MLLT3 knockdown had no effect on MYB levels. These
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Figure 4 Predicted core regulatory network of the
30 core motifs. An edge X-Y is drawn whenever
the promoter of at least one of the TFs associated
with motif Y has a predicted regulatory edge
for motif X (z value Z1.5) and the edge has
independent experimental support. The color of
each node reflects its cluster membership and
the size of the node reflects the significance of
the motif. Edges confirmed in the literature,
by ChIP or by siRNA are shown in red, blue and
green, respectively. In cases where there are
multiple lines of support only one evidence type
is shown. Supplementary Table 5 shows all
predicted edges and their experimental support.
GO terms significantly enriched among target
genes are shown as white nodes with black
edges. FOS/JUN (FOS,B,L1_JUNB,D), CREB
(ATF5_CREB3), GABPA (ELK1,4_GABPA,B2).
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results agree with previous RNAi studies that conclude that down-
regulation of MLL leukemogenic fusion proteins can promote growth
arrest but is not required for terminal differentiation24,25. Thus,
individual TF gene knockdowns affect the activities of multiple
motifs and elicit different, but overlapping, subsets of the regulatory
changes observed in the PMA time course. Taken together, the data
indicate that the independent perturbation of expression of multiple
TFs in response to PMA is both necessary and sufficient to initiate
partial differentiation.
Many TFs are involved in the differentiation process
The network predictions and the siRNA results above suggest that
upregulation and downregulation of the activities of multiple co-
operating TFs is required for differentiation. Of a curated list26 of
1,322 human TFs, 610 were detected by both CAGE and microarray in
at least one time point (Supplementary Table 12 online); however,
only 155 of these are covered by weight matrices, suggesting that other
factors may well be important in these cells. Of the 610 expressed TFs
64 were most highly expressed in the undifferentiated and 34 in the
differentiated state. In addition, 101 TFs were transiently induced or
repressed during differentiation. To elucidate the connection of these
TFs to the inferred network, we compared the predicted regulatory
inputs of co-regulated subsets of TFs with the predicted regulatory
inputs of the set of all 610 expressed TFs.
Whereas no motifs are overrepresented among inputs of statically
expressed TFs, inputs of dynamically expressed TFs showed enrichment
for a subset of motifs. TFs downregulated from 0 to 96 h PMA were
most enriched for three downregulated motifs of the core network:
OCT4 (3.4!), GATA4 (3.3!) and NFYA,B,C (2.2!) (Supplementary
Table 13a online). Similarly, TFs upregulated from 0 to 96 h were
most enriched for core network motifs that increase activity during
differentiation: SNAI1-3 (4.6!) and TBP (5.2!) (Supplementary
Table 13b). Finally, transiently regulated TFs were enriched for the
SRF (3.5!) and NHLH1,2 (3!) motifs (Supplementary Table 13c).
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Figure 5 Validation of predicted target promoter sets using siRNA knockdowns. (a) Difference in the average log expression ratio upon knockdown between
predicted target promoters and predicted nontargets (vertical axis) as a function of the z-value cut-off on target prediction (horizontal axis, more stringent
cut-offs are on the right) for knockdown of the TF genes MYB (red), SNAI3 (orange), RUNX1 (green) and EGR1 (light blue). (b) As in a but now for
knockdown of SPI1 followed by 1 h without treatment (light blue), 24 h without treatment (dark blue), 1 h of PMA treatment (orange) and 24 h of PMA
treatment (red). All straight lines are linear regression fits. (c) Pearson correlation coefficients between the average log expression ratio difference of targets
and nontargets and the cut-off on target predictions (horizontal axis). Red bars indicate correlation coefficients larger than 0.75 in absolute value; green
bars, absolute values between 0.5 and 0.75; and blue bars, less than 0.5. (d) Significance (z value) of the difference in log expression ratio between
predicted targets and nontargets (cut-off z ¼ 1.5) for all 28 TFs associated with a motif, measured as a z value (number of standard errors). Red bars
correspond to significant changes, that is, greater than two standard errors; green bars, changes between 1 and 2 standard errors; and blue bars, changes
less than 1 standard error. siRNA knockdowns were carried out in biological triplicate and knockdown was assessed by qRT-PCR (Supplementary Table 7).
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Notably, TFs that are predicted targets of SRF are mostly induced in
the first hour of PMA-induced differentiation. During this first hour
55 of the 57 genes whose expression was perturbed are induced and
30% encode TFs (Supplementary Fig. 17a online). The regulatory
inputs of these early-induced TFs are enriched for the motifs SRF, TBP
and FOSL2 (Supplementary Table 13d), which all correspond to
known PMA-responsive TFs27–30. Among the early-induced TFs, five
correspond to upregulated core network motifs themselves (FOSB,
EGR1-3 and SNAI1) and two (MAFB and EGR1) are known to induce
pro-differentiative changes31,32. It is also worth noting that significant
downregulation did not occur until the second hour, and this may
require both early induction of transcriptional repressors and the RNA
degradation proteins BTG2 and ZFP36 (tristetraprolin)33,34 (Supple-
mentary Fig. 17b). Together, these results suggest that induction of
SRF target genes in the first hour is critical to establishing the
differentiative program and is required before factors maintaining
the undifferentiated state are downregulated (Supplementary
Fig. 17b,c).
Web interface to data and analysis results
To facilitate the use of the data and analysis of results amassed here, we
provide an online tool, EdgeExpressDB, as part of the FANTOM4 web
resource, which allows users to explore our annotations of the
structure, expression and regulation of promoters genome-wide.
It also integrates published TF–promoter interactions, the siRNA
perturbations and genome-wide chromatin immunoprecipitation
experiments. Our complete set of regulatory-interaction predictions
provides a large collection of hypotheses that can be targeted for
validation, for example, through chromatin immunoprecipitation, gel
shift assays or reporter assays. The value of this resource is illustrated
by detailed examination of individual loci. For example, the osteo-
pontin gene (SPP1) is massively induced from 12 h of differentiation
(Supplementary Note). Our predictions confirm RUNX and PU.1 as
regulators and support a previous analysis in mouse implicating the
TGIF1 factor. In addition our analysis identifies NFAT, STAT, NKX6.2
and LIM domain and homeobox proteins as candidates for
further testing.
Finally, our set of human promoters, TF motifs, genome-wide
annotation of TF-binding sites and their predicted effects on the
expression of the target promoters are available through the Swiss-
Regulon website. A web interface, allowing researchers to automati-
cally perform Motif Activity Response Analysis (MARA) of their own
expression data in terms of our genome-wide predictions of TFBSs, is
also available at SwissRegulon.
DISCUSSION
We have devised a new integrated approach that combines genome-
wide identification of TSSs and their time-dependent expression with
computational modeling to reconstruct the transcriptional regulatory
dynamics of a differentiating human cell line. The CAGE tag sequen-
cing used here is tenfold deeper than in previous studies11, and this is
the first study to our knowledge to quantitatively monitor dynamic
expression changes of individual TSSs genome-wide. Using this data
we developed a new computational method in which promoter
expression profiles were modeled directly in terms of the TFBSs
occurring in their proximal promoter regions. This method allowed
us to infer which regulatory motifs are most predictive of expression
changes and the time-dependent activities of the corresponding TFs
ab initio. We identified more than two dozen different regulatory
motifs that significantly change their activity during PMA-induced
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Figure 6 Most significant motif activity changes (as measured by z value, red bars) for four TF gene knockdowns that induce motif activity changes that have
a differentiative overlap with the PMA time course of more than 50%. The corresponding motif activity changes observed in the PMA time course are shown
as gray bars.
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differentiation and a complex network of regulatory interactions
between them that have independent experimental support. Nota-
bly, although the modeling considers only TFBSs in proximal
promoter sequences, the core network in Figure 4 contains
most of the known regulators of macrophage differentiation.
Furthermore, siRNA perturbation of these TFs confirmed many
of their predicted targets, and by analyzing changes in motif
activity we found that each knockdown led to a distinct transcrip-
tional state that was associated with changes in the activities of
multiple motifs.
The changes in motif activity that we observed during THP-1
macrophage differentiation do not necessarily imply that the factor(s)
that act upon a motif are themselves transcriptionally regulated. For
example, PU.1 (SPI1) activity increases significantly in response to
PMA and we have confirmed that, besides a moderate increase in
mRNA expression, the SPI1 protein is also activated by phosphoryla-
tion35 and nuclear translocation36 (data not shown). For other motifs
such as E2F, multiple redundant factors can bind to the same sites37.
Motif activity analysis is conducted without any assumptions about
the TFs that act through these regulatory elements. That is, because
motif activity is inferred directly from expression changes of predicted
targets, the most active motifs can be identified before ascertaining the
responsible TF(s) and their mode of regulation. Thus, motif activity
analysis is a powerful approach compared to analysis of TF mRNA
expression alone.
What do our results teach us about the general structure of
regulatory networks in cellular differentiation? An often evoked
picture is that differentiation pathways consist of well-defined cascades
of regulatory events which are initiated by master regulators that sit at
the top of fixed regulatory hierarchies. A prime candidate for such a
master regulator in our system would beMYB, as its siRNA-mediated
knockdown reconstituted a significant fraction of the expression and
phenotypic changes observed under PMA-induced differentiation.
Indeed, this observation is consistent with earlier reports that MYB
antisense treatment of myeloid leukemia lines causes differentiative
growth arrest38 and that MYB is a repressor of expression of mature
macrophage-expressed genes such as CSF1R39. Our data indicate that
MYB probably acts on such genes indirectly, by a transcriptional
program that represses upregulation of SPI1 activity and downregula-
tion of proliferation.
However, several observations argue against MYB as a master
regulator: MYB downregulation is not among the first events in the
PMA time course, MYB knockdown far from completely mimics the
PMA-induced differentiation and there are several other TFs, which
are not downstream of MYB, whose knockdown reconstituted differ-
ent subsets of the PMA-induced expression changes (Supplemen-
tary Tables 8, 9 and 11). Moreover, it is known that additional factors
can also drive differentiation, for example, enforced expression of
SPI1 and CEBPA in mouse fibroblasts is sufficient to drive acqui-
sition of a macrophage-like phenotype40, and overexpression of
EGR1 and MAFB also drives differentiation, as we noted above.
Yet, evidence from mouse knockouts indicates that the whole EGR
family is dispensable for macrophage proliferation, differentiation
and function41.
Rather than a fixed hierarchy with one or very few master regulators
at the top, the picture that emerges is that of a recurrent network in
which multiple TFs mutually coordinate their activity changes to
implement the differentiation. In addition, whereas different partial
differentiation pathways can be initiated by multiple independent
perturbations, it appears that complete differentiation requires the
coordinated downregulation of multiple factors that maintain the
undifferentiated state. This observation draws some similarities to the
TF network that both maintains proliferation and prevents differen-
tiation in embryonic stem cells42. Enforced expression of four stem cell
transcription factors (MYC, OCT4, KLF4, SOX2) is sufficient to
dedifferentiate committed adult cells into a stem cell–like state43.
Maintenance of an undifferentiated proliferative state is important
in cancer, and it is worth noting that 10 of the 64 downregulated TFs
(16%) have Entrez gene annotations containing the term ‘myeloid
leukemia’ (compared to 50 of the remaining 1,258 TFs (4%); Supple-
mentary Table 14 online). In addition we have demonstrated that
knockdown of the MLL-MLLT3 leukemogenic fusion found in THP-1
also partially promotes differentiation.
From our time-course analysis, we see distinct phases of early,
middle and late, induction and repression. Our modeling predicts,
and the literature supports, SRF as the major effector of transcrip-
tional activation of immediate early genes (IEG)44. However, SRF
activation and IEG responses are not restricted to the PMA stimulus,
the monocytic lineage or differentiation28,45–47, suggesting that this
response has a more general function. We speculate that a generalized
immediate early response may be used to put the cell into a transient
receptive state, which permits downregulation of the multiple TFs that
maintain the undifferentiated state. This fits with the concept of stable
cellular states as attractors of the regulatory network dynamics. The
associated attractor basins48,49 of cellular states are analogous to local
minima in energy landscapes surrounded by slopes, and homeostatic
interactions between the TFs can be considered as providing a kind of
inertia to maintain this state. We suggest that the immediate early
response may help overcome this inertia, that is, by moving the system
out of its attractor basin.
METHODS
URLs. FANTOM4 web resource, http://fantom.gsc.riken.jp/4/; SwissRegulon,
http://www.swissregulon.unibas.ch. All methods are described in Supplemen-
tary Methods.
Accession codes. Accession numbers of the data sets, deposited in public
databases, are shown in Supplementary Table 15 online.
Note: Supplementary information is available on the Nature Genetics website.
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Appendix VIIb: Clusters of genes from Illumina microarray 
expression experiment with early, mid and late response 
characteristics 
Data selection 
For each time-point, the Rank Invariant normalization values, as well as the Flag 
Detection scores for each probe, were extracted from the files supplied by the 
Consortium.  The Flag Detection scores are determined as follows: 
• for each probe, the bead standard deviation (defined as the ‘average 
standard deviation associated with bead-to-bead variability for the sample 
in the group’ – Illumina BeadStudio User Guide) was divided by the 
intensity value to determine the variance of the measurements, yielding the 
flag detection score 
• for flag detection scores equal to 1, the probe is flagged as ‘present’ (P) 
• for flag detection scores between 0.99 and 1.00, the probe is flagged as 
‘marginal’ (M) 
• for flag detection scores less than 0.99, the probe is flagged as ‘absent’ (A) 
We excluded from consideration all probes that were flagged as ‘absent’ at any 
time-point. This resulted in a total of 9 187 probes. The probe identifiers were 
converted to EntrezGene identifiers.  Many of the probe identifiers did not have a 
corresponding gene identifier and were excluded from further analysis. This 
filtering step finally yielded 7 932 genes associated with the probes. 
Data transformation 
The 7 932 genes selected were subjected to the following transformation steps: 
• add a value of 50 to all data-points to eliminate negative values 
• perform a log2 transformation on the dataset 
• normalize the data of the 0hr by making zero mean and standard deviation 
of 1 
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• transform all other time point values using the mean and standard 
deviation determined for 0 hr.  
• to determine the change x in the expression over time for each probe 
relative to the expression level at point 0 hr, subtract the 0 hr value from 
all the other time-point values for each probe 
• to calculate the fold-change in expression for each time-point relative to 0 
hr, calculate 2^x for each time-point value x. 
The result of the data transformation is a fold-change value varying from 0 to 
infinity.  A fold-change value between 0 and 0.5 indicates that the expression of 
the probe is half or less of what it was originally (at 0 hr), and therefore the 
respective gene is considered significantly down-regulated. A fold-change value 
of 2 or more indicates that the expression of the probe is 2 or more fold greater 
than it was originally (at 0 hr) and we considered it to represent a significant up-
regulation of the gene. 
 
Clustering  
The transformed data was binned into the following categories for clustering: 
• Down-regulated: all values in the range 0 <= X <= 0.5 
o clustering value = -1 
• No regulation: all values in the range 0.6 < X < 2 
o clustering value = 0 
• Up-regulated: all values >= 2 
o clustering value = +1 
The tool used to perform clustering was TIGR MultiExperiment Viewer (version 
3.1), which is freely available from http://www.tm4.org.  For clustering we 
applied a Hierarchical Clustering algorithm using the Euclidean distance metric 
and average linkage clustering. 
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Selection of clusters 
Of the transformed 7 932 genes, 1 807 genes were not regulated throughout the 
time-points, 710 genes were down-regulated at the 24h time-point only, and 5 220 
genes were up-regulated at the 24h time-point only. These three clusters of genes 
were not selected. 
The remaining clusters were visually inspected and divided into 10 categories 
based on their regulation over time as presented in Table 1 (see Figure 2 for 
graphical representation).  In Table 1 we used the following classification of the 
time intervals in the gene response:  
• early regulation refers to the first four time-points (0.5h, 1h, 2h, 3h) 
• middle regulation refers to the next three time-points (4h, 8h, 10h) 
• late regulation refers to the last three time-points (12h, 18h, 24h) 
The heat-map of the selected clusters is depicted in Figure 1.  
Table 1:  Clustering categories for Illumina data based on the time of the response 
of genes to LPS stimulation. 
 
  Early 
Regulation 
Middle 
regulation 
Late 
regulation 
GeneCount 
Category 1 Up Up Up 4 
Category 2 Up None Up 40 
Category 3 Up None Down 5 
Category 4 None None Up 38 
Category 5 None Down Up 36 
Category 6 None Down None 15 
Category 7 None Down Down 15 
Category 8 Down None Up 31 
Category 9 Down None Down 7 
Category 10 Down Down Down 2 
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Figure 1 
Clustering image from TMeV.  Clusters were selected based on the visual 
inspection of expression profiles.  Each cluster was classified into an 
expression category based on their expression over time. 
Category2 
Category1 
Category3 
Category4 
 
Category6 
Category7 
 
Category9 
Category10 
 
174
 
 
 
 
Category 1 Category 3 
Category 5 Category 7 
Category 9 
‐1 
0 
1 
0.5h  1h  2h  3h  4h  8h  10h  12h  18h  24h 
Category 1 Category 2 Category 3 Category 4 Category 5 Category 6 Category 7 Category 8 Category 9 Category 10 
             
 
Figure 2  
Average expression profiles for the expression categories.  The average expression profile for each category was plotted along the 
time-points.  Values in the graph range from -1 (down-regulated) through 0 (no regulation) to 1 (up-regulation). 
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Appendix VIII Expression profile of transcription factors showing tissue restriction 
The expression profile of the 145 transcription factors expressed in 25% of tissues. (FRS – female reproductive system; MRS – 
male reproductive system). 
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326 AIRE 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 
430 ASCL2 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
579 BAPX1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
668 FOXL2 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1032 CDKN2D 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 1 
1053 CEBPE 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
1745 DLX1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
1746 DLX2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
1748 DLX4 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 
1761 DMRT1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
1961 EGR4 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
1993 ELAVL2 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 
2016 EMX1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
2020 EN2 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2103 ESRRB 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 
2118 ETV4 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 1 0 0 1 
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2294 FOXF1 0 0 0 0 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 
2295 FOXF2 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 
2297 FOXD1 0 0 0 0 0 0 1 1 0 0 0 1 0 0 1 0 0 0 0 0 1 
2302 FOXJ1 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 
2304 FOXE1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
2306 FOXD2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
2623 GATA1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
2672 GFI1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 
3007 HIST1H1D 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 
3008 HIST1H1E 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 
3009 HIST1H1B 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 0 0 0 0 1 
3110 HLXB9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
3198 HOXA1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 0 1 0 0 0 
3205 HOXA9 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 
3207 HOXA11 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
3209 HOXA13 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
3231 HOXD1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 
3234 HOXD8 0 0 0 0 0 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 
3642 INSM1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0 
3975 LHX1 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 1 0 0 1 
4210 MEFV 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4656 MYOG 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4796 NFKBIL2 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0 1 
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4821 NKX2-2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
4861 NPAS1 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0 0 1 0 0 1 
4901 NRL 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 1 
5013 OTX1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 1 
5076 PAX2 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 
5077 PAX3 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0 1 
5079 PAX5 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 
5081 PAX7 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
5453 POU3F1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 1 
5454 POU3F2 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
5455 POU3F3 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 1 0 0 0 
5462 POU5F1P1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
5992 RFX4 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 1 0 1 1 
6474 SHOX2 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
6493 SIM2 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 
6496 SIX3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
6664 SOX11 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 
6689 SPIB 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 1 0 0 0 1 
6877 TAF5 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 1 0 0 1 
6899 TBX1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 
6913 TBX15 0 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
7023 TFAP4 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 1 0 1 1 
7161 TP73 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 1 0 0 1 
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7291 TWIST1 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 1 0 0 1 
7310 U2AF1L1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 
7546 ZIC2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 
7621 ZNF70 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
7673 ZNF222 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 
7675 ZNF121 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 1 0 0 0 
7710 ZNF154 0 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 1 0 0 1 
7768 ZNF225 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 1 0 0 1 
8092 CART1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 
8193 DPF1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
8320 EOMES 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 1 
8345 HIST1H2BH 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 0 1 0 0 0 
8820 HESX1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
8970 HIST1H2BJ 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 
9970 NR1I3 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 
10215 OLIG2 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 
10655 DMRT2 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 
10794 ZNF272 0 0 0 0 0 1 0 0 1 0 0 1 0 0 0 0 0 1 0 1 0 
11077 HSF2BP 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 1 0 0 1 
11281 POU6F2 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 1 1 
25806 VAX2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 
26038 CHD5 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 
26108 PYGO1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
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26468 LHX6 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 1 0 0 1 
27023 FOXB1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 1 1 0 0 1 
27164 SALL3 0 1 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 1 0 0 1 
27288 HNRNPG-T 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 
27439 CECR6 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0 1 
30009 TBX21 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 
30012 TLX3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
50805 IRX4 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 1 0 1 
51022 GLRX2 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 1 0 0 1 
51402 LW-1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
51450 PRRX2 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
54626 HES2 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 
55552 HSZFP36 0 0 0 0 0 1 1 0 0 1 0 1 0 0 0 0 0 1 0 0 0 
55659 ZNF416 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 1 1 
56938 ARNTL2 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 
56978 PRDM8 0 1 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
57116 ZNF695 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
57332 CBX8 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0 0 1 0 0 1 
57343 ZNF304 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 
57801 HES4 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 
58495 OVOL2 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 1 0 0 1 
60529 ALX4 0 0 0 0 0 1 0 0 1 0 0 1 0 0 0 0 0 1 0 0 1 
63978 PRDM14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
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79192 IRX1 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 1 0 0 1 
79722 FLJ11795 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 1 0 0 0 1 
79816 TLE6 1 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 
79862 ZNF669 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 
80032 ZNF556 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
84127 RUNDC2A 0 0 0 0 0 1 1 0 1 0 0 1 0 0 0 0 0 0 0 0 1 
84911 ZNF382 0 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0 1 0 0 1 
85409 NKD2 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 1 
85446 ZFHX2 1 0 0 0 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 
89870 TRIM15 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 
90649 ZNF486 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 1 0 0 1 
94039 ZNF101 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 1 0 1 
94234 FOXQ1 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 0 0 0 1 
116448 OLIG1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 
126295 LOC126295 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 
129025 SUHW1 0 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0 0 0 0 1 
136051 DKFZp762I137 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
138474 TAF1L 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
140883 SUHW2 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0 1 
142689 ASB12 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
146434 ZNF597 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 1 0 0 1 
148268 ZNF570 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 
148979 GLIS1 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 1 0 0 1 
181
 
 
 
 
G
en
eI
D
 
G
en
e 
Sy
m
bo
l 
ad
re
na
l g
la
nd
 
bl
oo
d 
bl
oo
d 
ve
ss
el
 
bo
ne
 
bo
ne
 m
ar
ro
w
 
 F
R
S 
he
ar
t 
ki
dn
ey
 
liv
er
 
lu
ng
 
ly
m
ph
 
M
R
S 
m
uc
os
a 
pa
nc
re
as
 
pi
ne
al
 g
la
nd
 
pi
tu
ita
ry
 g
la
nd
 
sp
le
en
 
st
em
 c
el
l 
th
ym
us
 
th
yr
oi
d 
ot
he
r 
161253 FLJ38964 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 
162979 ZNF342 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 
163059 ZNF433 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 
163071 ZNF114 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
170302 ARX 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 
171392 ZNF675 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 
221527 ZBTB12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
245806 VGLL2 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 
253738 EBF3 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 
283078 MKX 0 0 0 0 0 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 1 
285676 ZNF454 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
339416 ANKRD45 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
339488 TFAP2E 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
341405 ANKRD33 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
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Cancer/Testis (CT) genes, normally expressed in germ line cells but
also activated in a wide range of cancer types, often encode
antigens that are immunogenic in cancer patients, and present
potential for use as biomarkers and targets for immunotherapy.
Using multiple in silico gene expression analysis technologies,
including twice the number of expressed sequence tags used in
previous studies, we have performed a comprehensive genome-
wide survey of expression for a set of 153 previously described CT
genes in normal and cancer expression libraries. We find that
although they are generally highly expressed in testis, these genes
exhibit heterogeneous gene expression profiles, allowing their
classification into testis-restricted (39), testis/brain-restricted (14),
and a testis-selective (85) group of genes that show additional
expression in somatic tissues. The chromosomal distribution of
these genes confirmed the previously observed dominance of X
chromosome location, with CT-X genes being significantly more
testis-restricted than non-X CT. Applying this core classification in
a genome-wide survey we identified>30 CT candidate genes; 3 of
them, PEPP-2, OTOA, and AKAP4, were confirmed as testis-
restricted or testis-selective using RT-PCR, with variable expression
frequencies observed in a panel of cancer cell lines. Our classifica-
tion provides an objective ranking for potential CT genes, which is
useful in guiding further identification and characterization of
these potentially important diagnostic and therapeutic targets.
gene index ! prediction
Cancer/Testis (C/T) genes are a heterogeneous group that arenormally expressed predominantly in germ cells and in
trophoblasts, and yet are aberrantly activated in up to 40% of
various types of cancer types (1). A subset of the CT genes has
been shown to encode antigens that are immunogenic and elicit
humoral and cellular immune responses in cancer patients (2).
Because of their restricted expression profile in normal tissues
and because the testis is an immunoprivileged site, the CT
antigens are emerging as strong candidates for therapeutic
cancer vaccines, as revealed by early-phase clinical trials (3–10).
Biologically, the CT genes provide a model to better understand
complex gene regulation and aberrant gene activation during
cancer.
Any gene that exhibits an mRNA expression profile restricted
to the testis and neoplastic cells can be termed a CT gene.
Existing definitions of CT genes vary in the literature, from
genes expressed exclusively in adult testis germ cells and malig-
nant tumors (1, 11) to dominant testicular expression (12),
possible additional presence in placenta and ovary and epige-
netic regulation (13), or membership of a gene family and
localization on the X chromosome (14). Reflecting this lack of
a consensus definition, an increasing number of heterogeneous
CT candidates have appeared in the literature, with available
expression profile information frequently limited to the original
defining articles. In some cases, e.g., ACRBP, the original
CT-restricted expression in normal tissues could not be con-
firmed by subsequent experiments (1). Partially due to this lack
of a clear and broadly applicable definition, or ‘‘type specimen,’’
for a CT gene, it has become increasingly challenging to identify
the CT genes that are most suitable for cancer vaccine devel-
opment. Moreover, this incoherent classification increases the
risk of pursuing unsuitable clinical targets. However, with more
expression data becoming available, CT gene transcripts of genes
originally thought to have the CT expression profile are being
detected in additional tissues (1), resulting in the more stringent
‘‘testis-restricted’’ description being altered to one of ‘‘testis-
preference.’’ Based on a compilation from the published liter-
ature, the CT database now lists !130 RefSeq nucleotide
identifiers as CT genes that belong to 83 gene families (www.
cta.lncc.br). An analysis of the human X chromosome has also
suggested that as many as 10% of the genes on this chromosome
may be CT genes (15). Given this increasing number of CT and
CT-like genes, their comprehensive classification based on ex-
pression profiles is essential for our understanding of their
biological role and regulation of expression.
In an attempt to resolve this and to identify new CT antigens,
we have taken an in silico approach to produce a comprehensive
survey of CT gene expression profiles by combining expression
information from an existing corpus of !8,000 cDNA libraries
(16) together with the depth and resolution provided by mas-
sively parallel signature sequencing (MPSS) expression libraries
(17), cap-analysis of Gene Expression (CAGE) libraries (18),
and a survey using semiquantitative reverse-transcription PCR
(RT-PCR) on a panel of 22 normal tissues. As a result, we have
created a coherent classification of CT genes, and new CT genes
have been identified using well-informed, structured prediction
and confirmation criteria.
Results and Discussion
CT classification. CT genes were classified into 3 groups, testis-
restricted, testis/brain-restricted and testis-selective, based on
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their expression profiles obtained from a manually curated
corpus of cDNA, MPSS, CAGE expression libraries and RT-
PCR (see Dataset S1 for MPSS and CAGE library annotation
and http://evocontology.org for the cDNA annotation). By merg-
ing expression information using different technology platforms,
we were able to leverage their individual strengths—the breadth
of tissue coverage associated with the cDNA/EST expression
libraries, the high sensitivity of CAGE/MPSS and the ability to
custom-tailor PCR primers. Of 153 genes, 39 with transcripts
present only in adult testis and no other normal adult tissue
except for placenta were classified as testis-restricted; 14 CT
genes with additional expression in other adult immuno-
restricted sites (all regions of the brain) were classified as
testis/brain-restricted, and 85 genes, designated as testis-
selective, were ranked by the ratio of testis/placenta expression
relative to other expression in normal adult tissues (see Fig. 1 for
Fig. 1. Merged expression profiles of CT-X (left array) and non-X CT genes (Right) based on expression data from RT-PCR and cDNA, MPSS and CAGE libraries
from tissues sources annotated as normal and ‘‘adult’’ (Lower) or ‘‘cancer.’’ Expression in normal testis, placenta, and selected tissues is marked. Color reflects
the support for the expression of a CT genes in a given anatomical site (blue for low combined expression evidence !1, red for strong support from at least 3
sources (for the normal tissue panel) with a total score!3) or 2 sources (the cancer panel lacking RT-PCR data), respectively. Themost abundant expression (red)
is seen in testis for most genes, particularly in the non-X CT group. Expression values were normalized on a per-gene basis relative to the combined normal
testis/placenta expression confidence (Lower) or the source of the highest cancer expression confidence (Upper). The 3 CT annotation groups (testis-restricted,
testis/brain-restricted and testis-selective) are highlighted. See Dataset S3 for the full list of CT classifications.
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the expression array, Fig. 2 for the PCR panel of selected
testis-restricted CT genes, and Fig. S1 and Dataset S2 for arrays
from individual expression sources).
An uneven chromosomal distribution of the CT genes was
observed, with 83 of 153 genes (54%) being on the X chromosome,
and 70 on non-X chromosomes (Fig. S2). Furthermore, 35 CT-X
genes were classified as testis-restricted, whereas only 4 non-X CT
genes belong to this group. An additional 12 CT-X genes were
found to be testis/brain-restricted, compared with 2 non-X testis/
brain-restricted CT genes. CT-X gene family members thus appear
to be under more stringent transcriptional restriction in somatic
tissues, whereas non-X CT genes are more broadly expressed. This
validates the CT gene classification into CT-X and CT non-X
groups, with the CT-X group being of particular interest for
therapeutic approaches.
Twenty-six CT-X and 59 non-X CT genes belong to the
testis-selective category, and 36 of these genes (5 CT-X and 31
non-X CT) had !50% of the expression evidence derived from
non-testis or placental libraries, indicating that these might not
qualify as CT genes.
Seven CT genes were not identified in any library at all (2 CT-X
and 5 non-X CT). An additional 8 CT-X genes (SPANX-N1,
PAGE1, CSAG1, SSX5/6/7/9, and CT45-2) were not present in any
testis-annotated library. Of these, SSX5 and SSX7 have been shown
to be expressed in testis by RT-PCR (19), suggesting a likely
discrepancy in mapping short sequence tags to their genomic
counterparts, an expected phenomenon for large and highly ho-
mologous gene families like SSX. In contrast, the absence of
testicular expression of SSX6andSSX9was confirmed in that study,
indicating that some of the currently recognized CT genes could
either be silent or expressed at extremely low levels in testis. The full
list with classification and raw expression scores across the merged
expression array can be found in Dataset S3.
Associations between different CT gene properties and their
assigned classification were analyzed using the APRIORI algo-
rithm. Besides being more likely testis-restricted, CT-X genes
were found to be more often members of multigene families than
non-X CTs. In addition, Gene Ontology terms showed CT-X
genes to bemore often in the ‘‘molecular function unknown’’ and
‘‘biological process unknown’’ categories, whereas the non-X
CTs are associated with known functions such as meiosis, sexual
reproduction, and gametogenesis (see Dataset S4 for all at-
tributes and annotations).
While the description of CT-X genes such as NY-ESO-1 (20),
SSX2 (21), andMAGE-A1 (22) match our classification—all are
in the testis-restricted category—not all CT genes were found to
be as testis-restricted as described in the literature. BAGE,
SPO11, LIPI, LDHC, and BRDT, considered to be testis-
restricted based on a tissue panel of 13 non-gametogenic normal
tissues (1), fall into the testis-selective category in our screen,
most likely due to a larger amount of expression sources
sampled. Despite the broader coverage we could not confirm an
expression of MAGE-A1, MAGE-C1, and NY-ESO-1 at low
levels in the pancreas reported in the same study. In agreement
with the study in ref. 1, we found IL13RA1, ACRBP, and SPA17
to be expressed in a wide variety of tissues, falling into the lower
end of the testis-selective category.
In the present study, we have ranked the testis-selective genes
based upon the ratios of their expression evidence in testis and
placenta relative to other somatic tissues, rather than using fixed
thresholds and the number of somatic tissues in which a CT
candidate is allowed as the distinguishing criteria for CT versus
non-CT genes (2). Genes without any somatic expression have
unique potential for cancer vaccines and other therapeutic
approaches to cancer. From past work involving screening of
larger sets of genes (23), a cutoff was introduced that defined CT
candidate genes as genes with 2-fold higher expression evidence
in testis and placenta relative to all other somatic normal tissues.
This approach was complementary to our current one and will
not require updated thresholds as the number of sampled tissue
sources increases.
Intriguingly, a number of CT genes were found to be expressed
in no somatic tissues except for brain, suggesting the presence of
a distinctive transcriptional control mechanism that functions
with tissue specificity in germ cells and in brain. There have been
relatively few studies of CT gene expression in different ana-
tomical regions of normal brain and similarly not many in brain
tumors (24, 25), except for NXF2, which was shown to be
expressed in normal brain (26). Our in silico study has discovered
a broader subset of CT genes with brain expression, among them
members of the otherwise fully testis-restricted GAGE and
MAGE families, found to be expressed in the hippocampus and
cerebral cortex. A previous study has similarly identified a group
Fig. 2. RT-PCR analysis of selected CT genes in the testis-restricted category (MAGEA1, GAGE, SSX2, NY-ESO-1, MAGEC1, and SPANX). Expression profile are
shown for a range of 22 normal tissues (Left) and 31 cancer cell lines (Right).
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of cancer/testis/brain (CTB) antigens (27). However, despite the
bioinformatic evidence, we have not been able to confirm the
expression of selected CT genes (MAGEA9,MAGEC2, PASD1,
and GAGE) in tissue samples from total brain, cerebellum,
caudate nucleus, thalamus, frontal cortex, occipital cortex, pons,
or amygdala by RT-PCR (data not shown), and whether these
genes are expressed in brain remains to be proven.
Distribution of CT Genes in Cancer Tissues. Our ranking by the
number of different cancer types and anatomical sites of CT
genes expressed in cancer-annotated libraries distinguishes CT-
‘‘rich’’ and CT-‘‘poor’’ tumors based on the in silico analysis
obtained from cDNA, CAGE, and MPSS libraries (Fig. 1 and
Dataset S5). The broadest distribution of CT genes was found in
germ cell tumors, melanomas and lung carcinomas, adenocar-
cinomas and chondrosarcomas. Breadth of cancer expression
was uncorrelated with tissue restriction in normal tissues (r !
0.18 for CT-X genes, r ! 0.02 for non-X CT genes using
Spearman rank correlation); for instance, the fully testis-
restricted CT genes, such as MAGEA2/A2B and CTAG2, were
found to be present in a variety of different tumor tissues.
Melanoma, non-small-cell lung cancer, hepatocelluar carci-
noma and bladder cancer have been identified as high CT gene
expressors, with breast and prostate cancer being moderate and
leukemia/lymphoma, renal and colon cancer low expressors (1).
Our in silico analysis confirms this distinction, in particular for
tumor tissues well represented by the available libraries, showing
a broad distribution of CT genes expressed in cancers of skin
including melanoma (43% of CT genes with cancer expression
were found in at least one melanoma library), lung (37%), and
liver (34%). Strong presence of CT expression found in the
present study but not by previous RT-PCR studies includes
tumors from germ cells (39%), stomach (28%), and cartilage
(chondrosarcomas, 26%). One reason for this discrepancy could
be the lack of RT-PCR data for certain tumors, e.g., gastric
cancer is much rarer than other carcinomas in the Western
world, and mesenchymal tumors are also not well represented in
many of the RT-PCR studies to date. Our in silico information
may thus serve as a guide for future experimental investigations,
especially useful for recently described CT genes not yet analyzed
in great detail. Discrepancies are also likely to occur due to the
potential inclusion of cancer cell line samples in the survey that,
unlike normal tissue samples explicitly labeled as normal, are
often not diistinguished from primary tumor samples. A third
reason for this observed discrepancy could be the bias that
resulted from differences in library numbers studied for each
tumor type: for instance, ovarian cancer is CT-rich by RT-PCR
but not evident from our in silico study, possibly due to the low
number of available ovarian cDNA libraries. However, colon
cancer, a CT-poor tumor, was correctly shown to have low
frequency of CT genes despite the large number of colon
libraries in the databases, and this would argue that the differ-
ence in library numbers may not have been a significant factor.
Last, the in silico finding of high CT expression in germ cell
tumor represents a special situation that can be explained by two
reasons. One is that a subset of CT genes, particularly the non-X
CTs, encode proteins with known specific functions in germ cells,
and their expression in germ cell tumors represents the pre-
served expression of lineage-specific markers—rather than ab-
errant gene activation, conceptually similar to the expression of
thyroglobulin by thyroid cancer or prostate specific antigen by
prostate cancer. The other reason would be that the germ cell
tumors from which the mRNA expression profiles were derived
could have been contaminated by the adjacent or entrapped
testicular tissue, which provides the source for CT gene tran-
scripts when the germ cell tumor was actually negative for the CT
gene in question.
CT Candidate Prediction. Prediction of CT candidates based on
their expression profiles in cDNA, MPSS, and CAGE libraries
resulted in 28 genes supported by 2 expression platforms in the
testis- or testis/brain-restricted category, including 10 known CT
genes and 18 novel CT candidates (Fig. S3 and Dataset S6). An
additional, less stringent screen for CT-X genes identified 47
genes in the same categories, including 34 known CT genes and
13 novel candidates. After manual curation, the list of novel
candidates was extended to include the highest scoring testis-
selective CT-X candidates, TKTL1 and NXF3, the latter being
a known CT gene, a member of the NXF2 CT family (28).
Of 33 novel CT candidate genes, 12 most promising genes were
manually selected for experimental validation by RT-PCR based
on an evaluation of available gene expression data in human
cancer. Of the 5 X- and 7 non-X-chromosomal candidates, 11
transcripts could be amplified, whereas transcripts from VCX2
were not detected in any of the 23 normal tissue RNA samples.
Three of the amplified gene transcripts exhibited testis-restricted
(AKAP4) or testis-selective (PEPP-2, OTOA) expression (data
not shown). RT-PCR products of these genes were also detected
in samples from a panel of 30 cancer cell lines.
PEPP-2, an X-linked human homeobox gene, encodes a
transcriptional factor with similar cancer/testis restricted expres-
sion patterns in both human and mouse (29); it is also a member
of a top 50 list of genes under strong positive selection between
human and chimpanzee (30). Otoancorin (OTOA) was reported
to be specific to sensory epithelia of the inner ear (31), but has
also been associated with ovarian and pancreatic cancer due to
its homology with mesothelin, a cancer immunotherapy target
(32). AKAP4 (CT-X), identified in the 2-platform screen, ex-
hibits weak expression in different cancer cell lines and encodes
a kinase anchor protein (33) involved in the cAMP-regulation of
motility (34) and was recently suggested as a CT gene in an
independent study (35).
All 3 confirmed genes are candidates for immunotherapy
based on their restricted expression, and further investigation of
their mRNA and protein expression in various tumors is war-
ranted and ongoing. Given the comprehensive nature of our
study and the limited number of confirmed novel CT candidates,
it seems that the number of true CT genes matching the criterion
of stringent testis-restricted expression profile has reached a
plateau.
Although it is clear that the CT designation has been inap-
propriately given to a large number of genes with wide normal
tissue expression, it is less evident how precisely the term CT
should be applied. There is no difficulty with CT genes whose
expression profile have a classic CT pattern; we estimate "39
genes presently in this category and"90% of them reside on the
X chromosome. The challenge for the remaining CT genes, most
of which are non-X coded, is that they are expressed in testis and
cancer, but are also expressed in a limited number of normal
tissues. Should these be designated CT? Perhaps the best solu-
tion at this point would be to assemble further information about
CT genes and their products, including function, binding part-
ners, evolutionary selection (36), control of gene expression,
identification of expressing normal somatic cells, aberrant non-
lineage expression in cancer, and immunogenicity, before estab-
lishing a uniform classification of CT genes.
Methods
Selection of CT Genes. A total of 153 CT genes (200 unique RefSeq transcript
identifiers) were selected from the CT Antigen DB (http://www.cta.lncc.br)
and by manual curation of the literature. Genes were annotated with their
most currentgene identifiers andmergedbasedon sharedNationalCenter for
Biotechnology Information RefSeq nucleotide identifiers (Dataset S7). Addi-
tional gene identifiers were obtained from RefSeq release 11 (37), IPI version
3.29 (38); genomic coordinates were taken from the University of California,
Santa Cruz Genome Browser hg18 human genome build (39). Of these 153
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genes, 83 that encode 107 RefSeq transcripts were mapped to the X chromo-
some (CT-X genes) whereas 70 genes were on autosomes (non-X CT genes).
Subcellular localization was based on predictions in the human version of the
LOCATE system (40). SEREX information was obtained from the Cancer Im-
munome Database website (http://ludwig-sun5.unil.ch/CancerImmu-
nomeDB). Ambiguities were resolved by manual curation.
Source of Expression Information. Gene expression profiles were determined
based on 4 different sources: 99 CAGE libraries from the RIKEN FANTOM3 project
(18),47MPSS libraries (17,23,41),acollectionof8401cDNAexpression libraries from
theeVOCsystem (16), and semiquantitativeRT-PCRacross 22normal tissue samples.
Sourcematerialswereannotatedwith regards to theanatomical site andpatholog-
ical status of their source tissues. In caseswhere the anatomical sourcewas unclassi-
fiable,cell typeinformationwasused.Bonemarrow/bloodlibrariesweredesignated
bonemarrow,andallcombinationswithmucosa(colon,stomach)weremergedinto
‘‘mucosa.’’ Libraries not explicitly annotatedas ‘‘normal’’were consideredasunclas-
sified. Libraries frompooled tissue sourceswere ignored, and pooled sampleswere
kept as long as the pathological and anatomical status was identical for all donors
(see Dataset S1 for annotated libraries).
Pseudoarrays. Expression information was organized into ‘‘pseudoarrays’’
based on expression information obtained from CAGE-, MPSS-, and cDNA-
libraries in the caseof cancer expressionandmergedwithRT-PCR results in the
case of normal tissue expression. Columns reflect the class of library in which
a CT transcript was identified and rows represent individual RefSeq tran-
scripts. Annotationwas based on the general library class description (normal,
cancer or unclassified) combined with pathological state and anatomical site.
To evaluate the relative levels of CT expression we converted expression
signals from the 4 sources into ‘‘expression evidence’’: For CAGE- and MPSS-
based expression data, expression evidence was based on detected tags per
million (TPM), with matches !3 TPM ("1 transcript per cell) filtered out.
Normalized and subtracted EST libraries prevent quantitaton of expression
strengthbasedonEST counts, therefore expression evidence is representedby
the number of cDNA libraries in which a given transcript was identified.
RT-PCR results were manually binned into 5 groups of expression, ranging
from 0 (not expressed) to 4 (strongly expressed). For each expression source,
evidence values were normalized on a per-transcript basis by setting the
highest expressionevidence innormal tissues toavalueof1, reflecting relative
changes in expression levels across tissues and pathological states. Pseudoar-
rays from the 4 expression sources were merged by summing the individual
expression evidence scores for a given transcript from each platform. Expres-
sion profiles for multiple transcripts associated with the same gene were
merged into a single representation, keeping the highest expression score for
overlapping annotations. In arrays where annotation was ‘‘merged’’ into single
columns basedon their class (e.g., all cancer expression information), the highest
expression score across all annotated libraries was kept for each gene.
Visualization and Ranking.Genes were divided into CT-X and non-X CT panels,
then individually ranked by their expression properties in normal tissues and
classified into the following 3 categories: (i) expression in testis and placenta
only (testis-restricted); (ii) expression in testis, placenta and brain-regions only
(testis/brain-restricted), and (iii) all other genes (testis-selective). Final ranking
within each category was obtained by sorting based on decreasing level of
normal tissue specificity as measured by the combined testis and placenta
expression evidencedividedby all normal expression evidence.All arrayswere
visualized using MeV 4.0 (www.tm4.org).
Clustering Methods. Associations between CT annotation and their classifica-
tion were investigated by recording their assigned class; presence or absence
in placenta, brain, testis, and developing ovary; their testis/placenta tissue
specificity; their X vs. non-X chromosomal status; membership in a gene
family; subcellular localization; and evolutionary status (36) followed by an
analysis with the APRIORI algorithm (42), which identifies association rules
matching a predefined threshold of support (30%) and confidence (! 0.8)
Search Criteria for CT Candidates. CT candidates were identified using the same
in silico expression sources, but with no filters for minimum TPM value and
satisfying the following criteria: (i) exhibit expression in testis and at least one
cancer-associated tissue at 10 TPM (CAGE, MPSS) or presence in at least one
EST/cDNA library with testis and cancer annotation; (ii) not be present above
those levels in any other tissue except for placenta, ovary, and brain; and (iii) be
supported independently by 2 platforms. Identified candidates were ranked
using the same approach used to classify known CT genes. To increase coverage
of CT-X genes, a second genome-wide search was conducted requiring support
from only a single platform. Candidates were selected for RT-PCR validation by
manual curation, removing hypothetical proteins, predicted genes and candi-
dates with multiple publications indicating expression in somatic tissues.
RT-PCR. RNA preparations were purchased from the normal tissue panels of
Clontech and Ambion or prepared from cancer cell lines using the RNAeasy kit
(Qiagen)andwereusedtopreparecDNAforRT-PCR.Atotalof1.0"gofRNAwas
reverse transcribed into cDNA in a total volume of 20"L using theOmniscript RT
kit (Qiagen) according to the manufacturer’s protocol using oligo(dT)18 primers
(Invitrogen). The cDNA was diluted 5 times and 3 "L was used in the PCR with
primers specific toeachanalyzedgene inafinal volumeof25"L. Primersused for
PCRamplificationweredesignedtohaveanannealingtemperature"60 °Cusing
Primer3 software (www.genome.wi.mit.edu/cgi-bin/primer/primer3www.cgi)
andwere chosen to encompass introns between exon sequences to avoid ampli-
fication of genomic DNA. DNase treatment was undertaken before cDNA syn-
thesis to analyze intronless genes. Primers were designed to target all known
variants of a gene in RefSeq and their specificity was confirmed by aligningwith
the National Center for Biotechnology Information sequence databases using
BLAST (www.ncbi.nlm.nih.gov/blast/blast.cgi). Primer sequences and amplicon
sizes are provided in Dataset S7.
JumpStart REDTaq ReadyMix (Sigma Aldrich) was used for amplification
according to the manufacturer’s instructions. Samples were amplified with a
precycling hold at 95 °C for 3 min, followed by 35 specific cycles of denatur-
ation at 95 °C for 15 seconds, annealing for 30 seconds (10 cycles at 60 °C, 10
cycles at 58 °C and 15 cycles at 56 °C) and extension at 72 °C for 30 seconds
followed by a final extension step at 72 °C for 7 min. #-actin was amplified as
control. PCR products were separated on 1.5% agarose gels stained with
ethidium bromide. For semiquantitative PCR analysis, RT-PCR products were
classified into 0 (negative) to 4 (strongest signal) based on the intensity of the
product on ethidium bromide-stained gels.
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Appendix X: Manual curation steps applied in filtering the 
expression array generated for the investigation of 63 potential 
mouse cancer/testis genes 
Remove column if annotation is: 
• Unclassifiable pathology 
• Pooled from different tissues 
• Non-cancer pathology 
• Whole body, head, neck, trunk, anatomical site, maxillary process, anterior 
limb or diaphragm 
Remove developmental stage information from annotation 
Remove cell type information from annotation unless there is no anatomical 
system information 
• Exception: keep cell type and discard anatomical system for 
‘fibroblast|synovium’ 
Remove ‘unclassifiable_AS’ from annotation (unclassifiable anatomical system) 
Remove column if annotation is now only ‘normal’ 
Merge: 
• Carcinoma = adenocarcinoma, teratocarcinoma 
• Bone = bone marrow 
• Brain = cerebellum, cerebral cortex, corpus striatum, diencephalon, 
hippocampus, hypothalamus, lateral ventricle, medulla oblongata, 
midbrain, olfactory lobe 
• Intestine = cecum, colon, small intestine 
• Visual apparatus = choroid, retina 
• Auditory apparatus = internal ear, spiral organ of Corti 
• Blood = B-lymphocyte, erythroblast 
• Lymphoreticular system = lymph node 
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For all annotations that are identical, merge them into one column and sum the 
values in each column for every gene. 
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Appendix XI Expression profile of mouse orthologs of human cancer/testis genes 
 
 
 
 
 
 
 
The gene expression profile of 63 mouse orthologs for which expression evidence is available.  The red squares within the array 
indicate a gene is expressed in a particular tissue, whereas black squares indicate there is no evidence of expression in that tissue.  
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